Technology - Investor's Business Daily03:20 Текст источника в новой вкладке

 
 
1. Tesla Drama Continues As Troubles Keep Mounting Higher For MuskПн., 20 авг.[−]

Tesla stock started to fall further Monday, but then mounted a recovery, on Elon Musk's acknowledgment of the hurdles standing in the way of his effort to take the company private and the emergence of another electric-car company attracting interest from a key investor.

X

Tesla stock tumbled as much as 7.6% before the start of regular trading. But shares turned positive at the close and ended the trading day up 1% to 308.44.

JPMorgan scrapped any modeling in its price target for the possibility that Musk will buy out some investors at $420 a share. Analyst Ryan Brinkman, who rates Tesla stock the equivalent of a sell, said such a deal is "potentially far from even being formally proposed."

The bearish analysis followed a report Sunday that Saudi Arabia's sovereign wealth fund considered a stake in another U.S. electric-car company. The Saudis' Public Investment Fund is the investor that Musk has described as a linchpin of his plan to take Tesla ( TSLA) private. The fund recently purchased almost 5% of Tesla, but is in talks for a separate $1 billion investment in Lucid Motors. That would give the fund control of that fledgling automaker, Reuters reported.

A Lucid spokeswoman declined to comment. Representatives for the Saudi fund couldn't immediately be reached for comment on the Reuters report. Reuters cited people familiar with the talks without identifying them.

Tesla and Lucid aren't at all on the same level. Lucid has only shown electric-car prototypes, whereas Tesla produces thousands of cars a month. But the prospect of controlling Lucid may appeal to the Saudis. Part of their goal is to diversify away from the oil industry.

Multiple Traumas For Tesla Stock

The news is combining to extend the trauma of last week, when Tesla shares slumped 14%. That's the steepest drop since February 2016.

Musk, 47, gave an alarming interview to the New York Times. The CEO said no one reviewed his tweet about taking the company private. There also was no prior scrutiny of his claim about having the funding secured to do so before he posted the tweet. He described prescription-drug use to sleep and the toll that leading Tesla has taken on his personal life. It has raised questions about the well-being of the larger-than-life chief executive.

Brinkman hiked his price target on Tesla stock to $308 after Musk's initial take-private tweet on Aug. 7. He then dropped Tesla stock back to the earlier level of $195. Brinkman cited the CEO's Aug. 13 blog post in which he said the Saudi PIF had asked for more information about how the transaction could be pulled off.

"We now believe that such a process appears much less developed than we had earlier presumed," Brinkman wrote in a note to clients. Taking Tesla private may be "more along the lines of high level intention" than a firm plan, the analyst said, so formally incorporating it into valuation analysis "seems premature at this time."

Tough Schedule

Tesla's troubles come as Musk's 120-hour workweek is coming under scrutiny. Musk, however, sees no option but to keep working at his current relentless pace. That's despite deepening concerns of board members and investors about his health and stability. Musk is trying to propel his company toward a possible rebirth as a private entity.

A few hours before sunrise in California on Sunday, Musk said he'd just gotten home from the electric-car factory. There, he has toiled — and often slept — for months to ramp up Model 3 sedan production. Musk also rebutted a post from digital-media mogul Arianna Huffington. Huffington had urged Musk to take time off lest he fall short of his ambitions to change the world. "Sorry," Musk wrote around 2:30 a.m.: "It is not" an option.


The exchange underscores Musk's determination to lead Tesla through recent turmoil. It accelerated after his Aug. 7 tweet suggesting he'd secured funding to take the firm private at $420 a share.

Rather than soaring toward that value, the stock has since plummeted 20% as parts of Musk's story unravel. Scrutiny also is intensifying on Tesla's board for its handling of the iconic CEO. Nothing will get easier this week. Musk and Tesla's board align with their separate sets of legal and financial advisors, all amid inquiries from U.S. securities regulators.

Tesla has marketed its top-of-the-line models that boast head-snapping acceleration as having "Insane" and "Ludicrous" modes. But features some consumers may want in an automobile aren't necessarily sustainable in an automobile executive.

Huffington Letter To Musk

Huffington, a board member at Uber Technologies, accused Musk of "demonstrating a wildly outdated, anti-scientific and horribly inefficient way of using human energy." She added in a tweet that the Tesla founder should change the way he works.

Still, Musk tweeted that Ford Motor ( F) and Tesla are the only two American car companies to have avoided bankruptcy. He dismissed the idea that he was able to cut his workload.

Musk's already chaotic world blew up again when he tweeted this month that he had "funding secured" to take Tesla private.

He later said that meetings with Saudi Arabia's sovereign wealth fund had given him confidence to announce the news. He also announced he had tapped Goldman Sachs ( GS) and Silver Lake to assist with the plan. Last week, the Securities and Exchange Commission sent the company a subpoena regarding the statement.

Huffington's attempted intervention comes at a time when she's been campaigning in support of the benefits of sleep. Her description accompanying the open letter describes her as a "flat shoe advocate and sleep evangelist."

It's unlikely Musk has lost much sleep over concerns about Newark, Calif.-based Lucid Motors. While its prototype Lucid Air sedan has been well-received, it's unclear whether the company has the funding to get production going. Lucid's website is taking refundable $2,500 deposits for the vehicles it plans to eventually sell.

The post Tesla Drama Continues As Troubles Keep Mounting Higher For Musk appeared first on Investor's Business Daily.


2. Apple Stock Down As It Pulls Gambling Apps In China After CrackdownПн., 20 авг.[−]

Apple stock slipped Monday after it pulled thousands of gambling apps from its Chinese store after the nation's state-run broadcaster accused the smartphone maker of dragging its feet on cleaning up banned content.

X

Government-controlled media including China Central Television attacked Apple ( AAPL) this month for hosting illegal and fake lottery-ticket apps. They said the apps resulted in massive losses for hoodwinked users. On Sunday, CCTV reported Apple pulled at least 4,000 apps tagged with the keyword "gambling" on Aug. 9 alone.

The U.S. company confirmed the action and said it simply complied with regulations. But it underscores both Beijing's resurgent crackdown on all forms of online content from games to social media and video services. It also highlights the difficulties facing foreign companies that do business in the world's second-largest economy.

"Gambling apps are illegal and not allowed on the App Store in China," Apple said in an emailed statement. "We have already removed many apps and developers for trying to distribute illegal gambling apps on our App Store, and we are vigilant in our efforts to find these and stop them from being on the App Store."

Apple stock lost 1% to close at 215.46.

Much At Stake For Apple Stock

Apple stock has much at stake in China, its largest market after the U.S. China also is the main production base for the world's iPhones and iPads. Its market position however has come under attack from a coterie of savvy domestic players from Huawei Technologies to Xiaomi, which offer users there more locally oriented services.

The heightened scrutiny from government regulators coincides with an escalating trade war with the U.S. The U.S. has levied punitive tariffs on Chinese goods in what's regarded as an attempt to counter the Asian country's ascendancy. The fear is that growing tensions may eventually spur Chinese consumers to boycott American goods, though that hasn't emerged on a large scale.

Thousands of apps is a drop in the ocean for Apple. But its response demonstrates the tricky position for firms operating in a country unpredictable in policing content. The CCTV report also serves as a timely reminder for companies such as Alphabet's ( GOOGL) Google. Google is trying to stake out a spot in the world's largest market for internet services. But it often finds itself navigating alien territory.

Apple itself has run afoul of Chinese regulators in the past. In 2013, it apologized and tweaked its customer policy. That came after CCTV accused the company of poor service standards. Last year, it took down hundreds of virtual private network apps. It responded to criticism about tools to bypass internet censors.

The post Apple Stock Down As It Pulls Gambling Apps In China After Crackdown appeared first on Investor's Business Daily.


3. 5G Wireless, Disappointing Acquisition Battle For Soul Of Keysight StockПн., 20 авг.[−]

Shares in Keysight Technologies ( KEYS) rallied after its last two earnings reports, as increased revenue related to 5G wireless services appeared a bright spot. Can Keysight stock make it three in a row?

X

Keysight is a measurement company that provides electronic design and test solutions to communications and electronics industries.

The Keysight stock chart is sending mixed signals heading into its fiscal third-quarter earnings report, due Tuesday. Note that it's risky to buy any stock just before it reports, since you don't know if it will gap up or tumble.

Keysight stock is trading about 4% below a technical buy point. An earnings beat and solid guidance could push it into a buy zone. Shares were up 0.6% to 60.19 at the close Monday.

But, there might be concern that it's a late-stage stock.

Effect Of 5G Wireless On Keysight Stock

The company broke out in September 2016 from a saucer-with-handle pattern and a $31 buy point.

While the Keysight stock chart shows a solid uptrend, the stock has consolidated after post-earnings rallies. That accounts for the "stair-stepping" pattern in its chart.

Investors have weighed positive trends, such as the rollout of 5G wireless services by Verizon Communications ( VZ), AT&T ( T) and other firms vs. overhangs on the stock.

Keysight agreed to buy Ixia in January, 2017 for $1.6 billion. The deal closed in April that year.

Acquisition Disappoints

Ixia provided testing and security solutions for corporate networks and telecom companies. Buying Ixia also gave Keysight intellectual property in wireless communications.

But, weakness in Ixia Solutions Group since the deal's closing has pressured Keysight stock.

On the company's earnings call in May, management said a recovery at Ixia may be around the corner.

Keysight stock jumped nearly 11% after it reported second-quarter earnings. Profit rose 30% to 83 cents a share topping views. Revenue jumped 31% to $990 million, including the Ixia purchase.

Keysight Stock Pattern

Keysight earnings call commentary on 5G was upbeat. 5G networks are expected to provide wireless broadband services to homes and communicate with self-driving cars and drones.

"Notably, (Q2) orders for 5G equipment grew double-digits year-over-year for the 10th consecutive quarter driven by a continued ramp in 5G R&D investment," said a Goldman Sachs report. "While the full 5G production ramp is likely to remain more of a 2020 event, we expect the pace of R&D investment to improve as full production nears, contributing to growth."

Over the past five months, Keysight's chart has formed a base on base as the stock pulled back following post-earnings rallies. When a consolidates so quickly after its breakout, that could be a worrisome sign. But, stocks like Micron Technology ( MU) have powered through consolidation phases to big gains.

For the third quarter, analysts estimate Keysight's profit will grow 30% to 79 cents a share. Revenue is projected to rise 12% to $963 million.

YOU MAY ALSO LIKE:

Micron Technology And Salesforce.com Formed The Base On Base To Big Stock Market Profits

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The post 5G Wireless, Disappointing Acquisition Battle For Soul Of Keysight Stock appeared first on Investor's Business Daily.


4. Alexion Pharma Could Grab Another Approval In Early 2019Пн., 20 авг.[−]

Alexion Pharmaceuticals ( ALXN) could add a fourth approved drug to its portfolio as soon as February 2019 after the Food and Drug Administration accepted its priority review application for a blood-disease drug on Monday.

X

Shares of Alexion lifted as much as 2.1% in early trading on the stock market today. Alexion stock ended the regular session up 0.2%, at 116.17. Shares have been consolidating since last September with a buy point at 149.44.

The priority review voucher came as a surprise, RBC analyst Kennen MacKay said in a report to clients. Drugs approved under priority review undergo an expedited eight-month process. The standard review period is 12 months.

This could allow the drug ALXN1210 to launch earlier than expected. ALXN1210 was studied as a treatment for paroxysmal nocturnal hemoglobinuria, or PNH. PNH is a chronic, progressive and potentially life-threatening blood disease.

"We model $34 million in U.S. 2019 ALXN1210 sales vs. global Street estimates of $35 million in PNH," he said. "While 2019 consensus estimates are not split by quarter, our U.S. estimate is based on a midyear launch, and we see an early launch likely leading to upside revisions."

Immune System Problems

Alexion already sells a treatment for PNH known as Soliris. ALXN1210 is meant to be a follow-up to Soliris, which also treats another blood disease and a neuromuscular condition. Both drugs work to prevent abnormal activity within the complement system, a part of the immune system.

If approved, ALXN1210 would be the first and only long-activity complement inhibitor for patients with PNH, Alexion said in a news release. In patients with PNH, the complement system becomes activated in an uncontrolled way. That could lead to the destruction of red blood cells.

The studies for ALXN1210 built on Alexion's work with Soliris, Alexion spokesman John Orloff said in a written statement. The FDA set a Feb. 18, 2019, review date for ALXN1210.

"Building on comprehensive results from the largest-ever Phase 3 development program in PNH, 11 years of proven (effectiveness) and safety with Soliris and 25 years of leadership in complement biology, we are on track with our efforts to establish ALXN1210 as the standard of care for patients with PNH," he said.

YOU MAY ALSO LIKE:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

Long-Term Retirement Investing Strategies With ETFs

Should You Buy A Stock Ahead Of Its Earnings Report?

The post Alexion Pharma Could Grab Another Approval In Early 2019 appeared first on Investor's Business Daily.


5. Chip Stocks Slide As Growth Concerns Weigh On Semiconductor SectorПн., 20 авг.[−]

For seven years after the stock market bottom in 2009, the Philadelphia Semiconductor Index, known as SOX, tracked closely with the performance of the Nasdaq Composite. That changed in 2016 when Nvidia ( NVDA) and other major chip stocks took off and vastly outperformed the Nasdaq for two years.

X

But since the start of 2018, semiconductor stocks have stumbled as concerns have grown about the health of the sector. Meanwhile, the Nasdaq is closing the performance gap with the SOX since the start of the recovery from the Great Recession.

The Philadelphia Semiconductor Index is up 5.5% year to date. That compares with a 13.3% rise in the Nasdaq Composite.

On Friday, the iShares Philadelphia Semiconductor ( SOXX) exchange traded fund, which tracks the performance of the SOX, closed below its 200-day moving average, a negative technical trading indicator.

The iShares SOX ETF dipped a fraction on the stock market today. It remains below its 200-day moving average line.

Worries Overhang Chip Stocks

A number of worries hang over chip stocks. For instance, semiconductor equipment suppliers such as Applied Materials ( AMAT) have been hit by delays in customers purchasing new manufacturing gear. Also, memory-chip makers such as Micron Technology ( MU) are facing a possible cyclical downturn in sales.

Slowing sales of smartphones have battered makers of wireless chips, such as Broadcom ( AVGO) and Qualcomm ( QCOM). Suppliers of chips for the iPhone have dipped as Apple ( AAPL) lowered production of last year's handsets ahead of the introduction of new models this fall.

Nvidia has seen the once-hot market for processors for cryptocurrency mining evaporate. But its graphics processors are still in high demand for gaming PCs and data centers. On Monday, Nvidia unveiled its latest gaming processors, the GeForce RTX series. Starting at $499, GeForce RTX graphics cards will be available starting Sept. 20.

RELATED:

Applied Materials Stock Plummets, Gets Volley Of Price-Target Cuts

Nvidia Guidance Miss Seen As Pause Ahead Of New Product Launch

Microchip Technology Inherits Mess From Microsemi Deal

Semiconductor Equipment Stocks Fall On Morgan Stanley Downgrade

The post Chip Stocks Slide As Growth Concerns Weigh On Semiconductor Sector appeared first on Investor's Business Daily.


6. Why Biotech Amgen Will Lead Peers In Blockbuster Migraine MarketПн., 20 авг.[−]

Amgen's ( AMGN) first-to-market status will keep Eli Lilly ( LLY), Teva Pharmaceutical ( TEVA) and Alder Biopharmaceuticals ( ALDR) at bay in a market of potential blockbuster drugs to prevent migraines, analysts said Monday.

X

The early launch of Amgen's Aimovig bodes well for similar drugs from Lilly, Teva and Alder, analysts with investment bank Leerink said in a note to clients. Ultimately, this class of migraine-prevention drugs could reach $4.5 billion in 2022 and $6.9 billion in 2025, they said.

Amgen's drug Aimovig is likely to retain 38% of the market at peak. Lilly's galcanezumab could follow at 24% of the market. They expect Teva's fremanezumab to grab 20%, with Alder's eptinezumab getting 19% of the market at its peak.

"We continue to believe that the four antibodies have more similarities than differences," they wrote.

On the stock market today, Teva stock closed up 5.9%, to 25.65, still riding high after U.S. officials approved its generic version of allergy drug EpiPen last week. Amgen stock rose 0.1%, to close at 197.56. Lilly stock lifted 0.3%, to 105.82. Alder stock dipped 0.5%, to 18.50.

Anti-CGRP Drugs

All four drugs belong to a class called anti-CGRP drugs. They are injections that block a peptide to prevent migraines. Earlier this year, the Food and Drug Administration approved Amgen and Novartis' ( NVS) Aimovig as a monthly injection to prevent migraines in adults.

Physician feedback suggests patients prefer the first injection in the office before moving toward injecting themselves at home, analysts said. The response so far has been dramatic, and there have been few complaints of injection-site pain or treatment fatigue.

Analysts had worried the injection aspect would limit anti-CGRP use to chronic patients or those who've failed on Allergan's ( AGN) Botox. But it seems physicians are also prescribing Aimovig regardless of whether they've tried Botox. Some are receiving Aimovig for residual headaches after Botox.

"One interesting phenomenon is that since Botox is approved for prevention in the chronic migraine population only, some physicians may prefer to try Botox initially in chronic patients, since Aimovig can always be added on later," they said.

Teva's Disadvantage

Teva is at the biggest disadvantage in the class. All four drugs target the same peptide, but Teva's and Lilly's do this by working with a receptor ligand. Thus, the two drugs are the most interchangeable of the anti-CGRP class to prevent migraines, analysts said.

Also, Teva's fremanezumab will launch without an auto-injector. Physicians suggested many patients may not be as comfortable self-administering a drug via syringe, analysts said. The other three are expected to launch with auto-injectors.

"The fact that multiple injections will be required in order to achieve the three monthly dosings that could be included on the label puts Teva at a disadvantage to both Amgen and Lilly despite both their medicines requiring monthly administration," analysts said.

Patients have the option of a less frequent quarterly injection at the physician's office. But that "may not be enough of an incremental convenience for them to choose fremanezumab over the other monthly auto-injectors," analysts said.

Further, patients may end up preferring Alder's drug for quarterly injections. Alder's eptinezumab is more effective and has a faster onset, analysts said.

YOU MIGHT ALSO LIKE:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Tame A Volatile Swing Trade With A Half Position

Looking For The Best Stocks To Buy And Watch? Start Here

The post Why Biotech Amgen Will Lead Peers In Blockbuster Migraine Market appeared first on Investor's Business Daily.


7. Fourth-Generation Apple Watch Could Debut In SeptemberПн., 20 авг.[−]

Media reports suggest that Apple ( AAPL) will unveil a fourth-generation Apple Watch smartwatch when it introduces its 12th-generation iPhone family next month.

X

Apple news website 9to5Mac reported Monday that the company has registered six new Apple Watch model identifiers in the Eurasian economic database ahead of the expected launch. The database lists the devices as Series 4 models running the WatchOS 5 operating system.

Last month, TF International Securities analyst Ming-Chi Kuo predicted that Apple would refresh its smartwatch lineup this fall with new models sporting slightly larger displays and enhanced heart-rate detection.

Bigger Apple Watch

Kuo said the new watches would have screen sizes of 1.57 and 1.78 inches. The current Apple Watch Series 3 lineup comes with screen sizes of 1.50 and 1.73 inches.

The Series 3 lineup was the first to feature built-in cellular, so users could make phone calls or send text messages without having their iPhone with them. Lower-priced models still have to be paired with an iPhone for full functionality. Apple introduced the Series 3 watches in September 2017.

The Cupertino, Calif.-based company sold an estimated 4.2 million smartwatches in the June quarter, topping views for 4 million units.

Apple competes in the smartwatch category with Fitbit ( FIT), Garmin ( GRMN), Samsung and others.

Fitbit Introduces Charge 3 Wearable

On Monday, Fitbit introduced its Charge 3 fitness tracker. It features a swimproof design with a touch-screen display, over 15 goal-based exercise modes and advanced health and fitness tracking features. The wearable device costs $149.95 and will be available in October.

Fitbit said the Charge 3 is designed for adults who prefer to own an advanced fitness tracker as opposed to a full smartwatch. For consumers who want a smartwatch, Fitbit offers the Ionic, which costs $299.95.

Apple stock slid 1% to 215.46 on the stock market today. Earlier in the session, Apple notched an all-time high of 219.18. It was the stock's third record high in as many trading days.

Fitbit stock rose 5.4% to 6.01.

RELATED:

Apple Stock Hits Fresh High As Investors Await New Products

The post Fourth-Generation Apple Watch Could Debut In September appeared first on Investor's Business Daily.


8. Netflix Annoys Subscribers With Video Ads Promoting Its ContentПн., 20 авг.[−]

Internet television network Netflix ( NFLX) bills its service as advertising-free, but that apparently doesn't apply to ads for its own content. The subscription video-on-demand service is catching flak for experimenting with advertisements for its own programming between shows.

X

Subscribers took to social media over the weekend to complain about the advertising test. The video ads pop up between episodes of TV series to promote other shows on the service.

"We are testing whether surfacing recommendations between episodes helps members discover stories they will enjoy faster," Netflix said in a prepared statement to Ars Technica. It said the ads feature a "skip" button. It also said it is mindful of "chatter on social channels" about the test.

Users complained about the Netflix ads, which it calls "recommendations," on Reddit and Twitter. Many referred to the ads as an annoyance. They say it hurts the experience of binge-watching multiple episodes of shows, according to Business Insider.

Netflix Conducts Hundreds Of Tests Each Year

In a statement to Cord Cutters News, Netflix said members will decide whether the test becomes permanent based on their usage of the feature.

"At Netflix, we conduct hundreds of tests every year so we can better understand what helps members more easily find something great to watch," the company said.

It added, "A couple of years ago, we introduced video previews to the TV experience, because we saw that it significantly cut the time members spend browsing and helped them find something they would enjoy watching even faster. Since then, we have been experimenting even more with video based on personalized recommendations for shows and movies on the service or coming shortly, and continue to learn from our members."

Netflix stock is down 18% since the company reported disappointing subscriber numbers for the second quarter on July 16. It rose 3.5% to 327.73 on the stock market today.

RELATED:

Netflix Stock Gets Price-Target Cut; Chief Financial Officer Steps Down

Roku Stock Surges Past Buy Point On Second-Quarter Earnings

The post Netflix Annoys Subscribers With Video Ads Promoting Its Content appeared first on Investor's Business Daily.


9. FANG Stocks News & Quotes: Facebook, Amazon, Netflix, GoogleПн., 20 авг.[−]

Collectively known as the FANG stocks, Facebook ( FB), Amazon.com ( AMZN), Netflix ( NFLX) and Google parent Alphabet ( GOOGL) are among the tech titans of our time.

X Facebook and Google alone capture the lion's share of all global online advertising, including in the fast-growing mobile format, while Amazon dominates e-commerce and cloud services with its Amazon Web Services business.

And although Netflix is facing increasing competition from Hulu and fellow FANG stocks — particularly Amazon and YouTube owner Google — its original programming and massive global expansion have cemented its leadership in the streaming industry.

Check this page regularly for ongoing coverage of the FANG stocks, including potential buy and sell signals.

FANG Stocks News & Quotes

Apple Stock Down As It Pulls Gambling Apps In China After CrackdownApple stock slipped Monday after it pulled thousands of gambling apps from its Chinese store after the nation's state-run broadcaster accused the smartphone maker of dragging its feet on cleaning up banned... Read More
Which Stocks Make This List Of The Fastest-Growing Companies?What do Amazon.com, Paycom Software and Palo Alto Networks have in common with Tabula Rasa Healthcare, ServiceNow and RingCentral? They've all earned a spot on the latest list of today's fastest-growing companies. The biggest stock market... Read More
Dow Jones Futures: Tesla Stock Falls Below 300; Pepsi To Buy SodaStream; China Trade War Talks LoomDow Jones futures rose modestly Monday morning, along with S&P 500 futures and Nasdaq futures. Tesla continued to slide after CEO Elon Musk tweeted early Sunday that changing his work habits is... Read More
Stocks Erase Losses As Nasdaq Again Bounces From This Key LevelStocks reversed higher as hopeful news on the trade war with China sparked late gains, while the retail sector led the market. The Nasdaq erased a 0.7% loss to close 0.1% higher... Read More
Amazon Blockbuster Industry Buzz Lifts These StocksTheater stocks mostly rallied Thursday on news that Amazon is in talks to buy Mark Cuban's Landmark Theatres chain. The online shopping giant is one several suitors in talks to acquire Landmark from... Read More
Amazon Stock Positioned To Follow Apple As Next To Hit $1 Trillion CapWith Amazon stock up 61% this year and near a record high, the e-commerce giant is on track to become the second company to exceed the $1 trillion market cap milestone, following... Read More
Key Indexes Thrive Despite China Sell-Off; Google Stock Alphabet Creates A New Buy PointTech, retail, health care, building and select banking shares advanced and helped pave the way to a broad-based rally in stocks today, overcoming a significant sell-off among former highflying ADRs and ADSs... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

RELATED:

Apple Stock Quotes & News

Tesla Stock Quotes & News

More Tech Stock News

Best Stocks To Buy And Watch

The post FANG Stocks News & Quotes: Facebook, Amazon, Netflix, Google appeared first on Investor's Business Daily.


10. Tesla (TSLA) Stock Quotes, Company News And Chart AnalysisПн., 20 авг.[−]
X


View TSLA Stock Quote Page
| View TSLA Ratings

Tesla Stock News & Analysis

Wall Street Up; This Warren Buffett Stock Reverses, But No Sell-Signal TriggersWall Street moved higher today despite a reversal lower by Apple, now famous for being an important Warren Buffett stock play. Retailing, transport, energy and select consumer-oriented companies paced the upside in... Read More
Tesla Drama Continues As Troubles Keep Mounting Higher For MuskTesla stock started to fall further Monday, but then mounted a recovery, on Elon Musk's acknowledgment of the hurdles standing in the way of his effort to take the company private and... Read More
Dow Jones Futures: Tesla Stock Falls Below 300; Pepsi To Buy SodaStream; China Trade War Talks LoomDow Jones futures rose modestly Monday morning, along with S&P 500 futures and Nasdaq futures. Tesla continued to slide after CEO Elon Musk tweeted early Sunday that changing his work habits is... Read More
Stocks Erase Losses As Nasdaq Again Bounces From This Key LevelStocks reversed higher as hopeful news on the trade war with China sparked late gains, while the retail sector led the market. The Nasdaq erased a 0.7% loss to close 0.1% higher... Read More
Tesla Stock Tumbles As Elon Musk Reveals Details Of 'Painful' YearTesla stock plunged below key indicators Friday, with the latest bit of bad news being a New York Times article in which Chief Executive Elon Musk reveals details of an "excruciating" year... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

Latest FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

View More Tech Stocks

The post Tesla (TSLA) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


11. Nvidia Guidance Miss Seen As Pause Ahead Of New Product LaunchПт., 17 авг.[−]

Chipmaker Nvidia ( NVDA) disappointed investors with its soft sales outlook for the current quarter, but Wall Street analysts see it as a pause before the company releases new graphics processors based on its Turing architecture.

X

Late Thursday, Nvidia topped estimates for its fiscal second quarter ended July 29, but its revenue guidance came in light. For the October quarter, Nvidia expects sales to rise 23% year over year to $3.25 billion, vs. expectations for $3.34 billion.

Nvidia stock dropped 4.9% to 244.82 on the stock market today. The stock hit an all-time high of 269.20 on June 14.

Oppenheimer analyst Rick Schafer sensed a buying opportunity in the stock's fall. He upgraded Nvidia to outperform from perform with a price target of 310.

"Shares could see near-term weakness following softer guidance, particularly after a strong run the past 2-3 years," he said. "With three solid, structural growth drivers in data-center artificial intelligence, gaming and autonomous (driving), we see continued outsized growth."

Schafer believes there is pent-up demand for the company's Turing-based graphics processors, which will go on sale in the fourth quarter. They are targeted at the $250 billion visual effects industry. Nvidia unveiled the chips on Monday at the Siggraph conference in Vancouver.

New Gaming Chips Coming

Morgan Stanley analyst Joseph Moore blamed the light sales guidance on the impact of product transitions. Analysts expect Nvidia to introduce versions of its Turing processors for gaming PCs at an event on Monday.

"Our sense is that the subseasonal guidance is more of a transitional handoff than fundamental problems in the market," he said. Moore reiterated his overweight rating on the stock with a price target of 273.

RBC Capital Markets analyst Mitch Steves said Nvidia's report shows a pause in growth ahead of the ramp of Turing products.

"We think the stock will take a small step back and the dip should be purchased on the back of the Turing product launch ramp," Steves said in a note to clients. He reiterated his outperform rating and price target of 310.

One factor spooking investors was the evaporation of cryptocurrency-related business last quarter. Falling prices for cryptocurrencies have greatly reduced demand for crypto-mining processors.

YOU MAY ALSO LIKE:

Nvidia Stock Falls As Guidance, Cryptocurrency Business Disappoint

Chip Stocks To Watch And Semiconductor Industry News

The post Nvidia Guidance Miss Seen As Pause Ahead Of New Product Launch appeared first on Investor's Business Daily.


12. Applied Materials Stock Plummets, Gets Volley Of Price-Target CutsПт., 17 авг.[−]

Applied Materials stock gapped down to its lowest level in a year on Friday after the company issued disappointing guidance with its fiscal third-quarter earnings report.

X

Shares of the semiconductor equipment maker plunged 7.7% to 43.77 on the stock market today. In intraday trading, Applied Materials stock plummeted as much as 10.1% to 42.62.

Late Thursday, Applied Materials ( AMAT) delivered fiscal third-quarter results that topped Wall Street's estimates. But its outlook spooked investors. The Santa Clara, Calif.-based company predicted adjusted earnings per share of 96 cents on sales of $4 billion for the current quarter. Wall Street expected adjusted earnings per share of $1.17 on sales of $4.46 billion for the fiscal fourth quarter.

Applied Materials stock received at least eight price-target cuts from Wall Street analysts following the earnings news. The most pessimistic of the bunch was RBC Capital Markets analyst Mitch Steves. He reiterated his sector perform rating on the stock and cut his price target to 50 from 55.

Current Quarter Seen As Trough

"While the company is calling for Q4 to be a trough EPS quarter, we think investors will continue to sit on the sidelines (near term) until the memory (chip) environment improves," Steves said in a report. "On the positive side, we emphasize that we are not long-term bears and believe the memory headwinds will abate, which would create an attractive entry point (can re-enter when memory stabilizes)."

Applied Materials' guidance includes the impact of delays in factory upgrades by customers Intel ( INTC), Samsung and Taiwan Semiconductor Manufacturing ( TSM), D.A. Davidson analyst Thomas Diffely said in a report.

The current quarter "marks the trough" for the company, Diffely said. "2019 should see a nice recovery."

Applied Materials has been hit by customers delaying equipment purchases for memory-chip and foundry businesses. The company's display equipment business has suffered from delays in OLED display production.

RELATED:

Nanometrics Boosted By Gear For Making 3D Nand Memory Chips

The post Applied Materials Stock Plummets, Gets Volley Of Price-Target Cuts appeared first on Investor's Business Daily.


13. Timing Is Key For Teva's Generic EpiPen — Will It Miss This Window?Пт., 17 авг.[−]

Teva Pharmaceutical ( TEVA) initially dipped Friday after commenting that it would launch a generic EpiPen in "the coming months," meaning it will likely miss the busiest buying month.

X

On the stock market today, Teva sank as much as 2.7%, but rose 0.5%, to 24.22, at the closing bell. Shares popped 7.3% in high volume on Thursday after the Food and Drug Administration approved its generic copy of Mylan's ( MYL) EpiPen, an emergency allergy injection. Mylan shares closed up 0.8%, at 38.15.

Leerink analyst Ami Fadia says the pharmaceutical company could fill a supply hole left by Mylan and Amneal Pharmaceuticals ( AMRX) in August — the busiest month for EpiPen orders. But Credit Suisse analyst Vamil Divan said Teva plans to launch its generic in "the coming months."

The pharmaceutical company "needs some time for launch preparations, suggesting a (fourth quarter) launch," he said in a report. "As a result, we expect EpiPen to benefit Teva in 2019 significantly more than 2018."

First True Generic EpiPen

This is the first true generic EpiPen, Leerink's Fadia said. Mylan has its own authorized generic EpiPen at about half the cost of the branded drug. Amneal makes an epinephrine auto-injector, but there's not enough evidence to say it's equivalent to EpiPen.

The drug name for EpiPen is epinephrine, and it's facing numerous supply constraints. The FDA drug shortages list includes epinephrine injections from Amphastar Pharmaceuticals ( AMPH), Amneal and Mylan. Privately held Kaleo hasn't noted any shortages.

But Teva likely has a limited window to enter the market while its rivals are at a disadvantage.

"The longer-term contribution from this product may not be significant for Teva should supply for both Mylan and Amneal eventually be stabilized," she said. "But in the near term we could see generic EpiPen providing an additional boost to Teva's 2018 numbers."

'Modest' Contributor For Teva

For 2018, Teva has guided to $18.5 billion to $19 billion in sales. Fadia assumes $5 million in sales of a generic EpiPen this year. Her sales views for Mylan's EpiPen and Amneal's epinephrine — $220 million and $70 million, respectively — had already assumed market share declines from generic competition.

Like Fadia, Credit Suisse's Divan expects a generic EpiPen to be only a "modest" contributor to the firm's top line in 2018. But, broadly, he sees the opportunity for generic epinephrine to be as large as $300 million.

Assuming no other generic EpiPen hits the market in 2019, Divan calls for Teva to grab 40% of the market. Its generic EpiPen could add 5 to 6 cents to earnings per share in 2019.

YOU MAY ALSO LIKE:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

Investing Basics: How To Sell A Stock

The post Timing Is Key For Teva's Generic EpiPen — Will It Miss This Window? appeared first on Investor's Business Daily.


14. Apple Stock Hits Fresh High As Investors Await New ProductsПт., 17 авг.[−]

For the second day in a row, Apple stock on Friday climbed to an all-time high. Apple ( AAPL) has been on a tear since delivering a beat-and-raise quarterly report on July 31.

X

Apple stock rose 2% to 217.58 on the stock market today. Earlier in the session, it notched a record high of 217.94.

Apple shares have been buoyed by investor enthusiasm over the tech behemoth hitting a market value of $1 trillion on Aug. 2. It is the first company to reach the milestone. Investors also are anticipating a product launch event next month where Apple is expected to introduce a trio of new iPhones.

Analysts say Apple will unveil three new smartphones with displays as big or bigger than the current flagship iPhone X. That handset has a 5.8-inch OLED display, the biggest screen to date for an iPhone.

3 New iPhones Expected

The three rumored iPhones include an updated 5.8-inch OLED model, a plus-size 6.5-inch OLED model and a 6.1-inch LCD screen handset. Apple has not yet announced a date for its fall product launch event, which usually occurs in early to mid-September.

Taiwan-based tech news website DigiTimes reported Friday that Apple next month also plans to introduce a 13-inch "entry-level" MacBook computer priced at $1,200. Plus, Apple is likely to come out with its long-awaited AirPower wireless charging pad in September, DigiTimes said. The AirPower device will be used to charge the Apple Watch, AirPods wireless earbuds and newer iPhones.

Some analysts also expect Apple to come out with refreshed iPad tablets and Apple Watch smartwatches this fall.

Earlier this week, Berkshire Hathaway ( BRKB), the holding company run by billionaire investor Warren Buffett, disclosed that it has boosted its stake in Apple. It bought 12.4 million shares of Apple in the second quarter, bringing its total to just under 252 million shares. It now owns just under 5% of the company, the Wall Street Journal reported.

RELATED:

Apple Could Reach $2 Trillion Market Cap With AR Glasses, Car

Amazon Stock Positioned To Follow Apple As Next To Hit $1 Trillion Cap

Apple Easily Beats June-Quarter Views, Guides Sales Targets Higher

The post Apple Stock Hits Fresh High As Investors Await New Products appeared first on Investor's Business Daily.


15. Alibaba Earnings Report Will Put Spotlight On China Internet StocksПт., 17 авг.[−]

Alibaba ( BABA)is set to report quarterly results on Thursday, which should provide a closer look into the stability of China internet stocks and an economy that has shown some signs of weakness.

X

It was a rough period for China internet stocks this past week, with several companies reporting earnings that missed expectations on some key metrics. Internet streaming providers YY ( YY) and Huya ( HUYA) fell by double digits in reaction to a third-quarter outlook below expectations. Internet giant Tencent Holdings ( TCEHY) fell 7% on an earnings report Wednesday that missed views, dragging down other internet stocks, including Momo ( MOMO), Weibo ( WB), Sina ( SINA) and Baozun ( BZUN).

E-commerce company JD.com ( JD) also fell short of views with its earnings report Thursday.

Also hurting China internet stocks in the earnings reports was a lower-than-expected outlook for the third quarter. Altogether it has raised concerns of possible weakness in China's economic growth, as retail sales in the country for July slowed further. Currency weakness is also a concern.

While the ongoing trade war between the U.S. and China has created some jitters it does not show up as a near-term concern among analysts that follow China internet stocks. Alibaba, as the largest e-commerce company in China, is likely to provide greater insight as to market direction.

Alibaba's Earnings Estimates

Alibaba reports fiscal first-quarter results before the market open Thursday.

The consensus is for Alibaba to report revenue of 81.3 billion yuan. That coverts to $11.8 billion, using Friday's exchange rate. The consensus on adjusted earnings is $1.22 per share.

Shares of Alibaba closed at 172.78, up 0.5% on the stock market today. Alibaba stock is down 18% since hitting a record high of 211.70 on June 5.

Raymond James analyst Aaron Kessler on Wednesday lowered his price target on Alibaba to 280 from 300, with macroeconomic and currency concerns being among the reasons for the reduction. But he maintained a strong buy rating on the stock.

Oppenheimer analyst Jason Helfstein, in a research report last week, maintained an outperform rating on Alibaba and price target of 230.

YOU MIGHT ALSO LIKE:

Bear Market Is Back In China: Should U.S. Investors Worry?

China Stocks: Under Pressure, But Livestreaming Market Explodes

Huya Stock Dives As Earnings Meet, Revenue Outlook Weak

YY Earnings Top Q2 Views, But Stock Dives Late On Weak Guidance

The post Alibaba Earnings Report Will Put Spotlight On China Internet Stocks appeared first on Investor's Business Daily.


16. Tesla Stock Tumbles As Elon Musk Reveals Details Of 'Painful' YearПт., 17 авг.[−]

Tesla stock plunged below key indicators Friday, with the latest bit of bad news being a New York Times article in which Chief Executive Elon Musk reveals details of an "excruciating" year and his emotional battles.

X

Shares of Tesla ( TSLA) fell below its 50-day and 200-day moving averages, often a signal that buying demand is drying up. Tesla stock tumbled 8.9% to close at , near 305.50 on the stock market today.

The New York Times article on Tesla, consisting of an hour-long interview by telephone, paints a picture of an emotional Musk acknowledging that his myriad executive responsibilities are taking a steep personal toll.

"And some board members have expressed concern not only about Mr. Musk's workload but also about his use of Ambien, two people familiar with the board said," the Times reported.

Asked if the exhaustion was taking a toll on his physical health, Musk answered: "It's not been great, actually. I've had friends come by who are really concerned."

Musk's Laughter And Tears

"This past year has been the most difficult and painful year of my career," Musk said, alternating between laughter and tears, according to the article. Musk said he had been working up to 120 hours a week.

Efforts are underway to find a No. 2 executive to help take some of the pressure off Musk, the article said.

As if that wasn't enough, the New York Times had an accompanying opinion piece on Musk by Recode editor Kara Swisher with this subtitle: "Let me answer the question many are thinking: Is he crazy?"

Swisher's answer: "No, he's not. Not, at least, in my various encounters with him over nearly two decades — including recently — in which he has been alternately funny, rude, compelling, obnoxious, accessible, easy to deal with, hard to deal with, always on, outspoken to a fault even when he might be at fault, angry, charming, intense and also strikingly confident."

But, she added, "In the past few months, the founder of Tesla and SpaceX has ear-boxed analysts on an earnings call; made bankruptcy jokes about the health of his companies; attacked journalists as shills; relentlessly baited short sellers who have bet on his downfall; and called a diver in the Thai crisis with whom he wrangled a "pedo" — as in phile. Yeah, he did that."

Meanwhile, Musk is spending about half his time building rocket ships at his other company, SpaceX. His goal is to colonize Mars. In his spare time Musk is digging tunnels under Los Angeles and designing flamethrowers for his recent upstart, Boring Company.

Cracking Under Pressure

Signs that Musk was cracking under pressure emerged at Tesla's annual shareholder meeting in June. Musk took the stage moving slowly and dressed in dark tones, and looking teary-eyed. In the beginning of his presentation Musk appeared to be holding back tears while choking up. Musk had previously spoken of enduring production hell with continuous Model 3 manufacturing woes.

Heading up to the shareholder meeting, proxy advisory groups sought to oust the three directors up for reelection, on a view they lacked the necessary experience for running a car company and were too closely tied to Musk.

There was also a separate nonbinding resolution calling for Tesla to remove Musk as chairman and replace him with an independent director. The resolution calls for him to keep his role as CEO. All those efforts failed to pass. Musk controls 21.9% of Tesla's shares outstanding.

Tesla stock has been on a roller coaster this past year as investors focused on whether the maker of electric cars could ramp production of its Model 3 sedan and do it without Tesla running out of cash.

The company reached its production goals recently and also turned in a better-than-expected quarterly earnings report. Tesla reported second-quarter earnings on Aug. 1 that showed another loss. It did, however, exceed revenue forecasts and defied skeptics in key areas, including Model 3 production.

Taking Tesla Private

Then came the surprising tweet by Musk on Aug. 7. "Am considering taking Tesla private at $420. Funding secured."

That sent Tesla stock to a record high of 387.46 that day. But as it turned out, the funding was not secured. The Securities and Exchange Commission is investigating.

It didn't take long for Tesla stock euphoria to fade. Exactly 48 hours after Musk triggered a frantic rally with his tweet private, shares erased all their gains.

What's also hounded Musk are short-sellers, who essentially place bets that Tesla's stock will fall. Musk has displayed an extreme dislike for short-sellers.

Tesla stock is one of the most shorted issues on Wall Street. About two months ago Musk tweeted he would torch them with one of the flamethrowers he had made as a moneymaking promotion for one of his other ventures, the tunnel-digging Boring Co.

"Short burn of the century coming soon," Musk wrote in the tweet. "Flamethrowers should arrive just in time."

For now, the only one getting burned is Musk.

YOU MIGHT ALSO LIKE:

Can Tesla Stand The Heat As It Burns Through Cash?

Tesla's Board Responds To Musk's Tweet Thunderstorm On Going Private

Elon Musk Blog Post Reveals How He Plans To Take Tesla Private

Elon Musk Hammers Critics For Articles That Pester Tesla Stock

The post Tesla Stock Tumbles As Elon Musk Reveals Details Of 'Painful' Year appeared first on Investor's Business Daily.


17. Symantec Stock Rises As Starboard Takes Stake, Seeks Board SeatsПт., 17 авг.[−]

Symantec stock climbed on Thursday after activist investor Starboard Value disclosed a nearly 6% stake in the the cybersecurity company and said it has nominated five directors to its board.

X

Symantec ( SYMC) stock surged 4.6% to close at 19.41 on the stock market today. The cybersecurity firm's stock had plunged 80% from 11 months ago.

Starboard's filing said Symantec shares "were undervalued and represented an attractive investment opportunity" and that it would engage in discussions to change the composition of the board.

Mountain View, Calif.-based Symantec in May reported fiscal fourth-quarter results that solidly exceeded expectations. But, shares plunged after the company disclosed an internal accounting probe in connection with concerns raised by a former employee.

Symantec Downturn Follows Acquisitions

Symantec in early August reported billings, a sales growth metric, that missed estimates. The company forecast September-quarter earnings and revenue below analyst forecasts.

Symantec had pursued acquisitions to spur growth. Symantec acquired Blue Coat Systems in 2016 for $4.65 billion. The company also purchased LifeLock, a provider of consumer identity-theft protection services, for $2.3 billion.

YOU MAY ALSO LIKE:

After Hours: Dow Tech Giant Soars To Buy Zone On Earnings

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The post Symantec Stock Rises As Starboard Takes Stake, Seeks Board Seats appeared first on Investor's Business Daily.


18. Applied Materials Stock Drops On Light Sales, Earnings OutlookЧт., 16 авг.[−]

Semiconductor equipment supplier Applied Materials ( AMAT) late Thursday beat Wall Street's targets for its fiscal third quarter, but disappointed with its outlook, and shares fell in extended trading.

X

Applied Materials stock slid 1.5% after-hours on the stock market today. During the regular session, it dipped 0.2% to 47.43.

The Santa Clara, Calif.-based company earned an adjusted $1.20 a share on sales of $4.47 billion in the quarter ended July 29. Analysts expected it to earn $1.17 a share on sales of $4.43 billion. On a year-over-year basis, earnings per share rose 40% while sales climbed 19%.

For the current quarter, the company said it expects to earn an adjusted 96 cents a share on sales of $4 billion, based on the midpoint of its guidance. Wall Street was modeling the company to earn an adjusted $1.17 a share on sales of $4.46 billion.

No Sales Growth Expected

On a year-over-year basis, Applied's guidance calls for flat sales in its fiscal fourth quarter. It sees adjusted earnings per share rising 3%.

"While we have seen some near-term adjustments in customer spending, fiscal 2018 is on track to be another record-setting year for Applied Materials," Chief Executive Gary Dickerson said in a news release. "We expect each of our major businesses to deliver strong double-digit growth."

He added, "Our future outlook remains positive as the A.I.-Big Data era requires new breakthroughs in technology, from materials to systems, providing Applied with a great opportunity to play a larger and more valuable role in the ecosystem."

RELATED:

After Hours: These 5 Stocks Are Big Movers Late

Semiconductor Equipment Stocks Fall On Morgan Stanley Downgrade

TSMC Cuts Outlook After Computer Virus; Applied Materials, Qualcomm Upgraded

Applied Materials Beats Second-Quarter Views, But Sales Guidance Light

The post Applied Materials Stock Drops On Light Sales, Earnings Outlook appeared first on Investor's Business Daily.


19. JD.com Earnings Fall Short In Rough Week For China StocksЧт., 16 авг.[−]

JD.com ( JD) stock fluctuated Thursday as earnings and revenue came in weaker-than-expected, the latest in a string of bad news for China internet firms and U.S.-listed Chinese stocks generally.

X

JD.com shares, which fell 3.6% at one point, closed at 31.97, down 1.2% on the stock market today. The stock is trading near a 17-month low.

The company reported revenue of 122.3 billion Chinese yuan, up 31% from the year-ago quarter in local currency. That converts to $18.5 billion, based on the exchange rate with the U.S. dollar on June 29, which JD.com used, according to the news release.

The 122.3 billion yuan was below the consensus estimate from Thomson Reuters of 122.7 billion yuan.

The e-commerce company reported adjusted income of 5 cents a share, missing the consensus of 10 cents and down 50% from the year ago period. The company ended the quarter with 313.8 million active customer accounts, up 21.5% from the year-ago period.

JD.com Stock Follows Others

JD.com's news followed the earnings report of Tencent Holdings ( TCEHY) before the market open Wednesday. Tencent surprised analysts when it missed expectations in a few key areas. Tencent is one of China's largest internet companies and a key investor in JD.com.

Shares of Tencent are off 31% from a record high reached in January. Tencent stock, which fell 7% Wednesday in reaction to quarterly results, was trading near 41.80, up 1.3% on Thursday.

YY ( YY) and Huya ( HUYA) both suffered double-digit percentage losses Tuesday. The two China internet stocks reported quarterly earnings that presented a weaker-than-expected outlook for the third quarter.

Retail Sales Slowing

The lowered outlook came as retail sales in China for July slowed further. Other economic indicators were softer than expected.

For the third quarter, JD.com said it expects revenue to grow 25% to 30% from the year-ago period, in the range of 104.5 billion to 109 billion yuan. The midpoint of 106.75 billion yuan, using today's exchange rate, converts to about $15.5 billion.

In June, Google-owner Alphabet ( GOOGL) invested $550 million in JD.com as part of a new strategic partnership. The two are exploring joint ventures in retail technologies.

They will also explore cooperation opportunities in areas such as artificial intelligence, augmented reality, virtual reality and unmanned technology, JD.com said.

YOU MIGHT ALSO LIKE:

China Internet Stocks Fall On Quarterly Earnings, Disappointing Data

How Nio Is Taking On Tesla In China — And What Challenges It Sees

The post JD.com Earnings Fall Short In Rough Week For China Stocks appeared first on Investor's Business Daily.


20. Can This Drug Class Conquer Joint Damage And Oust Opioids?Чт., 16 авг.[−]

Shares of Teva Pharmaceutical ( TEVA) and Regeneron Pharmaceuticals ( REGN) climbed Thursday on a successful test for their partnered pain drug, though analysts continued to question a key side effect.

X

In a Phase 3 study, Teva and Regeneron's drug fasinumab improved pain and function in patients with chronic pain due to osteoarthritis of the knee or hip. The 16-week analysis was conducted as part of a larger 52-week study.

Fasinumab belongs to a class of drugs known as nerve growth factor inhibitors, or NGF. And analysts are zeroing in on a known side effect: joint damage. Adjusted for the placebo impact, about 2% of patients showed joint damage at week 24, Teva and Regeneron said.

Analysts were quick to compare this with a rival drug made jointly by Pfizer ( PFE) and Eli Lilly ( LLY) — tanezumab. In July, the firms said less than 1.5% of patients treated with tanezumab experienced joint damage as compared with the placebo at week 16.

"The bigger focus for (fasinumab) is safety, and on that front we'll have to wait for detailed data, but the rate of (joint damage) appears slightly higher than that of Pfizer/Lilly's tanezumab," Piper Jaffray analyst Christopher Raymond said in a report to clients.

But investors were enthused. On the stock market today, Teva stock popped 7.3%, to 24.11. Regeneron stock lifted 2.7%, to 371.78. Shares of Dow Jones component Pfizer rose 0.6%, to 41.42, while Lilly climbed 1%, to 104.36.

Opioid Epidemic Impact

Fasinumab hit all its key goals in the study, Teva and Regeneron said in a news release. Patients treated with fasinumab experienced less pain and improved physical function at week 16 vs. their baselines than those who received a placebo.

Regeneron President and Chief Scientific Officer George Yancopoulos noted that patients with chronic pain due to osteoarthritis in the hip and knee tend to have "limited therapeutic choices" outside of nonsteroidal anti-inflammatory drugs or opioids.

That's why the market for anti-NGF drugs could be huge, Piper Jaffray's Raymond said. In 2017, the Department of Health and Human Services declared the opioid epidemic a public health emergency as a growing number of patients overdose.

Anti-NGF Drugs

But anti-NGF drugs are associated with joint damage, also known as rapidly progressive osteoarthritis, analysts say. The extent of that joint damage is key, Evercore analyst Umer Raffat said in his note to clients.

Type 1 damage is less severe and involves more than 1 millimeter of narrowing in joint space over the course of a year. Type 2 is permanent and typically involves greater than 50%, or 2 millimeters, of narrowing in joint space in a year.

In Teva and Regeneron's study, about 65% of patients completed a radiograph assessment for joint damage at week 24. Of those, about 2% showed evidence of some damage. But the companies say the majority of the damage was Type 1.

Long-Term Data Needed

Pfizer and Lilly, on the other hand, said less than 1.5% of patients treated with tanezumab experienced joint damage. The same effect wasn't evident in the placebo-treated patients at week 16. But the duo didn't outline which type of damage occurred.

"So here's what we really need: longer-term data," Raffat said. He also noted that, over time, joint damage could become more severe in patients treated with fasinumab or tanezumab. The 52-week data from Teva and Regeneron's fasinumab will be key, he said.

Piper Jaffray's Raymond remained bullish on fasinumab.

"This is just a preliminary safety read, and as the safety profile for the class and fasinumab comes into focus as the Phase 3 program proceeds, we continue to see the market for an effective, non-opioid chronic pain therapy as massive," he said.

YOU MIGHT ALSO LIKE:

How Much Money Do You Need To Start Investing?

How To Trade Stocks: Why Most Penny Stocks Fail To Make Investors Rich

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The post Can This Drug Class Conquer Joint Damage And Oust Opioids? appeared first on Investor's Business Daily.


21. Teva Pharma Approved To Make Generic Version Of Mylan's EpiPenЧт., 16 авг.[−]

The Food and Drug Administration on Thursday granted approval for Teva Pharmaceutical ( TEVA) to make the first generic version of Mylan's ( MYL) EpiPen, prompting Teva shares to pop in high volume.

X

The FDA will allow Teva to make generic epinephrine auto-injectors at 0.3 milligrams and 0.15 milligrams, the agency said in a news release. These are copies of what Mylan calls EpiPen and EpiPen Jr.

On the stock market today, Teva stock jumped 7.3%, to 24.11. Teva also benefited from a positive study with Regeneron Pharmaceuticals ( REGN) of a chronic pain drug. At the same time, Mylan stock rose 0.1%, to 37.85.

"Today's approval of the first generic version of the most-widely prescribed auto-injector in the U.S. is part of our long-standing commitment to advance access to lower cost, safe and effective generic alternatives once patients and other exclusivities no longer prevent approval," FDA Commissioner Scott Gottlieb said in a written statement.

EpiPen is an auto-injector used to treat emergency allergic reactions. Mylan acquired and began selling EpiPen in 2007. Since 2009, it's fought off an attempt by Teva to make a generic copy. Thursday's approval is the first generic EpiPen by an outsider to pass muster.

Generic EpiPen Approved

The generic EpiPen comes as Mylan faces a mounting list of challenges surrounding the branded drug. In the second quarter, Mylan's North American sales declined 22% to $1 billion as it sold fewer drugs, including EpiPen.

Also, earlier this month, Mylan said its manufacturing partner Pfizer ( PFE) is facing interruptions in production of EpiPen and EpiPen Jr. This has led to shortages of EpiPens at wholesalers and pharmacies for several months.

Meanwhile, pricing scrutiny has come down hard on Mylan. In 2016, that scrutiny hit a fever pitch as reports emerged that the price of an EpiPen two-pack had soared more than 500% since 2007. In response, Mylan launched its own lower-cost authorized generic EpiPen.

Teva Vs. Mylan

Mylan itself is a generic drugmaker. In terms of market cap, it's second only to Teva. Teva has a market cap north of $24 billion, while Mylan is worth more than $19 billion. But the two have a history of undercutting one another's branded drugs with generic knockoffs.

Most recently, Mylan gained approval in October 2017 to make a generic version of Teva's multiple sclerosis drug Copaxone. The smaller firm is allowed to market a 40-milligram, three times weekly copy and a daily version at 20 milligrams.

As a result, North American sales of Teva's Copaxone toppled 46% year over year to $464 million in the second quarter. The drugmaker cited generic competition in the U.S. for its decline.

YOU MIGHT ALSO LIKE:

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

Investing Basics: How To Sell A Stock

The post Teva Pharma Approved To Make Generic Version Of Mylan's EpiPen appeared first on Investor's Business Daily.


22. This Biotech Is Aiming To Help Overcome Public-Speaking FearsЧт., 16 авг.[−]

Biohaven Pharmaceutical ( BHVN) stock jumped 6% on Thursday after its anti-anxiety treatment showed promise in patients tasked with public speaking.

X

The drug, known by the test name as BHV-0223, improved anxiety compared with a placebo in patients previously diagnosed with social anxiety disorder and public speaking anxiety. Biohaven is working with the Yale University School of Medicine to develop the drug.

Based on the results, Biohaven said it will also work on developing a treatment for general anxiety disorder. The firm is looking to target a chemical called glutamate and a receptor. It has several potential drugs for neurologic and neuropsychiatric disorders.

The findings "suggest the therapeutic potential of glutamate modulation in the treatment of anxiety disorders," Michael Bloch, a Yale University School of Medicine spokesperson, said in a written statement.

Public Speaking Fear

Researchers studied 21 people with diagnosed anxiety disorders. They tasked participants with performing a 10-minute anxiety-provoking public speaking task an hour after receiving either BHV-0223 or a placebo.

On a 100-point scale, BHV-0223 reduced anxiety by 8.3 points in drug-treated patients vs. those who received the placebo. Relative to patients' own speech baselines, BHV-0223 had a 14.4-point advantage over the placebo.

"Approximately 20% of Americans have experienced an anxiety disorder in the past year but many current treatments are encumbered by side effects including sedation, cognitive impairment and potential for addiction," Biohaven Chief Executive Vlad Coric said in a written statement.

On the stock market today, Biohaven stock lifted 6%, near to 35.10.

YOU MIGHT ALSO LIKE:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

How To Trade Stocks: Why Most Penny Stocks Fail To Make Investors Rich

The post This Biotech Is Aiming To Help Overcome Public-Speaking Fears appeared first on Investor's Business Daily.


23. Best Buy Purchase Of GreatCall Deemed Good CallЧт., 16 авг.[−]

Wall Street is giving consumer electronics retailer Best Buy ( BBY) a thumbs-up for its purchase of connected health services provider GreatCall.

X

Best Buy announced late Wednesday that it is buying GreatCall for $800 million in cash. The deal will strengthen the retailer's services and allow it to address the growing needs of the aging population.

San Diego-based GreatCall sells easy-to-use mobile products and connected devices tailored for aging consumers. It has more than 900,000 paying subscribers for emergency response and concierge services. It makes Jitterbug mobile phones and Lively wearable devices.

GreatCall is profitable and has annual revenue of over $300 million, GreatCall Chief Executive David Inns said in a written statement. The combination with Best Buy will enable GreatCall to expand its reach and scale, he said.

Best Buy's Biggest Acquisition

The acquisition meets Best Buy's goal of growing its health- and wellness-related products and services, the company said. The transaction is the largest in the retailer's history. Best Buy expects to close the deal in its fiscal third quarter, which ends in October.

Richfield, Minn.-based Best Buy believes the acquisition will be neutral to adjusted earnings this year and next and be accretive the following year.

"We know technology can improve the quality of life of the aging population and those who care for them," Best Buy Chief Executive Hubert Joly said in a news release. "Now, we have a great opportunity to serve the needs of these customers by combining GreatCall's expertise with Best Buy's unique merchandising, marketing, sales and services capabilities."

Morgan Stanley analyst Simeon Gutman looked favorably on the acquisition.

"We view it positively given its long-term growth prospects and potential synergies," he said in a report to clients.

Best Buy already has a foothold in the connected health market through its Assured Living safety monitoring service, Gutman said.

Getting The Jump On Amazon, Google

"The acquisition of GreatCall potentially establishes Best Buy as a leader in this growing space," he said. It also gives the company a first-mover advantage in a segment that Amazon ( AMZN) and Alphabet's ( GOOGL) Google might pursue over time, Gutman said.

"This deal has strategic merit," UBS analyst Michael Lasser said in a report. "While Best Buy currently sells GreatCall's hardware, we think it could use its physical footprint and omnichannel reach to further penetrate this space."

There are 50 million Americans age 65 and up, so GreatCall now reaches less than 2% of its addressable market, Lasser said.

GreatCall also has a growing business-to-business segment that places sensors in the rooms of nursing homes and facilities. Those sensors can monitor behavior and alert nurses if conditions change, he said.

Best Buy shares rose 0.7% to close at 76.91 on the stock market today.

RELATED:

Best Buy Stock Gaps Down On Weak Outlook Despite Strong Earnings

The post Best Buy Purchase Of GreatCall Deemed Good Call appeared first on Investor's Business Daily.


24. Wall Street Bets On Biotech IPOs Amid 'Science Fiction' FrenzyЧт., 16 авг.[−]

The first seven months of 2018 saw 38 biotech companies file initial public offerings — bullishly outpacing last year amid improved sentiment for the sector.

X

Medical advancements from these companies are starting to sound like something out of "Frankenstein." Life sciences firms, including biotech companies, are working on futuristic solutions to disease, like 3D printed organs and organs-on-a-chip.

There are biotech companies like Rubius Therapeutics ( RUBY), which is looking to marry red blood cells and genetic engineering. Others like Neon Therapeutics ( NTGN) and Forty Seven ( FTSV) are jumping on the immuno-oncology boat popularized by Merck ( MRK) and Bristol-Myers Squibb ( BMY).

And Wall Street brokers are lining up to open their coffers, said Steve London, a partner in the health sciences department at law firm Pepper Hamilton. London helps life-science companies navigate various phases including startup through IPO and beyond.

"It's so exciting to see this," London told Investor's Business Daily. "It does sound like science fiction, but I am absolutely certain (the advancements) will happen. The only question is how long will it take? And that's where Wall Street starts making its bets."

Four Dozen IPOs

During the first days of August, several more biotech companies filed IPOs, bringing the 2018 total to nearly four dozen, said Matt Kennedy, a senior IPO market strategist for Renaissance Capital. Renaissance Capital manages exchange traded funds that focus on recent IPOs.

To compare, in the first seven months of 2017 there were 21 biotech companies that filed IPOs, he told IBD. In the first seven months of 2018, the number of IPOs from biotech companies grew 81% vs. the prior year.

"So biotech activity has increased faster than the overall IPO market," he said.

According to Capital Renaissance's second-quarter report, a third of all IPOs came from biotech companies. IPOs in the broader technology sector raised the most proceeds, averaging a "stellar" 61% return. That boosted the quarterly average gain to 29%.

Returns haven't been as robust from biotech companies, however. So far this year, they've had a 12% return from the offer price to the close on July 31, Kennedy told IBD. That compares with 59% returns for those that filed IPOs in 2017, and an even better 89% return in 2016.

"(Biotechs) have traded pretty well on their first day with a little over 14% on the first day and then an average of minus 3% after that," he said. "That makes sense. For some of these companies, they are perceived as being hotter, then sentiment changes and they become more sensitive."

Politics, Trump And Biotechs

Shares of biotech companies tend to be tricky and are particularly susceptible to political winds. Year to date, the overall sector's stocks are up north of 8%. The industry group is ranked No. 42 out of 197 groups IBD tracks. But that's down from the fifth-place slot just 26 weeks ago.

And now the midterm elections are looming. Further, President Donald Trump has reiterated his goal to bring down drug prices. Uncertainty about government policy can be "very damaging" to life-science companies' stocks, Pepper Hamilton's London said.

"Now we're looking out toward the midterm elections and what might happen," he said. "Will health care policy be revisited? Will there be some sort of push to address drug prices? Will there be a faster FDA review period or slower as a result of the elections?"

All said, it's better to get in now — while they can, said James Nolan, a partner at Velocity Fund Partners. Velocity is a private equity firm focused on life sciences and health care services.

Open Market For Biotech Companies

Right now, the market is open to IPOs, Nolan told IBD. That allows biotech companies to create full platforms for developing a multitude of drugs.

Maybe they'll be acquired in the future, but it's not necessary right off the bat. These companies have time to grow their valuations.

Biotech companies operating in a closed market don't have that option. They generally develop a single product before selling to Big Pharma. Under those circumstances, their valuations tend to be much lower — as are the returns for private investors.

"When you don't have an IPO market, you're forced to develop one thing," he said. "And that's when you flip it. So when you have this opening in the IPO market, you move and you move quickly because it fluctuates."

Scientific Advancements Abound

There's no telling when the cycle could shift, Nolan said. A tweet from Trump, poor clinical results or general market malaise could prevent biotech companies from filing IPOs. On the flip side, strong clinical results or easing legislative pressure could boost the sector.

Nolan noted news from Biogen ( BIIB) and Japanese pharma Eisai recently on an Alzheimer's disease study. Biogen stock rocketed nearly 20% in a day on top-line results. But shares crashed 10% later in the month when the biotech offered a deeper look at the results.

But that doesn't change the fact that Biogen's news got "everyone looking" at biotech companies, Nolan said. "It was enormous. That gets people to recognize that new products that are innovative will have the best returns on the planet."

Sometimes the products are so interesting they've prompted "crossover investors," said Pepper Hamilton's London. So-called crossover investors take a position in the last private round before also jumping in during the IPO.

Acquisition: The End-All Goal?

That could be due to the publicity surrounding these biotech companies, he said. CRISPR gene editing is no longer theoretical. Three companies are soon to begin clinical studies in humans. Immuno-oncology drugs are getting robust responses in lung cancer and melanoma.

Investors definitely want a piece of the action, London said. The riskiest part is deciding which biotech companies deserve the attention. He suggested weeding out potential duds by focusing on those that have clinical study results. In biotechnology, not all companies do.

"If it's a drug, you have to look at where it is in the clinical trial process," he said. "What are the results of those trials? How close are they to getting their (investigational new drug application) approved?"

And, of course: Is this a takeover candidate?

"Investors in these kinds of biotech companies that have no drug or product on the market are betting one of the big players will come in and buy the company out before commercialization," he said. "That's the near-term horizon of what investors should be looking for."

YOU MAY ALSO LIKE:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

Long-Term Retirement Investing Strategies With ETFs

The post Wall Street Bets On Biotech IPOs Amid 'Science Fiction' Frenzy appeared first on Investor's Business Daily.


25. Amazon (AMZN) Stock Quotes, Company News And Chart AnalysisЧт., 16 авг.[−]
X


View AMZN Stock Quote Page
| View AMZN Ratings

Amazon Stock News & Analysis

Which Stocks Make This List Of The Fastest-Growing Companies?What do Amazon.com, Paycom Software and Palo Alto Networks have in common with Tabula Rasa Healthcare, ServiceNow and RingCentral? They've all earned a spot on the latest list of today's fastest-growing companies. The biggest stock market... Read More
Why Amazon Could Soon Join 3 Hot IBD 50 Growth Stocks In This Rare Bullish PatternAmazon.com could soon join hot IBD 50 growth stocks Planet Fitness, Idexx Laboratories and Atlassian in forming a rare bullish chart pattern: the ascending base. Amazon stock is extended 20% from a cup-with-handle... Read More
Amazon Blockbuster Industry Buzz Lifts These StocksTheater stocks mostly rallied Thursday on news that Amazon is in talks to buy Mark Cuban's Landmark Theatres chain. The online shopping giant is one several suitors in talks to acquire Landmark from... Read More
Amazon Stock Positioned To Follow Apple As Next To Hit $1 Trillion CapWith Amazon stock up 61% this year and near a record high, the e-commerce giant is on track to become the second company to exceed the $1 trillion market cap milestone, following... Read More
Retail Sales Strong In July Amid Amazon Prime DayRetail sales rose 0.5% in July, the Commerce Department reported Wednesday. Outside of autos, retail sales grew 0.6%, on a month highlighted by the record-breaking Amazon Prime Day and matching sales across... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Amazon (AMZN) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


26. AI News: Artificial Intelligence Trends And Leading StocksЧт., 16 авг.[−]

Investors beware: there's plenty of buzz around artificial intelligence (AI) as more and more companies say they're using it. In some cases, companies are using older data analytics tools and labeling it as AI for a public relations boost. But identifying companies actually getting material revenue growth from AI can be tricky.

X AI uses computer algorithms to replicate the human ability to learn and make predictions. AI software needs computing power to find patterns and make inferences from large quantities of data. The two most common types of AI tools are called "machine learning" and "deep learning networks."

Nvidia ( NVDA) is one company that can lay claim to AI-driven growth. Internet and tech companies buy its processors for cloud computing. Nvidia's AI chips also are helping guide some self-driving cars in early trials.

Startups are racing to build AI chips for data centers, robotics, smartphones, drones and other devices. Tech giants Apple ( AAPL), Google-parent Alphabet ( GOOGL), Facebook ( FB) and Microsoft ( MSFT) have forged ahead in applying AI software to speech recognition, internet search, and classifying images. Amazon.com's AI prowess spans cloud-computing services and voice-activated home digital assistants.

Then, there are tech companies that embed AI tools in their own products to make them better. Those include video streamer Netflix ( NFLX), payment processor PayPal ( PYPL), Salesforce.com ( CRM) and Facebook.

Customers of tech companies — spanning banks and finance, health care, energy, retail, agriculture and other sectors — are expected to increase spending on AI to get productivity gains or a strategic edge on rivals.

Bookmark this page to stay on top of the latest AI trends and developments.

Artificial Intelligence News

Which Stocks Make This List Of The Fastest-Growing Companies?What do Amazon.com, Paycom Software and Palo Alto Networks have in common with Tabula Rasa Healthcare, ServiceNow and RingCentral? They've all earned a spot on the latest list of today's fastest-growing companies. The biggest stock market... Read More
Nvidia Upgraded To Buy; Micron Technology Gets Price-Target CutA Wall Street analyst on Wednesday upgraded graphics-chip maker Nvidia one day before its earnings report, and cut his price target on memory-chip maker Micron Technology. Wells Fargo analyst Aaron Rakers turned... Read More
AI Companies Race To Get Upper Hand In Cybersecurity — Before Hackers DoArtificial intelligence, for all its mind-boggling potential, is a double-edged sword. Sure, AI might save lives through early cancer or heart disease detection. In cybersecurity, though, even AI companies worry that the... Read More
What To Expect When Snap Reports Quarterly EarningsSnap reports second-quarter earnings after the market close Tuesday, as the social networking company faces a challenging time. The company replaced its chief financial officer in May with a 20-year veteran from... Read More
FANG Stocks: Investors Look For Next Alpha Wolf To Lead PackThe second-quarter earnings season has shaken up the big internet companies that make up the FANG stocks — Facebook, Amazon.com, Netflix and Google-parent Alphabet — and the Street is wondering which will be... Read More
How Boeing Could Use Blockchain To Manage, Track DronesAs regulators grow more concerned about integrating drones into air traffic control, Boeing thinks blockchain and artificial intelligence can offer a solution. At the Farnborough Airshow on Tuesday, Boeing announced that it's creating... Read More
After Big Gap Up, This IoT Stock May Launch Another BreakoutWhat do 78 of the Fortune 100 companies and 24 of the top 25 tech titans have in common? They're all customers of electronic measuring and Internet of Things (IoT) stock Keysight Technologies.... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

RELATED:

Technology Stocks And Related News

Looking For The Next Nvidia? Start With This Simple Investing Routine

The post AI News: Artificial Intelligence Trends And Leading Stocks appeared first on Investor's Business Daily.


27. Cisco Stock Touches A Buy Point As Earnings, Guidance Beat ViewsЧт., 16 авг.[−]

Cisco Systems ( CSCO) stock neared a buy range in late trading Wednesday after the computer networking giant reported fiscal fourth-quarter earnings and revenue that topped views and forecast October-quarter revenue above estimates.

X

Shares in the maker of computer networking gear and security software popped 6% to 46.50 in after-hours trading on the stock market today. Shares inched past a buy point of 46.47. Cisco stock had dropped 0.3% to 43.86 in Wednesday's regular session.

Cisco stock is up nearly 37% from a year ago. Shares in the company had weakened since May 10.

Cisco said adjusted earnings were 70 cents, up 15% from a year ago, with revenue rising 6% to $12.8 billion, topping analyst forecasts.

Cisco Shifting To Software, Services

A year earlier, Cisco earned 61 cents a share on sales of $12.13 billion. Analysts expected Cisco to report earnings of 69 cents on sales of $12.77 billion for the period ended July 31.

For the October quarter, Cisco said it expects adjusted profit of 71 cents vs. estimates of 69 cents. Cisco forecast top-line growth of 6%. Analysts had projected 4% growth.

Cisco is shifting away from its core business of selling network switches and routers. With acquisitions, Cisco aims to increase revenue from software and services.

"Our results demonstrate a combination of strong customer adoption of our latest innovations, the ongoing value customers see in our software and subscription offerings, and excellent execution across our customer segments and geographies," CEO Chuck Robbins said in a release.

Nineteen out of Cisco's last 20 acquisitions have been software related. In July, Cisco acquired Duo Security for $2.35 billion, marking its biggest cybersecurity acquisition since its purchase of Sourcefire.

YOU MAY ALSO LIKE:

After Hours: Dow Tech Giant Soars To Buy Zone On Earnings

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The post Cisco Stock Touches A Buy Point As Earnings, Guidance Beat Views appeared first on Investor's Business Daily.


28. With China Stocks Faltering, JD.com Next Up To Report EarningsЧт., 16 авг.[−]

With China stocks down sharply in the past two days, one of the largest internet companies in that country, JD.com ( JD), is set to report quarterly results Thursday morning.

X

JD.com follows the earnings report of Tencent Holdings ( TCEHY), which came before Wednesday's open. Tencent, also one of China's largest internet companies, surprised analysts when it missed expectations in a few key areas. China internet stocks were down across the board Tuesday and Wednesday.

On Monday, internet streaming service providers YY ( YY) and Huya ( HUYA) also reported earnings that presented a weaker-than-expected outlook for the third quarter. The lowered outlook came as retail sales in China for July slowed further.

Other economic indicators were softer than expected. China internet stocks plunged across the board Tuesday, with the losses extending into Wednesday.

Whether the dive in China stocks continues Thursday could depend on what JD.com reports and what it has to say.

E-Commerce Giant

JD.com is one of the largest e-commerce companies in China, along with Alibaba ( BABA).

Analysts expect JD.com to report revenue of $17.8 billion, up 30% from the year-ago period. The forecast on adjusted earnings is 10 cents a share, the same as the year-ago quarter.

JD.com fell short of estimates when it reported first-quarter results three months ago. JD.com stock received several price target cuts as a result.

Overall, stocks closed sharply lower Wednesday, despite some strong early economic data, as tariffs imposed on U.S. goods by Turkey triggered selling across global markets.

YOU MIGHT ALSO LIKE:

China Internet Stocks Fall On Quarterly Earnings, Disappointing Data

Trade-War Turmoil Hits Top Chinese Internet Stocks As Alibaba Falls

Partner Of Alibaba, JD Soars On First-Quarter Earnings Beat

The post With China Stocks Faltering, JD.com Next Up To Report Earnings appeared first on Investor's Business Daily.


29. Pandora, Live Nation, Customer Service Don't Help T-Mobile StockСр., 15 авг.[−]

T-Mobile US ( TMUS) on Wednesday announced new partnerships with music streaming service Pandora Media ( P) and Live Nation Entertainment ( LYV) while also launching a new initiative to improve customer service.

X

T-Mobile stock didn't get a boost from the company's latest "Uncarrier" announcement. Shares in T-Mobile dipped 0.8% to close at 65.41 amid a broad market sell-off. Some analysts had speculated that T-Mobile could make an announcement related to live-TV streaming.

Shares in Live Nation, an event organizer and ticket distributor, were down 1.4% to 48.49 on the stock market today. Pandora stock slipped a fraction to 8.01.

T-Mobile's announcements come amid the regulatory review of its proposed merger with debt-laden Sprint ( S). Japan-based SoftBank ( SFTBY) controls Sprint while Germany's Deutsche Telekom ( DTEGY) owns T-Mobile.

One big hurdle to approval is that a T-Mobile merger with Sprint would reduce the number of national wireless firms to three from four. Regulators blocked AT&T's acquisition of T-Mobile in 2011 on grounds that it would hurt competition.

Uncarrier Brand Drives Growth

A resurgent T-Mobile has taken revenue and subscriber market share since 2014, owing to its "Uncarrier"-branded marketing campaign and price discounts. The Uncarrier promotions are aimed at setting T-Mobile apart from bigger rivals AT&T ( T) and Verizon Communications ( VZ).

T-Mobile said its improved customer service will set itself apart from AT&T, Verizon and cable TV firms Comcast ( CMCSA) and Charter Communications ( CHTR). T-Mobile said it will rely less on automated "chatbots" and more on live experts to handle customer service.

YOU MAY ALSO LIKE:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Pandora, Live Nation, Customer Service Don't Help T-Mobile Stock appeared first on Investor's Business Daily.


30. China Internet Stocks Hammered As Tencent Earnings Show Surprise MissСр., 15 авг.[−]

China internet stocks took another hammering for the second straight day Wednesday as one of the nation's largest companies, Tencent Holdings ( TCEHY), reported quarterly results that fell short in some key areas.

X

Shares of Tencent closed at 41.25. down 6.7% on the stock market today. The stock is down 32% since hitting a record high of 61 on Jan. 6.

The leader in gaming and messaging services in China reported second-quarter net income of 17.9 billion yuan, or $2.6 billion. That's down 2% from the year-ago period and missed analyst forecasts of 19.3 billion yuan. Online ad sales also missed Wall Street predictions. Revenue rose 30% from the year-ago period and missed views.

The Tencent earnings report, which came before the market open Wednesday, follows that of two other China internet companies, YY ( YY) and Huya ( HUYA). The two providers of internet livestreaming services reported results late Monday.

YY and Huya both suffered double-digit percentage losses Tuesday. The two reported quarterly earnings that presented a weaker-than-expected outlook for the third quarter. The lowered outlook came as retail sales in China for July slowed further. Other economic indicators were softer than expected. China internet stocks plunged across the board Tuesday, with the losses extending into Wednesday.

On Wednesday, Huya stock closed at 25.83. down 6.4%. YY closed at 73.40, down a shade under 3%.

Alibaba, JD.com Down

Alibaba ( BABA), the largest internet company in China, skidded 1.6%, closing at 169.83. JD.com. ( JD), also a leading e-commerce company, fell 4.5%, closing at 32.36.

Among other China internet stocks, Momo ( MOMO) gave back 2.1%. Baozun ( BZUN) lost 3%. Weibo ( WB) fell 3.7%. Sina ( SINA) fell 2.1%.

Overall, stocks opened sharply lower Wednesday, despite some strong early economic data, as tariffs imposed on U.S. goods by Turkey triggered selling across global markets.

YOU MIGHT ALSO LIKE:

Sina Stock Takes A Tumble Despite Quarterly Earnings Beat

Weibo Stock Wavers Despite Earnings Beat, Growing User Base

Best Chinese Stocks To Buy And Watch

These Tech Unicorn IPOs On Horizon — Are They Good Investments?

The post China Internet Stocks Hammered As Tencent Earnings Show Surprise Miss appeared first on Investor's Business Daily.


31. Gilead Skids On HIV Rivalry As Second Exec In A Month Plans ExitСр., 15 авг.[−]

Gilead Sciences ( GILD) toppled Wednesday after rival GlaxoSmithKline ( GSK) reported positive results for its HIV treatment and following Gilead's announcement that a key executive will depart next month.

X

On the stock market today, Gilead stock dropped 3.2%, to 74.84. Shares of Glaxo lifted 1.7%, to 40.46. Meanwhile, other biotech stocks lost north of 1.5%.

RBC Capital Markets analyst Brian Abrahams noted Gilead stock fell slightly more than other large-cap biotech stocks, but he doesn't see a "major fundamental concern." Abrahams remains bullish on the long-term prospects for Gilead's HIV drug business and overall operations.

Doctors tend to view Glaxo's treatment as applicable to a niche population of patients, he said in a note. The drugmaker developed a two-drug regimen as a once-monthly injection. It compared the experimental treatment to a daily, three-drug, oral regimen.

"The consistent feedback we received is that it could be used in a select number of patients — particularly those with compliance issues or who dislike the stigma of a daily pill," he said. "As a high volume intramuscular injection every month, it would have much more of a niche role."

Glaxo's HIV Treatment

Glaxo switched patients whose virus was suppressed for six months to its regimen. The injectable regimen wasn't inferior to the standard of care at week 48, Glaxo said in a news release. This could be competitive with Gilead, which makes 11 treatments for HIV/AIDS.

RBC's Abrahams notes it's not surprising Glaxo's HIV treatment proved successful. But a subcutaneous injection — as opposed to an intramuscular injection — given every three to six months would be more disruptive to the market, he said.

"As such, though we are watching injectables (including Gilead's) to see if their profiles improve to potentially enable broader adoption, at this point we do not see major impact on Gilead's HIV franchise near- or long-term," he said.

Chief Medical Officer Departs

Gilead also announced late Tuesday that Chief Medical Officer Andrew Cheng will depart to pursue another opportunity. Cheng joined Gilead in 1999 to lead the development of HIV/AIDS drugs. He was appointed chief medical officer in March.

Cheng will remain with the firm until Sept. 7 to help with the transition. Meanwhile, Gregg Alton, a nearly 20-year veteran of Gilead, will become the chief patient officer. The firm also promoted Diana Brainard, who joined in 2010, to senior vice president of HIV and emerging viral infections.

The news of Cheng's looming departure comes less than a month after the biotech announced Chief Executive John Milligan will step down at the end of the year. But Gilead says the two departures are not related, RBC's Abrahams said.

"So we do not see this reflecting any major structural issue — which we believe had been a concern," he said. "We note Gilead has a very experienced Chief Scientific Officer John Hutchinson and additional depth."

YOU MIGHT ALSO LIKE:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

Investing Basics: How To Sell A Stock

The post Gilead Skids On HIV Rivalry As Second Exec In A Month Plans Exit appeared first on Investor's Business Daily.


32. Amazon Stock Positioned To Follow Apple As Next To Hit $1 Trillion CapСр., 15 авг.[−]

With Amazon stock up 61% this year and near a record high, the e-commerce giant is on track to become the second company to exceed the $1 trillion market cap milestone, following the recent trail of Apple ( AAPL).

X

Analyst Brian White at Monness Crespi Hardt said in a note to clients Wednesday that he expects Amazon ( AMZN) to hit the $1 trillion mark by the end of this year. Apple reached the threshold two weeks ago.

The current market valuation of Amazon is $921 billion. White thinks Amazon will achieve it based partly on the strength of its cloud-computing unit, Amazon Web Services.

"As the No. 1 public cloud vendor in the world and enterprises feverishly shifting workloads into the cloud this year, AWS has shined with the highest growth rate among Amazon's three major business segments," White wrote.

He expects AWS to reach $25.5 billion in revenue this year, up 46% from the year-ago period.

Opportunities For Amazon

Last week, White noted, Samsung Heavy Industries selected AWS as its preferred cloud provider to support the company's digital transformation initiatives. Moreover, the Pentagon has a $10 billion, 10-year, Joint Enterprise Defense Infrastructure cloud contract in the offing, with a single cloud provider expected to be chosen. Amazon is said to be in the lead for that contract.

White thinks Amazon can also grab the $1 trillion badge on the strength of advertising, which remains "a significant, long-term opportunity for the company."

Amazon shares closed at 1882.62, down 1.9% on the stock market today. Amazon stock on Monday hit a record high of 1,925.

Last month, Amazon blew past earnings estimates with second-quarter results. It delivered $5.07 per share, which was double what analysts expected. The strong profitability outplayed any concern that revenue missed estimates, as did its third-quarter outlook. Revenue rose 39% to $52.9 billion. That missed estimates for $53.4 billion.

Following the quarterly results, multiple analysts raised their estimates on Amazon stock.

YOU MIGHT ALSO LIKE:

Apple Could Reach $2 Trillion Market Cap With AR Glasses, Car

Amazon Stock Quotes, Company News And Chart Analysis

FANG Stocks News & Quotes: Facebook, Amazon, Netflix, Google

Amazon's Alexa Is Shifting From A Clever Gadget To A Money-Making Machine

The post Amazon Stock Positioned To Follow Apple As Next To Hit $1 Trillion Cap appeared first on Investor's Business Daily.


33. Cabot Microelectronics Stock Falls As Investors Mull KMG AcquisitionСр., 15 авг.[−]

Shares in Cabot Microelecronics ( CCMP) fell Wednesday after the maker of specialty chemicals used in semiconductor manufacturing said it would buy KMG Chemicals ( KMG) for about $1.6 billion, including debt.

X

Cabot Microelectronics stock toppled 9.4% to close at 109.99 on the stock market today. The stock has gained 61% from a year ago, including Wednesday's sell-off.

While KMG sells products related to Cabot Microelectronics' semiconductor business, it recently made an acquisition seeking growth in the energy business. KMG in April 2017 acquired Flowchem, a maker of pipeline performance products, for $495 million from Arsenal Capital Partners.

Cabot Microelectronics is the leading maker of chemical slurries used in chip manufacturing.

How KMG Fits Into Cabot Business

"Semiconductor materials players can be easily overlooked," said Michael Harrison, analyst at Seaport Global Securities. "They're a key enabler in the advancement of semiconductor technology. And, materials is a much more steady business than capital equipment."

Harrison says KMG's electronics chemical business has ties to Cabot Microelectronics's chip business. KMG garners two-thirds of sales and half its annual EBITDA — earnings before interest, taxes, depreciation and amortization — from the electronic chemicals unit.

"(Pipeline) performance materials is very different from anything Cabot currently does," he added.

The market for KMG's drag-reducing agents used in pipelines is about $400 million globally, says Harrison. Lubrizol has about 70% market share, followed by Flowchem at 20%.

Cabot Microelectronics' earnings accelerated, growing 18%, 29%, 57% and 69% over the past four quarters. The company has focused on semiconductor production that requires high-end materials, boosting profits.

Cabot Leads In Slurries

Chipmaking equipment cleans, smooths, bakes, chemically coats and etches electrical pathways in ultrathin silicon wafers. Cabot Microelectronics' products polish and flatten the surfaces of silicon wafers that are cut into electronic chips.

The chip industry calls the process chemical-mechanical planarization, or CMP. The most advanced memory chips and brainy microprocessors require more CMP steps per wafer, says Diane Scott, analyst at Techcet, a market research firm and consultancy.

According to Techcet, the slurry and pad segment of the CMP consumables market will reach $3.12 billion in 2022, up from $2.53 billion in 2018. Cabot holds more than 30% of the worldwide slurry market.

Chipmakers are shifting to new 3D scaling production technologies for memory and logic devices. A 3D Nand memory chip requires about 15 to 16 CMP steps, twice the number of other memory devices, says Cabot.

Aurora, Ill.-based Cabot Microelectronics is the chip industry's biggest provider of chemical slurries, composed of tungsten and other metals. Its largest customers are Samsung, Taiwan Semiconductor Manufacturing ( TSM) and Micron Technology ( MU).

In Pads, Cabot No. 2 Behind Dow

Cabot is also the second biggest maker of polishing pads, behind DowDuPont ( DWDP). Cabot moved into the pad market by acquiring NexPlanar in 2015.

"Moving into pads was very logical," said Harrison. "If you make toothpaste, it's very logical to get into toothbrushes."

Cabot churned out $120 million in free cash flow in 2017 and has a strong balance sheet. Aside from the NexPlanar deal in 2015, Cabot purchased Epoch Material in 2009 and QED Technologies in 2006.

YOU MAY ALSO LIKE:

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Cabot Microelectronics Stock Falls As Investors Mull KMG Acquisition appeared first on Investor's Business Daily.


34. Is This 'As Good As It Gets' For This Biotech's Breast Cancer Drug?Ср., 15 авг.[−]

Puma Biotechnology ( PBYI) sank Wednesday as an analyst suggested this could be "as good as it gets" for sales of the company's breast cancer drug Nerlynx.

X

During the second quarter, Nerlynx brought in $50.8 million in sales. That beat the Street view for $46 million, RBC Capital Markets analyst Kennen MacKay said in a report. But the label only suggests patients take Nerlynx for a year.

Given the breast cancer drug was approved in July 2017, it's possible patients could begin to drop off in the third quarter, MacKay said. Puma argues it's possible patients will continue, but out of 33 patients taking Nerlynx in July 2017, only five active patients remained this July.

"What if this is as good as it gets?" MacKay asked in a report. "Nerlynx could see plateau or decline as soon as (the second half of 2018) with one-year treatment duration."

In response, Puma stock toppled 5.4% to close at 42.45, on the stock market today. Broadly, biotech stocks dipped more than 1.5%.

Following Herceptin's Example?

Nerlynx is currently approved to treat some breast cancer patients who've already used trastuzumab-based adjuvant therapy. Trastuzumab is sold by Roche ( RHHBY), under the brand name Herceptin. Adjuvant therapy follows the main treatment to keep cancer at bay.

The National Comprehensive Cancer Network doesn't recommend extending adjuvant therapy beyond one year in breast cancer. In fact, the instructions for Herceptin only allow patients to receive it for 52 weeks as an adjuvant treatment.

It's likely Nerlynx will face a similar dilemma based on its label recommendation for one year of treatment, MacKay says. Though he does offer a caveat: At the one-year mark, those taking Nerlynx are likely past the worst of diarrhea as a side effect.

"So there is low burden on the patient to continue given the convenience of oral dosing and lack of safety concerns," he said.

Can Nerlynx Accelerate?

There were 2,076 patients actively taking the breast cancer drug in July, MacKay said. But new patient enrollment is slowing. In April — the latest month for which there was data — 280 new patients began taking Nerlynx. That declined 18.1% month over month.

April was also the first month in seven in which new patient enrollment dipped below 300.

"The Nerlynx launch is seeing steady growth, but limited acceleration," he said. "We see acceleration of Nerlynx growth as critical to maintain growth beyond the anticipated growth slowing in (the third quarter) due to patients beginning to stop treatment."

Patients discontinuing use after one year will complicate predicting future sales from the breast cancer drug, he said. But shifts in commercial strategy, improvements in side effects, changes to guidelines or changes in pricing/reimbursement could help Puma.

YOU MIGHT ALSO LIKE:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

How To Tame A Volatile Swing Trade With A Half Position

Looking For The Next Nvidia? Start With This Simple Routine

The post Is This 'As Good As It Gets' For This Biotech's Breast Cancer Drug? appeared first on Investor's Business Daily.


35. Verizon 5G Push Taps Apple, YouTube As Streaming Competition Heats UpСр., 15 авг.[−]

Verizon Communications ( VZ) will offer early customers to its 5G broadband service an Apple TV 4K set-top or subscription to YouTube live TV — at no charge for either — as the telecom giant takes on AT&T ( T), Dish Network ( DISH), T-Mobile US ( TMUS) and others in streaming video.

X

Verizon has focused on building a 5G wireless network rather than launching a live TV streaming service of its own. The Dow Jones component is aiming to line up content partners.

Verizon is testing 5G broadband services to residential homes in four cities. Verizon 5G tests are taking place in Sacramento, Los Angeles, Houston and Indianapolis.

A broad 5G rollout in 2019 by Verizon could pressure the stocks of cable TV firms Comcast ( CMCSA) and Charter Communications ( CHTR).

Verizon Taps Apple TV, Just Like AT&T

While Verizon 5G customers may get perks such as Apple TV discounts, the phone company hasn't disclosed what it'll charge for 5G service to homes.

Verizon's offer of a free Apple TV 4K set-top to initial 5G subscribers borrows a tactic from AT&T. When AT&T launched its DirecTVNow streaming service in 2017, it had an online promotion for a free Apple TV.

The promotion required customers to prepay for three months of service. AT&T has used the promotion on and off since then.

AT&T added 342,000 DirecTV Now subscribers in the June quarter. It has 1.8 million DirecTV Now subscribers overall. AT&T packages video streaming with its wireless services.

Verizon Dangles Free Apple Set-Top, YouTube TV

YouTube Live normally costs $40 monthly. Verizon didn't disclose whether it will be getting a discount from YouTube parent Alphabet ( GOOGL) or from Apple on the 4K set-tops. The Apple TV 4K set top costs about $180.

While Verizon's promotion could be short term, it will add to the phone company's costs in rolling out 5G services.

Verizon says it's not interested in acquiring a media company. AT&T closed its purchase of Time Warner in mid-June. The Department of Justice has appealed a court ruling allowing the deal to close.

Deutsche Telekom ( DTEGY)-controlled T-Mobile is expected to roll out a live TV service of its own in the back half of 2018. In December, it acquired Denver-based Layer3 TV, which offers cable TV-like services to homes via broadband connections.

Verizon stock gained 0.7% to close at 53.24 on the stock market today.

YOU MAY ALSO LIKE:

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Verizon 5G Push Taps Apple, YouTube As Streaming Competition Heats Up appeared first on Investor's Business Daily.


36. This Biotech Is Up 91% This Year — But Is Gassed After SprintСр., 15 авг.[−]

Intercept Pharmaceuticals ( ICPT) shares have climbed 91% year to date, but their sprint is nearing an end, an analyst predicted Wednesday as he downgraded the stock.

X

Intercept stock dived 8.5% to close at 102.20, on the stock market today. Meanwhile, rival Madrigal Pharmaceuticals ( MDGL) sank 1.3%, to 233.78. Broadly, biotech stocks dipped more than 1.5%.

RBC Capital Markets analyst Brian Abrahams kept his price target at 115 and downgraded Intercept stock to a sector perform rating from outperform. Year to date, shares have beat the broader market, which has risen just 10%, he said in a report to clients.

But Intercept stock had to jump a massive hurdle to do so. Last year, shares were hard hit over safety concerns tied to liver disease drug Ocaliva. Ocaliva is the branded name for obeticholic acid, or OCA, as a treatment for primary biliary cholangitis.

"Following what we viewed as an inappropriately sharp sell-off on OCA safety/label concerns, we believe valuation now more accurately reflects reward/risk into (the first half of 2019) Phase 3 Regenerate (nonalcoholic steatohepatitis) data," Abrahams said.

Regenerate Study Could Succeed

Intercept also is testing OCA as a treatment for nonalcoholic steatohepatitis, or NASH, in a late-stage study called Regenerate. Patients have inflammation and liver cell damage, as well as fat in their livers. Abrahams sees a 70% chance the study will succeed.

"Further, we also continue to see substantial market potential in NASH (estimated $2.7 billion opportunity), particularly given the emergence of new noninvasive diagnostics that should assist Intercept in building out the market," he said.

But Intercept stock is unlikely to continue its run-up, Abrahams said. Now, the risk vs. reward ratio is more balanced. Risks include prior mixed results for OCA in NASH, safety worries, competition and the need for Intercept to build out the market.

Intercept stock could see $20-$30 upside per share on NASH success, or $60-$70 downside if OCA fails in NASH. Intercept now appears to be more in line with Madrigal, which is also working on a treatment for NASH. Its drug is in Phase 2 testing.

Abrahams noted that Intercept's OCA is later-stage and shows clear benefits on improving fibrosis in the liver, but Madrigal's drug called MGL-3196 is potentially safer.

YOU MIGHT ALSO LIKE:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How Much Volume Should You Look For In A Stock?

Investing Basics: How To Sell A Stock

The post This Biotech Is Up 91% This Year — But Is Gassed After Sprint appeared first on Investor's Business Daily.


37. Apple Could Reach $2 Trillion Market Cap With AR Glasses, CarСр., 15 авг.[−]

Two weeks after Apple ( AAPL) became the first company to reach a market value of $1 trillion, one analyst believes it can double its value in the years ahead thanks to services, augmented reality glasses and a self-driving car.

X

Respected analyst Ming-Chi Kuo of TF International Securities published a report Tuesday that outlined Apple's path to a market cap of $2 trillion, Business Insider and other media outlets reported.

He predicted that Apple will release augmented reality glasses by 2020, followed by an Apple Car three to five years later. Kuo's note is speculative, but Apple has been developing technologies related to both potential products.

"Services, AR, and Apple Car will create Apple's next trillion-dollar market cap," Kuo said in the note to clients.

AR Glasses Could Be Apple's Next Big Product

Services is currently Apple's fastest-growing business, with offerings such as the App Store, iCloud, Apple Music and Apple Pay. Apple Chief Executive Tim Cook has said other services are on the way. The Cupertino, Calif.-based company has been investing heavily in original TV shows for an upcoming streaming video service.

AR glasses could be the company's next big hardware product, Kuo said. Augmented reality superimposes digital imagery and data into a person's field of view. Today Apple is making augmented reality a feature of its iPhones and iPads, but it is working to shift the technology from handheld displays to eyeglasses.

"We predict that AR is the next-generation revolutionary UI (user interface)," Kuo said.

Other companies pursuing AR glasses include Alphabet's ( GOOGL) Google, Microsoft ( MSFT), Vuzix ( VUZI) and privately held Magic Leap.

Apple Car Looks Like 'Star Product'

Kuo predicted that Apple will debut its rumored electric, self-driving car between 2023 and 2025. He called it the company's next "star product."

Apple sees a potentially huge replacement market for autos driven by new technologies such as electrification and autonomous driving. The company also could enter the car financing market with the Apple Car, Kuo said. That would further boost its services business.

"Apple's leading technology advantages (e.g. AR) would redefine cars and differentiate Apple Car from peers' products," Kuo said. "Apple can do a better integration of hardware, software, and service than current competitors in the consumer electronics sector and potential competitors in the auto sector."

Apple shares rose 0.2% to close at 210.24 on the stock market today. It is trading just below its all-time high of 210.95, reached on Monday.

RELATED:

Apple Becomes First Company To Hit $1 Trillion Market Cap

Magic Leap's First Augmented-Reality Glasses Get Underwhelming Reviews

AR Glasses: Coming Soon To A Face Near You

The post Apple Could Reach $2 Trillion Market Cap With AR Glasses, Car appeared first on Investor's Business Daily.


38. Nvidia Upgraded To Buy; Micron Technology Gets Price-Target CutСр., 15 авг.[−]

A Wall Street analyst on Wednesday upgraded graphics-chip maker Nvidia ( NVDA) one day before its earnings report, and cut his price target on memory-chip maker Micron Technology ( MU).

X

Wells Fargo analyst Aaron Rakers turned positive on Nvidia, moving it to outperform from underperform. He based that on a long-term view of its competitive positioning in video game graphics and processors for data centers and autonomous vehicles.

Rakers set a price target of 315. Nvidia shares dipped 0.9% to close at 259.08 on the stock market today.

Nvidia is well positioned to leverage its expertise in high-performance computing into emerging markets for artificial intelligence, he said. Those markets include self-driving cars, robotics and artificial intelligence in health care and other opportunities.

Also, the company's new Turing GPU architecture and Quadro RTX products should provide a sales lift starting in the fourth quarter, Rakers said.

Santa Clara, Calif.-based Nvidia is scheduled to report fiscal second-quarter results after the market close Thursday. Analysts expect Nvidia to earn $1.66 a share on sales of $3.1 billion. That would translate to year-over-year increases of 80% in earnings per share and 39% in revenue.

Micron Target Lowered

Meanwhile, Rakers lowered his price target on Micron to 63 from 70, but kept his outperform rating. He took the action after evaluating pricing pressures for DRAM and Nand flash memory chips and rising capital expenses for producing next-generation chips.

At the same time, Rakers sees a healthy demand environment for Micron's memory chips thanks to customer investments in artificial intelligence, machine learning, Big Data and analytics.

Micron stock fell 6.2% to 47.49 on Wednesday.

Silicon Motion Upgraded To Buy

Elsewhere in the chip sector, Silicon Motion Technology ( SIMO) received a stock rating upgrade.

Cowen analyst Karl Ackerman upgraded Silicon Motion to outperform from market perform. He raised his price target on the stock to 70 from 55.

Silicon Motion stock popped 2.5% higher to 59.99. In intraday trading, it hit an all-time high of 61.85.

He likes the company's prospects for rising sales of controllers for solid-state drives.

Ackerman also lowered his rating on data storage provider Western Digital ( WDC) to market perform from outperform. He cut his price target on the stock to 70 from 100. Western Digital stock sank 1.6% to 63.95.

RELATED:

Why Nvidia, Applied Materials Earnings Are So Important

IBD Stock Of The Day: Nvidia Nears Buy Zone On Next-Generation Chip Debut

LED Lighting Maker Cree Tops Wall Street Views For June Quarter

IBD Stock Of The Day: Nanometrics Breaks Out After Three Strong Quarters

The post Nvidia Upgraded To Buy; Micron Technology Gets Price-Target Cut appeared first on Investor's Business Daily.


39. LED Lighting Maker Cree Tops Wall Street Views For June QuarterВт., 14 авг.[−]

Light-emitting-diode maker Cree ( CREE) late Tuesday beat Wall Street's estimates for its fiscal fourth quarter, providing evidence for the company's turnaround story. But its guidance disappointed investors.

X

Cree shares fell 1.8% in after-hours trading on the stock market today. During the regular session, the stock dipped 0.2% to 50.16.

The Durham, N.C.-based company earned an adjusted 11 cents a share on sales of $409 million in the quarter ended June 24. Analysts expected it to earn 8 cents a share on sales of $399.7 million. On a year-over-year basis, earnings per share rose 175% while sales climbed 14%.

The June quarter was the second in a row in which Cree posted year-over-year gains in revenue and earnings per share.

Earnings Guidance In Line, Sales Outlook Light

For the current quarter, Cree expects to earn an adjusted 12 cents a share on sales of $405 million, based on the midpoint of its guidance. The earnings guidance was in line with Wall Street's average analyst forecast, but sales were short of the target of $414.6 million.

Cree is in the early stages of a potential turnaround effort, which started in September when the company hired Gregg Lowe as president and chief executive. Lowe was CEO at Freescale Semiconductor from 2012 to 2015, when it was bought by NXP Semiconductors ( NXPI).

In addition to lighting-class LEDs and lighting products, Cree makes power-switching and radio-frequency semiconductors. In March, it acquired the RF power business from Infineon Technologies for about $425 million.

Cree credited strong growth and gross margin improvement in its power and RF chip business for the June-quarter beat.

'Good Momentum'

"Fiscal year 2018 finished with good momentum," Lowe said in a news release. "The demand for silicon carbide and GaN (gallium nitride) technologies continues to grow, as evidenced by the excellent results of our Wolfspeed business."

He added, "We are expanding our manufacturing footprint and broadening our product portfolio to extend our leadership position in this market and drive growth."

Cree has a middling IBD Composite Rating of 62. It ranks No. 11 out of 35 stocks in IBD's Electronics-Semiconductor Manufacturing industry group. CTS ( CTS) leads the group, followed by Texas Instruments ( TXN).

Cree shares broke out of a cup-with-handle base at a buy point of 48.62 on Aug. 3. Before that, it broke out of a double-bottom base with a buy point of 42.94 on May 15.

RELATED:

Chip Stocks To Watch And Semiconductor Industry News

The post LED Lighting Maker Cree Tops Wall Street Views For June Quarter appeared first on Investor's Business Daily.


40. Tesla Special Committee Created To Evaluate Elon Musk Bid To Go PrivateВт., 14 авг.[−]

A Tesla ( TSLA) special committee, comprising three members of its board, will evaluate Chief Executive Elon Musk's effort to take the electric-car maker private, the company said Tuesday.

X

In its statement about the Tesla special committee, the board said no formal proposal from Musk regarding going private has been presented. It added it has not "reached any conclusion as to the advisability or feasibility of such a transaction."

The committee consists of Brad Buss, a Tesla director since 2009 and former chief financial officer of SolarCity. Also on the panel is Robyn Denholm, a Tesla director for three years and former CFO at Juniper Networks ( JNPR). The third is Linda Johnson Rice, a Tesla director since last year and current CEO of Johnson Publishing.

Musk in a blog post Monday gave a lengthy explanation of how he hopes to take his electric-car company private, saying a Saudi Arabian sovereign wealth fund has approached him multiple times to discuss the prospect.

Hiring Financial Advisors

In a tweet late Monday, Musk also said he had hired Silver Lake and Goldman Sachs ( GS) as his financial advisors on his proposal. He's also using the law firms of Wachtell, Lipton, Rosen & Katz as well as Munger, Tolles & Olson.

Musk last week revealed his intention to take Tesla private at $420 a share and said the funding was secured.

The Tesla special committee has full power and authority, the board said. It can take any and all actions it deems necessary to evaluate and negotiate a potential going-private transaction.

It also may consider alternatives to any transaction proposed by Musk, the board said.

Shares of Tesla dropped 2.5% to close at 347.64 on the stock market today.

YOU MIGHT ALSO LIKE:

Tesla Stock Stumbles Quickly After Musk Talks Of Going Private

Tesla Earnings Beat On Revenue As Model 3 Production Hits Targets

The post Tesla Special Committee Created To Evaluate Elon Musk Bid To Go Private appeared first on Investor's Business Daily.


41. Match Stock Falls As Tinder Group Sues Parent IAC For DamagesВт., 14 авг.[−]

Match Group ( MTCH) stock fell Tuesday after a group of founders, executives and early employees of its mobile app Tinder sued Match parent IAC/InterActive ( IAC) seeking damages of at least $2 billion.

X

Match stock fell 3.1% to close at 48.45 on the stock market today. IAC stock slipped 0.6% to 189.97. Tinder's subscriber growth has fueled a rise in Match stock. Shares in Match are up 152% from a year ago.

The plaintiffs allege that IAC deliberately undervalued Tinder to avoid paying them billions of dollars, said a Reuters report.

The lawsuit filed in state Supreme Court in Manhattan stated that IAC and Match prevented the plaintiffs from cashing in stock options.

Paid Tinder Users Near 4 Million

Match said it added 299,000 paid Tinder subscribers in the June quarter vs. 224,000 in the year-earlier period. Tinder had 3.8 million paid subscribers as of June 30, up 81% year over year.

IAC owns more than 80% of Match. IAC spun off Match in 2015.

Shares in Match plunged in May when Facebook said it would leverage its social media platform for online dating services. Facebook is still testing its online dating service.

YOU MAY ALSO LIKE:

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Match Stock Falls As Tinder Group Sues Parent IAC For Damages appeared first on Investor's Business Daily.


42. China Internet Stocks Fall On Quarterly Earnings, Disappointing DataВт., 14 авг.[−]

Shares of China internet stocks YY ( YY) and Huya ( HUYA) tumbled Tuesday as both reported quarterly earnings late Monday that presented a weaker-than-expected outlook for the third quarter.

X

Other China internet stocks were down as retail sales in China for July slowed further.

YY shares closed at 75.64, down 13.7%, on the stock market today. Huya closed at 27.60, down 16.1%.

Other China Internet Stocks Fall

Among the other China internet firms to fall: Shares of Alibaba ( BABA) slipped 2.9% to close at 172.53. JD.com ( JD) finished at 33.87, down 3.4%. And Tencent Holdings ( TCEHY) ended the session at 44.20, down 3.4%.

Also falling was China-based Baozun ( BZUN), which reported quarterly earnings before the market open Tuesday. Baozun dropped 5.8% to 49.64.

Baozun reported revenue of 175.2 million, up 31% in local currency from the year-ago period. It reported adjusted earnings of 14 cents per share, topping views of 13 cents. Baozun provides services that help companies sell goods online.

Huya, YY Outlook Falls Short

After the market close Monday, Huya reported revenue of $156.9 million. That beat the analyst estimates for $145.7 million. Huya earnings of 6 cents per share matched views for adjusted earnings per share.

But Huya said it expects third-quarter revenue of 1.19 billion to 1.22 billion yuan, or about $172.7 million to $177 million. That would be more than double vs. a year earlier in local currency terms, but signals a possible miss of analyst forecasts for 1.22 billion yuan. Huya is a provider of internet livestreaming services.

YY, also a provider of livestreaming services, reported revenue of $570.2 million. That beat the consensus estimate of $536.2 million. Revenue was up 45% in local currency from the year-ago quarter. YY reported adjusted earnings of $2.03, beating views of $1.77. It expects third-quarter revenue of 3.89 billion to 4.02 billion yuan, about $564.5 million to $583.3 million. But that also is below analyst expectations.

YOU MIGHT ALSO LIKE:

Why This Stock Breakout Is Special; Tesla Rival Files For IPO

The Big Picture: Turkey Stuffs Stocks Again; Time To Play Defense?

Amazon, Netflix Use This Potential Breakout Cloud Stock With 110% Growth

Why This Small-Cap Winner Just Triggered A Key Sell Signal

The post China Internet Stocks Fall On Quarterly Earnings, Disappointing Data appeared first on Investor's Business Daily.


43. Why This Medtech Player Could 'Significantly Exceed' Quarterly ViewsВт., 14 авг.[−]

Medtronic ( MDT) touched a record high Tuesday after an analyst suggested that the medtech player could "significantly exceed" analyst forecasts over the next few quarters.

X

Shares rose a fraction to close at 91.05 on the stock market today. Medtronic stock broke out a flat base last month, hitting a buy point at 88.75. As of Tuesday's close, it was 2.6% extended from that point.

Needham analyst Mike Matson boosted his price target on Medtronic stock to 119 from 103, and upgraded shares to a strong buy rating from buy. He noted that Medtronic stands a chance of exceeding fiscal year 2019 estimates based on more realistic guidance.

"Medtronic's organic revenue growth has been over 6.5% for the past two quarters as it lapped 4% organic growth," Matson said in a note to clients. "Medtronic's comparisons decrease to 2% and 3% in its fiscal first quarter and fiscal second quarter, respectively."

With many of the same growth drivers in place, Medtronic's revenue and earnings per share could "significantly exceed the consensus in the next few quarters," he said.

Organic Growth Expected

Medtronic is slated to report its fiscal first- quarter results early next Tuesday. Medtronic is the biggest stock in the medical-products industry group. That group ranks third out of the 197 groups that Investor's Business Daily tracks.

For the quarter, analysts polled by Zacks Investment Research expect Medtronic to report adjusted profit of $1.11 per share, declining a penny from the year-ago period. Analysts also model $7.23 billion in sales, down 2.1% year over year.

But organic revenue growth should remain strong, Matson said. In June, Medtronic guided to 4% organic revenue growth from fiscal years 2018-22.

Double-Digit Return

"We believe the revenue growth target is realistic and achievable given Medtronic's recent product launches and pipeline, broad-based strength across its business units' pipelines and emerging markets," he said.

Medtronic also aims to deliver double-digit total shareholder return, including both earnings per share growth and dividend yield, he said.

As it stands, Medtronic stock is trading at a 20% discount to its large-cap medical technology peers, he said. Medtronic's growth profile warrants a discount.

Matson sees a 31% upside for the stock, enough to justify a strong-buy rating.

YOU MIGHT ALSO LIKE:

How Much Volume Should You Look For In A Stock?

Looking For The Next Nvidia? Start With This Simple Routine

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The post Why This Medtech Player Could 'Significantly Exceed' Quarterly Views appeared first on Investor's Business Daily.


44. Salesforce.com Stock Warms Up To Software Maker's Appetite For DealsВт., 14 авг.[−]

Salesforce.com stock has reacted favorably to the company's purchase of MuleSoft, a sign that investors may be getting more comfortable with the enterprise software maker's acquisition spree, says a Morgan Stanley analyst.

X

Salesforce.com ( CRM) stock has climbed nearly 17% since its March 20 purchase of MuleSoft. The $6.5 billion cash-and-stock deal marked Salesforce.com's biggest acquisition.

In 2016, several acquisitions pressured Salesforce.com stock. The deals raised worries over the company's organic growth.

Keith Weiss, a Morgan Stanley analyst, on Tuesday hiked his price target on Salesforce.com stock to 178 from 153.

"Post its $6.5 billion acquisition of MuleSoft back in March, Salesforce's share price has outperformed its software peer group to reach all-time highs, in stark contrast to the historical underperformance in shares following other large M&A deals," Weiss said in a note to clients.

MuleSoft Fuels Digital Transformation

Salesforce.com stock climbed 1.5% to close at 146.57 on the stock market today. Shares in the company are up 60% from a year ago.

MuleSoft, which went public in 2017, sells software that automates the integration of new tools with legacy enterprise platforms and speeds application development.

"Unlocking data trapped in legacy systems via MuleSoft brings Salesforce to the forefront of driving digital transformation for its customers," Weiss said. "Consensus expectations likely underestimate this growth potential."

Taking On Adobe

Salesforce.com in July agreed to buy Datorama for a reported $800 million. That purchase boosts the company's digital marketing strategy vs. Adobe Systems ( ADBE).

Before that, Salesforce.com spent $4.6 billion on acquisitions in 2016. They included e-commerce platform Demandware, Krux, business analytics platform BeyondCore, and startup Quip. Shares in Salesforce fell 13% in 2016.

Salesforce.com sells software under a subscription model. Its software helps businesses organize and handle sales operations and customer relationships. The company has expanded into marketing, customer services and e-commerce.

YOU MAY ALSO LIKE:

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Salesforce.com Stock Warms Up To Software Maker's Appetite For Deals appeared first on Investor's Business Daily.


45. Endo Has A Huge Opportunity — And Allergan May Want A Piece Of ItВт., 14 авг.[−]

Endo Pharmaceuticals ( ENDP) is closing in on a $400 million opportunity for treating cellulite in the U.S. — and that could prompt top dog Allergan ( AGN) to seek a partnership, an analyst said Tuesday.

X

There was significant interest on Endo's second-quarter earnings conference call about its drug, called collagenase clostridium histolyticum, or CCH, for cellulite treatment. Cellulite occurs when connective tissue under the skin, made of collagen, hardens and contracts, causing dimples.

Cellulite affects 80%-90% of women post puberty. Endo's drug aims to break the collagen tethers to release the dimples and, potentially, smooth the skin. Mizuho analyst Irina Koffler says there are a number of reasons for Allergan to seek a partnership to market CCH internationally.

"Allergan could get global rights to this product, which may drive revenue synergies with its other body contouring assets and facial injectables," she said in a note to clients. "We believe that Allergan already has all of the necessary commercial infrastructure to market CCH Cosmetic."

Further, Allergan is soon to face competition from Evolus ( EOLS), which is making an injectable drug that could rival massive moneymaker Botox. As such, Allergan would benefit "from a new and innovative product to introduce to physicians in 2020," she said.

Cellulite Treatment Rivalries

Endo is testing CCH Cosmetic in Phase 3 studies. Results are expected in late 2018. The market is already saturated with rival products from Allergan and Hologic ( HOLX), but none have 100% customer satisfaction, Mizuho said.

"We learned that doctors categorize cellulite treatment as either relatively effective (but expensive and debilitating) or less invasive and less effective," she said.

Cellfina, a cellulite treatment from privately held Merz Pharmaceuticals, costs $4,000-$6,000 and provides durable results. But it comes with pain, bruising and very specific recovery instructions. One website notes 73% of Cellfina patients surveyed say it's worth it. Allergan's drugs, Kybella and Botox, have 75% and 95% worth-it ratings.

In contrast, Hologic's Cellulaze only has a 33% satisfaction rating, due to lacking effectiveness.

Challenges In Cellulite

An expert cited by Koffler says he's already tried Endo's drug, Xiaflex, as an off-label cellulite treatment. Xiaflex is the branded name for CCH when used to treat scar tissue in the hand and in male genitalia. He says Xiaflex could prove to be overzealous in severing collagen tethers.

"There are other fibrous (connective tissues) that provide support and structure to the skin," Koffler said. "Physicians have had negative prior experience with an existing laser that destroyed the underlying structural support to the skin and cause skin laxity."

Other physicians have noted the same concern, Koffler said. They say it's difficult to treat cellulite without knowing where the collagen tethers are in relation to the dimples.

Endo says there are no approved devices to visualize the tethers. The firm also said it hasn't seen laxity problems in testing.

Market Opportunity In Cellulite

The market opportunity in cellulite is significant, Koffler said. Physicians say cellulite can lead to eroding self confidence in women.

Koffler sees the opportunity for CCH Cosmetic to be in line with Allergan's CoolSculpting, which aims to improve the appearance of double chins.

"Because of the significant sales of topical agents and noninvasive products, our (key opinion leader) believes that a product that produces a noticeable improvement in the appearance of cellulite, and is economical and has a short recovery time would be 'wildly popular,'" Koffler wrote.

At the same time, these treatments are unlikely to be as popular as liposuction, the doctor said.

On the stock market today, Endo stock rose 6% to close at 16.10. Allergan shares lifted a fraction, to 184.46.

YOU MAY ALSO LIKE:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

Long-Term Retirement Investing Strategies With ETFs

Looking For The Next Nvidia? Start With This Simple Routine

The post Endo Has A Huge Opportunity — And Allergan May Want A Piece Of It appeared first on Investor's Business Daily.


46. Cisco Estimates Beatable, But Guidance Likely Messy, Says AnalystВт., 14 авг.[−]

When Cisco Systems ( CSCO) reports fiscal fourth-quarter earnings late Wednesday, investors should be on guard for "messy" October-quarter guidance, says an analyst.

X

Analysts see Cisco earnings up 13% to 69 cents from a year earlier. They project a revenue climb of 5% to $12.77 billion.

"Street Q4 estimates appear beatable, and we note investor expectations are relatively low compared to last quarter," Piper Jaffray analyst Andrew Nowinski said in a note to clients . "While we expect Q4 to be a solid quarter ... we expect fiscal Q1, 2019 guidance to be messy."

He noted that the computer-networking gear maker has adopted new revenue-recognition rules. Another factor, he says, will be Cisco's acquisition of Duo Security in July. Cisco acquired Duo Security for $2.35 billion, marking its biggest cybersecurity acquisition since its purchase of Sourcefire.

Security Market Growth Questioned

The company earlier this year changed how it reports sales for its core business of selling network switches and routers. With acquisitions, Cisco aims to increase revenue from software and services.

Morgan Stanley, in a preview of Cisco earnings, says the company's growth in security services may have stalled prior to the Duo Security deal.

"Our surveys and channel checks suggest Cisco's security pipeline is plateauing, seemingly at odds with management's long-term plan for low-to-midteens (revenue) growth," said the report.

Cisco earnings for the current first quarter could get a boost from a court settlement with rival Arista Networks ( ANET). Arista on Aug. 6 said it will pay $400 million to Cisco to resolve a long-running legal fight. The settlement is awaiting court approval.

Cisco stock added 0.6% to close at 44 on the stock market today.

YOU MAY ALSO LIKE:

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Cisco Estimates Beatable, But Guidance Likely Messy, Says Analyst appeared first on Investor's Business Daily.


47. Huya Stock Dives As Earnings Meet, Revenue Outlook WeakВт., 14 авг.[−]

Huya stock plunged late Monday after the China livestreaming specialist met Q2 earnings estimates but guided low on Q3 revenue.

X

Huya ( HUYA) reported revenue of $156.9 million. That beat the consensus estimate of $145.7 million. Huya earnings of 6 cents per share matched the consensus adjusted EPS estimate.

But Huya guided Q3 revenue to 1.19 billion to 1.22 billion yuan, or about $172.7 million to $177 million. That would be more than double vs. a year earlier in local currency terms, but signals a possible miss of the consensus for 1.22 billion yuan.

Shares initially rose in late trade but then crashed 8.5% on the stock market today. Huya stock closed Monday at 32.84, up 2%. Huya held its initial public offering in May, pricing Huya stock at 12.

The company will hold its quarterly conference call with analysts at 8 p.m. ET Monday.

Huya says it's the largest provider of internet livestreaming broadcasts in China in terms of monthly active users and time spent on its mobile app.

Huya said livestreaming revenue rose 124.5% in local currency to $149.9 million, compared with the year-ago quarter, primarily due to the increase in spending per paying user and the increase in the number of paying users on Huya's platform.

Huya parent YY ( YY) also reported earnings late Monday. YY earnings and revenue easily topped views, but Q3 revenue guidance was light. YY stock fell sharply in late trade.

YOU MIGHT ALSO LIKE:

Why This Stock Breakout Is Special; Tesla Rival Files For IPO

The Big Picture: Turkey Stuffs Stocks Again; Time To Play Defense?

Amazon, Netflix Use This Potential Breakout Cloud Stock With 110% Growth

Why This Small-Cap Winner Just Triggered A Key Sell Signal

The post Huya Stock Dives As Earnings Meet, Revenue Outlook Weak appeared first on Investor's Business Daily.


48. YY Earnings Top Q2 Views, But Stock Dives Late On Weak GuidanceВт., 14 авг.[−]

YY stock fell sharply in after-hours trading Monday after the China internet company reported quarterly earnings that stomped estimates but guided low on Q3 revenue.

X

YY ( YY) reported revenue of $570.2 million. That beat the consensus estimate of $536.2 million. Revenue was up 45% in local currency from the year-ago quarter. It reported adjusted earnings of $2.03, beating views of $1.77.

The Chinese internet sees Q3 revenue of 3.89 billion to 4.02 billion yuan, about $564.5 million to $583.3 million. But that's below expectations.

YY stock initially rose in late trading but reversed to plunge 11% on the stock market today. YY stock closed Monday down 1.4% to 87.67, near 2018 lows. The YY earnings report didn't come out until 6 p.m. ET, making after-hours trading even murkier than usual. YY's conference call was not scheduled until 9 p.m. ET Monday.

YY offers video and livestreaming services that consumers use to discover and participate in a wide range of online activities, including the broadcasting of live online games, live music shows, dating shows, sports broadcasting and online learning.

YY said its mobile livestreaming monthly active users increased by 21% year over year to 80.2 million. Total livestreaming paying users increased by 21% to 6.9 million.

Recent YY spinoff Huya ( HUYA), which livestreams video games, also reported quarterly results late. Earnings were in line, while revenue topped. But, like YY, Huya revenue guidance was light. Huya stock also tumbled in after-hours action.

YOU MIGHT ALSO LIKE:

Why This Stock Breakout Is Special; Tesla Rival Files For IPO

The Big Picture: Turkey Stuffs Stocks Again; Time To Play Defense?

Amazon, Netflix Use This Potential Breakout Cloud Stock With 110% Growth

Why This Small-Cap Winner Just Triggered A Key Sell Signal

The post YY Earnings Top Q2 Views, But Stock Dives Late On Weak Guidance appeared first on Investor's Business Daily.


49. Elon Musk Blog Post Reveals How He Plans To Take Tesla PrivateПн., 13 авг.[−]

Tesla ( TSLA) Chief Executive Elon Musk in a blog post Monday gave a lengthy explanation of how he hopes to take his electric-car company private, saying a Saudi Arabian sovereign wealth fund has approached him multiple times to discuss the prospect.

X

Musk last week revealed his intention to take Tesla private at $420 a share and said the funding was secured. In his blog post Monday, he reiterated that and named Saudi Arabia's Public Investment Fund as a primary investor.

But that follows conflicting news reports over whether the Saudi investment fund would provide the needed money. A report about Tesla from Reuters on Saturday said the Saudi group has no interest so far in financing Musk's multibillion dollar plan.

But a Bloomberg report on Tesla published Sunday said the investment group "is working to be part of any investor pool that emerges to take Tesla private." The fund, which recently built a stake just shy of 5%, is exploring how it can be involved, the Bloomberg report said.

Tesla shares ticked up 0.3% to close at 356.41 on the stock market today.

1,100 Word Blog Post

Musk's 1,100-word account of events is the blog post came after the billionaire entrepreneur's explosive tweet last week. The tweet said "Am considering taking Tesla private at $420. Funding secured." The tweet sent Tesla stock up 11%.

In a follow-up letter to employees that same day, titled " Taking Tesla Private," Musk said the reason for doing this "is all about creating the environment for Tesla to operate best." But Musk made no reference on the deal's funding.

Reports said the Securities and Exchange Commission was investigating the matter.

Five days before the tweet, according to Musk, he notified the company's board of directors about his plan.

"It was agreed that as a next step, I would reach out to some of Tesla's largest shareholders," Musk wrote.

Musk Approached 'Multiple Times'

"To be clear, when I made the public announcement, just as with this blog post and all other discussions I have had on this topic, I am speaking for myself as a potential bidder for Tesla," he wrote.

Going back almost two years, he said, the Saudi group fund had approached him "multiple times" about taking Tesla private. "They then held several additional meetings with me over the next year to reiterate this interest and to try to move forward with a going-private transaction," Musk wrote.

"If the board process results in an approved plan, any required regulatory approvals will need to be obtained and the plan will be presented to Tesla shareholders for a vote."

YOU MIGHT ALSO LIKE:

Tesla Stock Stumbles Quickly After Musk Talks Of Going Private

Tesla Earnings Beat On Revenue As Model 3 Production Hits Targets

The post Elon Musk Blog Post Reveals How He Plans To Take Tesla Private appeared first on Investor's Business Daily.


50. Hologic Shares Fall As Device Pulled From Market On FDA ConcernsПн., 13 авг.[−]

Hologic ( HOLX) fell to a two-month low Monday after it pulled a vaginal rejuvenation device from the market, following Food and Drug Administration concerns of a similar device causing "serious risk."

X

On the stock market today, Hologic stock slipped 4%, to 39.02. Shares fell below a buy point it achieved in July at 42.31. Broadly, medical systems stocks slid a fraction.

Hologic said in a filing with the Securities and Exchange Commission on Monday that it will suspend marketing and distribution of its TempSure Vitalia and related products. Hologic subsidiary Cynosure asked customers to send unused products back to the company.

"Cynosure has carefully considered the FDA's broader concerns and elected to suspend marketing and distribution of Vitalia," the firm said in its filing.

Doubt Over Devices

The FDA recently cast doubt on vaginal rejuvenation tools. Such devices deliver heat to the vaginal tissue via laser to treat the symptoms of menopause, urinary incontinence or sexual function. Hologic spent about $1.6 billion to acquire Cynosure, which makes the technology, in 2017.

In July, the FDA suggested there's not enough clinical evidence to support claims these laser-based procedures actually work. Some devices have FDA clearance or approval. But officials say they haven't looked at the devices' safety or effectiveness.

"These products have serious risks and don't have adequate evidence to support their use for these purposes," the FDA said. "We are deeply concerned women are being harmed."

Further, the FDA asserted that companies are making "deceptive health claims." That includes marketing to women undergoing early menopause after breast cancer treatment.

"The deceptive marketing of a dangerous procedure with no proven benefit, including to women who've been treated for cancer, is egregious," the FDA said.

Doesn't Affect MonaLisa

Hologic's most notable vaginal rejuvenation device is the MonaLisa Touch. The firm stressed that its decision regarding Vitalia "does not affect other Hologic gynecology products such as the MonaLisa Touch laser."

The company previously projected $7 million in TempSure Vitalia sales in the fourth quarter. Hologic's decision regarding Vitalia will affect that number. The company is unsure by how much.

Needham analyst Mike Matson noted that the Vitalia device has FDA clearance. Hologic has not received any reports of side effects from it.

"We believe part of the reason for Hologic's distinction in the two products is that there is much less clinical data for Vitalia (typically used for vaginal laxity) than for MonaLisa Touch (typically used for vaginal dryness)," he said in a report to clients.

In the near-term, this will cause some pain for the company. But it should lead to a longer-term gain, Matson said. Sales of Vitalia account for less than 1% of his estimate for Hologic.

"Despite the near-term financial impact, we think that Hologic is doing the right thing by proactively removing Vitalia from the market and over the longer run this should serve to improve Hologic's image and brand in the aesthetics market," he said.

YOU MAY ALSO LIKE:

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How Much Volume Should You Look For In A Stock?

Investing Basics: How To Sell A Stock

The post Hologic Shares Fall As Device Pulled From Market On FDA Concerns appeared first on Investor's Business Daily.


51. Alnylam Gets An FDA Nod — But Pfizer, Others May Decimate ItПн., 13 авг.[−]

Alnylam Pharmaceuticals ( ALNY) crumbled Monday after U.S. officials approved a rare-disease drug that treats a smaller-than-expected pool of patients.

X

On the stock market today, Alnylam shares plunged 6.6% to close at 90.95. Earlier, the stock lost as much as 9.5% in high volume. Meanwhile, shares of rival Ionis Pharmaceuticals ( IONS) climbed 2.7%, to 50.01.

Specifically, the Food and Drug Administration approved Alnylam's gene-silencing therapy, known as Onpattro, to treat the nerve damage component of a disease in which built-up protein causes systemic issues.

But there are more patients with a cardiac complication associated with hereditary ATTR amyloidosis. Alnylam showed in clinical studies that Onpattro had "favorable effects" on the cardiac side. Still, as it stands Onpattro is only approved for the nerve component.

"We see competition from (Pfizer's ( PFE)) tafamidis, (Prothena's ( PRTA)) PRX004 and others as decimating the market opportunity for Onpattro in 18 months-plus time," Instinet analyst Christopher Marai said in a report to clients.

Onpattro In Cardiac Patients

Marai kept his reduced rating on Alnylam stock, and cut his price target to 73 from 86. He expects tafamidis from Dow Jones component Pfizer to hit the market in 2019. Before then, Onpattro could hit $400 million in the first 12-18 months with 1,200 patients, he said.

Goldman Sachs analyst Terence Flynn noted Alnylam is still in talks with the FDA to get approval for Onpattro to treat cardiac patients. But this could potentially require more data from a clinical study, he said in his note to clients.

"We view the lack of cardio data in the U.S. label as disappointing and note that this could represent a disadvantage vs. Pfizer's competitor drug, tafamidis," he said. "As a result, we are lowering our U.S. penetration rates."

Now, Flynn assumes $2.1 billion in peak global sales of Onpattro. He also slashed his price target on Alnylam stock to 155 from 193, and removed shares from his conviction list.

European Approval?

European regulators appear more willing to approve Onpattro for cardiac patients. In July, the Committee for Medicinal Products for Human Use issued a positive opinion of the drug and included a note that it had shown "a positive impact on cardiac parameters."

Ionis and Akcea Therapeutics' ( AKCA) drug Tegsedi is already approved in Europe to treat patients with the nerve component of hereditary ATTR amyloidosis. But the EU committee's review said the data from Tegsedi studies didn't support use in cardiac patients.

"As such, we expect a more favorable label for Onpattro in Europe," Chardan analyst Gbola Amusa said in a note.

Onpattro will go for $450,000 annually with a net price of $345,000. Alnylam also is talking with insurance companies for value-based pricing. In this scenario, Alnylam would receive a reduced payment if a patient fails or ceases to respond to the drug.

Gbola assumes worldwide sales of $1.77 billion for Onpattro and follow-on drugs in 2030.

YOU MIGHT ALSO LIKE:

How Much Money Do You Need To Start Investing?

Long-Term Retirement Investing Strategies With ETFs

New Option Strategy Limits Risk Around Earnings

The post Alnylam Gets An FDA Nod — But Pfizer, Others May Decimate It appeared first on Investor's Business Daily.


52. Netflix Stock Gets Price-Target Cut; Chief Financial Officer Steps DownПн., 13 авг.[−]

A Wall Street analyst on Monday trimmed his price target on Netflix stock after lowering his forecast for subscribers at the internet television network for this year and next. Also Monday, Netflix announced that its chief financial officer is stepping down.

X

Imperial Capital analyst David Miller kept his outperform rating on Netflix ( NFLX), but cut his 12-month price target to 494 from 503. Netflix stock is down about 15% since the company reported disappointing second-quarter subscriber numbers on July 16. Its shares hit a record high of 423.21 on June 21.

Netflix stock fell 1.3% to 341.31 on the stock market today. It is trading well below its 50-day moving average, a negative technical trading indicator.

Miller trimmed his Netflix global subscriber estimate to 141.2 million from 141.4 million for 2018. He decreased his global subscriber estimate for 2019 to 164.4 million from 166.3 million.

He made the moves "in the interest of being conservative," he said in a report.

Netflix Chief Financial Officer To Step Down

Netflix announced Monday that Chief Financial Officer David Wells is leaving the company after 14 years. He plans to stay at the company until a successor is found, according to a news release. Wells has been chief financial officer since 2010.

Wells said he wanted a change and intends to focus on philanthropy and undisclosed "big challenges."

"With Netflix's strong financial position and exciting growth plans, this is the right time for us to help identify the next financial leader for the company," Wells said in a statement.

Monness Crespi Hardt analyst Brian White said he isn't concerned about Wells' departure.

"Given the tremendous success of Netflix over the years and a future that we view as very bright, we believe the company will be able to attract a high-quality CFO," he said in a report. He reiterated his buy rating on Netflix stock with a price target of 430.

White sees the timing of the announcement as coincidental to Netflix's disappointing Q2 report and guidance.

Minimal Impact From Loss Of Disney Content

Meanwhile, Miller thinks Netflix will see minimal impact from Walt Disney ( DIS) pulling its content from the service on Jan. 1.

"Based on our research, we think the Disney content on Netflix right now represents about 6.3% of total viewer hours on the platform," he said. "The question then becomes, how many Netflix subscribers abandon the service because of the absence of Disney content? We suspect very few, if any at all."

Plus, Netflix will be able to reallocate the roughly $300 million it pays Disney into making its own content to attract and retain subscribers, Miller said.

Disney is planning to launch its own direct-to-consumer streaming video service late next year.

Four weeks ago, Netflix reported adding 5.2 million subscribers in the second quarter. It missed its own forecast for 6.2 million made in mid-April. It also disappointed with its guidance for new subscribers in the current quarter.

Netflix subscribers at the end of the June quarter totaled 130.1 million worldwide.

RELATED:

Roku Stock Surges Past Buy Point On Second-Quarter Earnings

Disney Will Apply This Formula For Box Office Dominance To Streaming

Netflix Stock Falls On Possible Walmart Streaming Video Service

The post Netflix Stock Gets Price-Target Cut; Chief Financial Officer Steps Down appeared first on Investor's Business Daily.


53. Apple Stock Rating Lowered To Negative On Qualcomm, Services ConcernsПн., 13 авг.[−]

A Wall Street research firm on Monday lowered its rating on Apple stock to negative from neutral on concerns about the company's legal fight with Qualcomm ( QCOM) and potential antitrust issues with its services business.

X

The forensic accounting team at CFRA Research made the change after reviewing Apple's ( AAPL) latest 10-Q disclosure document with the U.S. Securities and Exchange Commission. But Apple stock rose 0.7% to close at 208.87 on the stock market today. Intraday, it hit a record high of 210.95.

Based on the filing, Apple is accruing Qualcomm royalties at levels below historic costs, CFRA analyst Nicholas Rodelli said. That has benefited Apple's gross profit margin by 75 basis points since early 2017, Rodelli said in a report.

Apple has withheld its royalties to Qualcomm for six quarters and counting. It won't make payments to Qualcomm until lawsuits over the wireless chipmaker's intellectual property are resolved. But the amount Apple is setting aside for payments presumes it will win a lower royalty rate, Rodelli said.

"We're initiating a Negative Bias rating on Apple, keyed primarily to underappreciated Qualcomm-related risks," Rodelli said. "Apple's operating performance and reported financial results likely have benefited from Apple accruing Qualcomm royalties at the amount Apple itself believes it ultimately will pay — if it prevails in litigation — as opposed to the amount Apple historically paid Qualcomm."

He added, "Apple's nearly risk-free period of withholding billions of dollars from Qualcomm without adverse consequence is set to end as litigation milestones draw near."

Apple Facing Antitrust Risk On Services

Apple also is facing an increasing antitrust risk related to its burgeoning services business. There, it extracts a 30% take-rate on third-party revenue, Rodelli said.

The revenue share is particularly concerning when it involves competitors using its platform, he said. Streaming music service Spotify ( SPOT) has to give 30% of its revenue to Apple when users pay through Apple's iOS platform. That gives a business advantage to Apple's own service, Apple Music.

"Given the increasing importance of services to Apple's investment case, coupled with Apple's anticipated aggressive rollout of additional services (e.g., Video/TV) that compete with third-party applications, we question the sustainability of Apple's 30% take-rate," Rodelli said.

RELATED:

Magic Leap's First Augmented-Reality Glasses Get Underwhelming Reviews

Apple Supplier Hints At Greater 3D-Sensing iPhone Production

The post Apple Stock Rating Lowered To Negative On Qualcomm, Services Concerns appeared first on Investor's Business Daily.


54. Netflix (NFLX) Stock Quotes, Company News And Chart AnalysisПн., 13 авг.[−]
X


View NFLX Stock Quote Page
| View NFLX Ratings

Netflix Stock News & Analysis

Netflix Annoys Subscribers With Video Ads Promoting Its ContentInternet television network Netflix bills its service as advertising-free, but that apparently doesn't apply to ads for its own content. The subscription video-on-demand service is catching flak for experimenting with advertisements for... Read More
Netflix Stock Rebounds But Chips Weigh On Nasdaq; Nike Powers Higher, Buoys DowNetflix stock was poised to end a six-session losing streak Monday, while Nike stock blasted off in the Dow Jones. Netflix was the top-performing FANG stock by a wide margin, up more... Read More
Dow Jones Futures: Tesla Stock Falls Below 300; Pepsi To Buy SodaStream; China Trade War Talks LoomDow Jones futures rose modestly Monday morning, along with S&P 500 futures and Nasdaq futures. Tesla continued to slide after CEO Elon Musk tweeted early Sunday that changing his work habits is... Read More
FANG Stocks Take Heat As Distribution Hits Nasdaq; Netflix Slumps 3.5%FANG stocks were down sharply in afternoon trading Wednesday, with shares of Netflix down 3.5% and Google parent Alphabet lower by more than 2%. Big dividend stocks in the Dow Jones industrial... Read More
Netflix Stock Gets Price-Target Cut; Chief Financial Officer Steps DownA Wall Street analyst on Monday trimmed his price target on Netflix stock after lowering his forecast for subscribers at the internet television network for this year and next. Also Monday, Netflix... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Netflix (NFLX) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


55. Magic Leap's First Augmented-Reality Glasses Get Underwhelming ReviewsСб., 11 авг.[−]

The first augmented-reality glasses from hot startup Magic Leap are now shipping to customers, but early reviews say the AR specs have a long way to go before they become a mainstream consumer product.

X

The glasses, called Magic Leap One, cost $2,295 and are being sold to early adopters in six major U.S. cities. The privately held Plantation, Fla.-based company is pitching its first AR system as its Creator Edition because it is designed for software developers who want to make games and other apps on the new augmented-reality platform.

Magic Leap officials are setting low expectations for the device, saying it provides just a glimpse of where the technology is headed.

"This is our Apple-1, not our iPhone X moment," Magic Leap founder and Chief Executive Rony Abovitz told Variety. "This is the very first step of what we are doing. We're being heads down and modest about what we'll do next."

Magic Leap Two On The Way

The consumer version of the product will be Magic Leap Two, Abovitz said. That second-generation product will include support for AT&T's ( T) 5G wireless network and get a broader marketing push, he said. Abovitz declined to say when the follow-on version might launch or how much it will cost.

"Let's focus on Magic Leap One Creator Edition," he told Variety. "We just launched it and we're in early orbit. This is our Alan Shepard, John Glenn moment. Then we'll talk to you about Gemini."

Apple ( AAPL), Alphabet's ( GOOGL) Google, Microsoft ( MSFT) and a host of tech companies are pursuing augmented reality because they see it as the next stage of personal computing. Augmented reality overlays digital imagery and information onto what a person sees in the real world.

The Verge reviewed Magic Leap One and said it showed promise but "is still very much a work in progress."

CNBC said the technology is impressive but "we're years away from the Magic Leap that's ready for the rest of us."

Limited Field Of View

Complaints about the first-generation product include its limited field of view and bulky headset. The device can't project digital information across your entire field of view, only a moderately sized rectangle in the center of your vision.

In a blog post, Mike Boland, chief analyst at ARtillry Intelligence, said Magic Leap One could turn out to be "the Palm Pilot on the way towards the iPhone."

Magic Leap One consists of three components: a headset, a handheld controller and a small wearable computer. The system is powered by Nvidia ( NVDA) graphics and central processors. The product officially launched on Wednesday.

The company has raised more than $2.3 billion in funding from the likes of Alibaba ( BABA), AT&T, Fidelity, Google, JPMorgan ( JPM) and Qualcomm ( QCOM).

RELATED:

AR Glasses: Coming Soon To A Face Near You

The post Magic Leap's First Augmented-Reality Glasses Get Underwhelming Reviews appeared first on Investor's Business Daily.


56. Cybersecurity Stocks: Many Are Hot But The Buyer Should BewareСб., 11 авг.[−]

The performance of cybersecurity stocks in the current round of earnings reports offers insight on this seemingly hot tech sector — and why the investor should beware.

X

At first glance, cybersecurity seems to be on fire with lots of prospects for growth, but you still have to be careful picking stocks in this sector. Earnings show that investors favor some cybersecurity names over others.

In other words, it's not a rising tide that lifts all boats.

The results for June-quarter winners thus far have been alluring. Fortinet ( FTNT) stock soared by more than 14% the day after its Aug. 1 earnings. Rapid 7 ( RPD) climbed nearly 9% after reporting Monday. CyberArk Software ( CYBR) jumped 11% off Tuesday's results. And SailPoint Technologies ( SAIL) catapulted 13% a day after Wednesday's report.

When the losers fell, though, they fell hard. Proofpoint ( PFPT) tumbled more than 7% a day after its July 26 report. Already struggling Symantec ( SYMC) dropped nearly 8% on its Aug. 2 earnings. And Carbon Black ( CBLK) plunged more than 10% off Tuesday's report. FireEye ( FEYE) managed to confine its loss to less than 2% off its Aug. 1 results, but only because it finished at the high end of the next day's trading.

The troubles for some continued into Friday's action. ForeScout Technologies ( FSCT) fell 5% to close at 35.97 on the stock market today. Mimecast ( MIME) dropped 3% to 38.98. Palo Alto Networks ( PANW) and Okta ( OKTA) have yet to be heard from, as they both report Sept. 6.

High Ranking

IBD's Computer-Software Security group is ranked No. 9 out of 197 industry groups. Fortinet, Palo Alto, Qualys ( QLYS) and CyberArk have the highest Composite Ratings in the security software group as earnings reports continue to roll in.

Picking the right industry group to watch is often one key to finding winning stocks. But any group has a mix of companies that aren't necessarily direct competitors.

In the case of IBD's Computer-Software Security group, there is a wide range of products and services sold by companies. Some cybersecurity firms still sell hardware appliances while others have shifted to cloud computing platforms. And market forecasts are different for those products.

Take Palo Alto and Fortinet. Both compete in the corporate "firewall" security market vs. Cisco Systems ( CSCO), Check Point Software Technologies ( CHKP) and others. Firewalls are located between private networks and the internet, and they block unauthorized traffic.

This year is shaping up to be the start of an upgrade cycle, with companies buying next-generation firewall products. And Fortinet has been gaining market share vs. Check Point, analysts say.

Artificial Intelligence Ups Endpoint Competition

Hackers often aim to compromise networks by targeting employees or management with administrative access to company computer systems. CyberArk's software monitors and manages privileged accounts. SailPoint, meanwhile, sells identity management software that helps companies monitor security breaches.

Rapid 7 sells cloud-based software services to businesses to protect them against security attacks.

Some cybersecurity markets are growing at a healthy rate but they're crowded, with startups battling incumbents. That seems be the case with "endpoint" software makers Symantec and Carbon Black, analysts say.

Startups using artificial intelligence tools, including Cylance and CrowdStrike, operate in the endpoint market — detecting malware on laptops, mobile phones and other devices that access corporate networks. IDC forecasts the endpoint cybersecurity market will grow to $12.5 billion in 2021, up from $9.6 billion in 2016.

YOU MAY ALSO BE INTERESTED IN:

AI Companies Race To Get Upper Hand In Cybersecurity — Before Hackers Do

Five Things To Mull In Taking Profits Or Going Long On Cybersecurity

Google & Facebook Vs. Amazon & AT&T: The Digital Ad Showdown Begins

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Cybersecurity Stocks: Many Are Hot But The Buyer Should Beware appeared first on Investor's Business Daily.


57. Alnylam Stock Slips As FDA Approves First Gene-Silencing DrugПт., 10 авг.[−]

Alnylam Pharmaceuticals ( ALNY) grabbed a series of firsts on Friday as the Food and Drug Administration approved its first drug — a new gene-silencing treatment that targets the nerve damage component of a fatal rare disease.

X

But Alnylam stock, which had been halted, fell 4.5% near 93 in after-market trades the stock market today, possibly due to patent concerns. Shares were up 3.3% to 97.37 when trading was halted shortly after 12:20 p.m. ET and trading didn't resume until after the closing bell.

This is the first approval for a drug that treats peripheral nerve damage resulting from hereditary ATTR amyloidosis. Patisiran, now branded as Onpattro, is also Alnylam's first approved product, and is the first in a class of drugs that silence genes through a process called RNA interference.

Alnylam's launch could be at risk, however. A European biotech named Silence Therapeutics is seeking to block Alnylam from selling Onpattro in Portugal, claiming it has patents on the technology used to create patrisan. The patent battle also is pending in the UK with a hearing set for early December. In addition, Silence says it has patents in the U.S., but hasn't asserted them.

Alnylam didn't immediately return a request for comment from Investor's Business Daily, though it said in a Securities and Exchange Commission filing that it submitted "substantive defenses" to Silence's claim in December 2017.

Part Of 'Broader Wave'

FDA Commissioner Scott Gottlieb called the approval "part of a broader wave of advances that allow us to treat disease by actually targeting the root cause." This enables "us to arrest or reverse a condition, rather than only being able to slow its progression or treat its symptoms."

Patients with hereditary ATTR amyloidosis have a genetic mutation that prevents a form of protein from keeping its normal structure. This leads the protein to build up throughout the body, causing widespread difficulties, including nerve damage. That nerve damage can result in weakness, numbness or pain.

Onpattro targets the nerve damage by silencing the gene responsible for producing the disease-causing proteins. It does this through a process called RNA interference. The FDA notes RNA interference can individually turn off nearly 22,000 genes.

Ionis Pharmaceuticals ( IONS), which is nearing approval for a rival drug, rose 1%, to 48.70. Dow Jones stock Pfizer ( PFE) also is working on a treatment and saw its shares dip a fraction.

Rivals In Amyloidosis

Hereditary ATTR amyloidosis affects about 50,000 people worldwide. Alnylam tested Onpattro in 225 patients who received an infusion every three weeks for 18 months. Onpattro-treated patients showed improved muscle strength, sensation, reflexes and autonomic symptoms.

Ionis, too, is nearing approval for its drug known as inotersen. The FDA is set to consider Ionis' treatment on Oct. 6. Ionis and partner Akcea Therapeutics ( AKCA) already have approval in Europe where they sell the drug under the brand name Tegsedi.

Pfizer is working on treating a similar condition known as transthyretin cardiomyopathy. In this condition, the buildup of abnormal protein affects the heart.

Piper Jaffray analyst Edward Tenthoff noted investors could be disappointed with the approval in treating the nerve damage component of hereditary ATTR amyloidosis. The cardiomyopathy group of patients is much broader, he said in a report to clients.

However, "we believe superior (effectiveness) and first-to-market advantage will enable Alnylam to rapidly penetrate this orphan market with premium pricing," he said. According to Bloomberg, the drug will cost about $450,000 per year.

YOU MAY ALSO LIKE:

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How To Build Long-Term Profits In Stocks? Take Many Gains At 20%-25%

How To Trade Stocks: Why Most Penny Stocks Fail To Make Investors Rich

The post Alnylam Stock Slips As FDA Approves First Gene-Silencing Drug appeared first on Investor's Business Daily.


58. Biotech Stock Reverses Gains Despite 'Surprisingly Strong' ReportПт., 10 авг.[−]

Puma Biotechnology ( PBYI) jumped as much as 11% Friday after its "surprisingly strong" second quarter but reversed course amid analyst doubt for future sales of breast cancer drug Nerlynx.

X

RBC Capital Markets analyst Kennen MacKay says Nerlynx sales are "clearly on track to beat unchanged fiscal year 2018 guide." But he cut his price target on Puma stock to 69 from 77 as it appears fewer patients will begin starting therapy with Nerlynx.

On the call, Puma management indicated some patients may continue treatment with Nerlynx after the one-year mark recommended by the Food and Drug Administration. If so, this would be critical to maintaining sales momentum, MacKay said in a note to clients.

"Future quarters may begin to see loss of patients following one year of therapy," he said. "Given Nerlynx's limited prescribing experience we await more robust support for durations of therapy beyond one year in a substantial portion of treated patients."

On the stock market today, Puma stock jumped as much as 11.4% in high volume. But shares reversed those gains and ended the regular session down 8.1%, to 44.70. Broadly, biotech stocks lost a fraction.

Will Nerlynx Sales Taper?

During the second quarter, Nerlynx brought in $50.8 million in sales, rising 41% over the first quarter and 153% over the fourth quarter of 2017. Nerlynx was first approved in July 2017, so Puma's first sales of the drug weren't reported until late 2017.

Nerlynx sales beat expectations for $46 million, MacKay said. But he expects Nerlynx's launch to become more muted as Puma struggles to retain patients after one year. He calls for challenges in sustaining growth beyond the fourth quarter if patients come off therapy at the one-year mark.

"Notably, management no longer presented the breakdown of new patient starts, which follows the first quarter's controversial datapoint suggesting a decline in new patient starts in April to 280 patients vs. January-March starts in the 320-350 patient rate," he said.

For the year, Puma kept guidance for $175 million to $200 million in sales. This is attainable, MacKay said. Before the report, the Street had modeled $217 million for the year.

"Though we note this trajectory would imply moderate growth slowing into the second half of 2018," he said. "We look for signs that current total prescription trends do not taper and lead to fiscal year 2018 results well ahead of guidance."

YOU MAY ALIKE LIKE:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Invest In Stocks For Free: New Apps Aim For Beginners

Looking For The Best Stocks To Buy And Watch? Start Here

The post Biotech Stock Reverses Gains Despite 'Surprisingly Strong' Report appeared first on Investor's Business Daily.


59. Intel Stock Tumbles On Sell Rating, AMD Stock Gets UpgradeПт., 10 авг.[−]

Investment bank Goldman Sachs on Friday downgraded chip giant Intel ( INTC) to sell from neutral, while upgrading rival Advanced Micro Devices ( AMD) to neutral from sell. Intel stock dropped on the news and AMD stock dipped a fraction.

X

Goldman Sachs analyst Toshiya Hari lowered his rating on Intel on concerns about rising competition and declining profit margins. He cut his 12-month price target on Intel stock to 44 from 49. Hari raised his price target on AMD stock to 21 from 13.25.

Intel stock fell 2.6% to 48.85 on the stock market today. It cut below its 200-day moving average, a key support level. It has been trading below its 50-day moving average since late June.

AMD stock dipped 0.2% to 19.06. It is trading just below a nearly 12-year high of 20.18, reached on July 30. The stock broke out of a 44-week consolidation period on June 7 at a buy point of 16.75.

Facing Competitive Threats

Intel is facing increasing competition from AMD and customers of Taiwan Semiconductor Manufacturing ( TSM), Hari said in a report.

Intel's struggles with its 10-nanometer chip manufacturing process are likely to hurt its profit margins and competitive positioning, he said.

The Santa Clara, Calif.-based company has pushed back production of 10-nanometer chips multiple times because of yield issues. It now expects to produce 10-nanometer PC chips in the second half of 2019, followed by data-center processors. Meanwhile, AMD is already sampling 7-nanometer server processors, Hari said.

Taiwan Semi also is beating Intel to market with 10-nanometer and 7-nanometer chips, he said.

AMD is likely to gain market share from Intel in central processing units for PCs and servers, Hari said.

"The delay in Intel's new products will allow AMD to gain share in not only client (i.e. desktop PC, notebook PC) CPUs, but also in the lucrative server CPU market," Hari said.

RELATED:

Microchip Technology Stock Falls On Mixed Quarterly Results, Outlook

Semiconductor Equipment Stocks Fall On Morgan Stanley Downgrade

Recent IPO NLight Tops Second-Quarter Views In First Public Report

The post Intel Stock Tumbles On Sell Rating, AMD Stock Gets Upgrade appeared first on Investor's Business Daily.


60. Microchip Technology Inherits Mess From Microsemi DealПт., 10 авг.[−]

Microchip Technology ( MCHP) revealed some unexpected problems at recently acquired Microsemi when it reported June-quarter results, which gave investors jitters on Friday. Microchip stock dropped hard on the news.

X

Chandler, Ariz.-based Microchip late Thursday said Microsemi had stuffed its sales channel with inventory to inflate its revenue figures ahead of the $10 billion deal closing on May 29. Shares plunged 10.9% to 87.41 on the stock market today.

Microchip blamed its lower sales guidance partly on efforts to reduce the excess chip inventory that Microsemi shipped to distributors and contract manufacturers. On a conference call with analysts, Microchip Chief Executive Steve Sanghi also criticized the prior management at Microsemi.

"While excessive shipments into distribution and contract manufacturers have been the main issue at Microsemi, we also found a culture of excessive extravagance and high spending," Sanghi said.

He added: "The company had millions of dollars of sponsorships and several luxury suites in sports stadiums, luxury private plane travel, and generous sponsorships for many conferences, stadiums, and other venues that are a waste of shareholders' money. We are undoing commitments to all such spending."

Replaced Leadership

Microchip also has replaced all the top leadership at Microsemi since acquiring the company.

It also said trade tensions between the U.S. and China could impact its chip sales to Chinese hardware makers. Those customers are concerned about possible U.S. tariffs on their products.

In the quarter ended June 30, it earned an adjusted $1.61 a share on sales of $1.21 billion. Earnings per share beat views by 13 cents while sales were in line with targets.

For the current quarter, Microchip expects to earn an adjusted $1.74 a share on sales of $1.51 billion. Wall Street had predicted it would earn $1.69 a share on sales of $1.58 billion for the September quarter.

Microchip Stock Gets Price-Target Cuts

At least five Wall Street analysts cut their price targets on Microchip stock after its fiscal first-quarter report.

Morgan Stanley analyst Craig Hettenbach lowered his price target on Microchip stock to 98 from 103. He kept his equal-weight rating.

"There are company-specific elements at play, led by a material inventory correction at Microsemi," he said. "Commentary about tariffs leading to lower business confidence and a reduction in sell-through in distribution in China is a new development, with broader negative implications for the (semiconductor) group."

Microchip is working to reduce about $200 million of excess Microsemi inventory in the sales channel. That will weigh on sales for the next couple of quarters, analysts said.

Fixing The Problems At Microsemi

Rosenblatt Securities analyst Hans Mosesmann said Microchip management should have no problems fixing the problems at Microsemi.

"Microsemi sold the company dishonorably to Microchip with major inventory shenanigan practices that (will) impact Microchip for the next two quarters," Mosesmann said in a report.

He added, "Microchip's management has proven again and again that it executes acquisitions near-flawlessly and with the continued secular market share prospects in MCUs (microcontroller units), analog, and system platforms, Microchip is a high-quality play in semiconductors."

Microchip management has shown an ability to "transform sleepy assets into highly profitable and/or high-growth sales vectors," Mosesmann said. He reiterated his buy rating and price target of 125 on Microchip stock.

RELATED:

Chip Stocks To Watch And Semiconductor Industry News

The post Microchip Technology Inherits Mess From Microsemi Deal appeared first on Investor's Business Daily.


61. Amazon's Alexa Is Shifting From A Clever Gadget To A Money-Making MachineПт., 10 авг.[−]

When the Alexa smart speaker was introduced three years ago as Amazon Echo, consumers and product reviewers didn't know what to make of it.

X

It makes a lot of sense now.

Amazon's ( AMZN) device was initially used for common things like playing music, keeping lists and answering questions. It since has become a smart-home utility with numerous features that's now positioned to generate buckets of cash for the world's largest e-commerce company.

The name of the device has evolved from Echo to Alexa, the name given to the female voice for the artificially intelligent smart speaker. She responds to questions and requests and lives in the Amazon cloud. It has been one of the top-selling devices sold by Amazon over the past two years.

Alexa started out as one device but has since expanded to a line of several devices. They range from the low-end Echo Dot, priced at $49.99, to the high-end Echo Plus at $149.99. The smart-speaker field has turned out to be one of the hottest categories in consumer electronics.

Amazon doesn't reveal sales of its Echo product line. But in his 2017 letter to shareholders, Chief Executive Jeff Bezos said, "Our 2017 projections for Alexa were very optimistic, and we far exceeded them. We don't see positive surprises of this magnitude very often — expect us to double down."

Amazon said customers bought "tens of millions" of Echo devices last year. It also says the number of Alexa-enabled devices had tripled in the past year thanks to partnerships with a wide array of hardware providers.

'Alexa, Let's Buy Groceries'

Early this month Amazon announced that Alexa is now linked to the company's supermarket chain, Whole Foods Market, for the home delivery of groceries. Users can order groceries for delivery in the dozens of cities where Amazon offers its Prime Now food delivery services. To find out if the service is available, users can say "Alexa, shop Whole Foods."

If available, they can create a grocery shopping list as the days go by, such as saying "Alexa, add eggs and milk to my Whole Foods cart."

Once ready for grocery delivery, users can say "Alexa, checkout."

The shopping list is sent to the user's smartphone for review. A two-hour delivery time window can then be selected. Prime now members can also choose to pick up their groceries instead.

"Everyone in the family can use Alexa to add what they need," Amazon said in a statement. "No more waiting in line at the store and worrying if you are forgetting something."

Monetizing Amazon Echo

Amazon is looking to monetize Alexa in a variety of different fields. It offers its Amazon Music Unlimited service for Echo, and says it has tens of millions of paying customers.

Amazon also is partnering with hotel companies, allowing travelers to continue using Alexa while they are traveling. It's already set up so that users can buy goods available on Amazon's e-commerce website. It can also track their packages and get notices when they arrive.

"I think we're having a lot of success with devices and customers are enjoying those," said Dave Fildes, Amazon's director of investor relations, during the company's second-quarter conference call on July 26. He was responding to an analyst's question about the impact that Alexa is having on Amazon's retail business.

Brian Olsavsky, Amazon chief financial officer, on the conference call said the current goal is expanding the home assistant to places where it can be useful.

"We also are developing new machine learning tools to help developers more easily build Alexa skills," he said. "We feel like we're getting great traction there."

Amazon is spending millions on improving Alexa's list of applications, which it calls skills. About 45,000 skills are available.

Amazon's Market Dominance

Skill sets vary widely, including trivia games, guided meditation, news reports, stock-market action and weather reports. It can also connect to a wide variety of smart-home devices, such as controlling TV sets or lighting. The devices have the potential of being the central hub of a smart-home ecosystem.

"Amazon has poured considerable resources into improving Alexa's library of skills," wrote Cowen analyst John Blackledge in a recent report to clients.

Alexa is far ahead of its second place competitor, the Google Home device from Alphabet ( GOOGL). Amazon entered the market about two years before Alphabet.

The research group Consumer Intelligence Research Partners says the Amazon device leads the smart speaker category, with 70% market share in the U.S. Google Home is second with 24% share.

Blackledge said about 23% of U.S. households with a broadband connection have an Echo.

Amazon is also expanding the line into France, India and Japan. It plans to expand into Mexico, Italy and Spain later this year.

YOU MIGHT ALSO LIKE:

No Need To Ask Jeeves When You Can Ask Apple, Amazon, Facebook, Google

Sonos IPO Jumps As Smart-Speaker Market Gains Momentum

Alexa, Why Did Morningstar Rate You As A Durable Business Pillar?

The post Amazon's Alexa Is Shifting From A Clever Gadget To A Money-Making Machine appeared first on Investor's Business Daily.


62. Dropbox Stock Falls Despite Quarterly Earnings BeatПт., 10 авг.[−]

Dropbox stock fell in after-hours trading, following its second-quarter results reported after the market close Thursday that beat on the top and bottom line.

X

Dropbox ( DBX) reported revenue of $339.2 million, up 27% from the year-ago period. That beat analyst predictions for $331 million. It reported adjusted earnings of 11 cents per share, beating estimates of 6 cents.

Shares of Dropbox were down 10.7%, near 30.72 during after-hours trading on the stock market today. Dropbox stock closed Thursday at 34.43, up 9.1%.

The company made its initial public offering on March 23, pricing Dropbox stock at 21. Shares hit a record high of 43.50 on June 18.

Dropbox also announced that Dennis Woodside is stepping down as chief operating officer. He'll remain at the company until early September and serve as an advisor through the end of the year, Dropbox said.

Dropbox provides data-storage and business-collaboration services. Dropbox competes against Box ( BOX), Atlassian ( TEAM), privately held Slack and Citrix Systems ( CTXS).

The company ended the quarter with 11.9 million paying users, up 2 million from the year-ago period. It said average revenue per paying user was $116.66, as compared to $111.19 for the same period last year.

(An earlier version of this story incorrectly relayed analyst revenue predictions for Dropbox.)

YOU MIGHT ALSO BE INTERESTED IN:

After Hours: Tesla Saga Continues; These 4 Stocks Are Moving On Earnings

IPO Stocks Take Flight In 2018 — Here's How To Catch One

The post Dropbox Stock Falls Despite Quarterly Earnings Beat appeared first on Investor's Business Daily.


63. Microchip Technology Stock Falls On Mixed Quarterly Results, OutlookПт., 10 авг.[−]

Microchip Technology ( MCHP) late Thursday delivered mixed results for its fiscal first quarter and disappointed with its sales guidance, prompting investors to sell in extended trading.

X

The Chandler, Ariz.-based company earned an adjusted $1.61 a share on sales of $1.21 billion in the June quarter. Analysts expected it to earn $1.48 a share on sales of $1.21 billion. On a year-over-year basis, earnings per share rose 23% while sales climbed 25%.

For the current quarter, Microchip expects to earn an adjusted $1.74 a share on sales of $1.51 billion, based on the midpoint of its guidance. Wall Street was modeling it to earn $1.69 a share on sales of $1.58 billion for the September quarter.

Microchip Technology stock fell 7.7% in after-hours trading on the stock market today. During the regular session, it rose 0.3% to 98.08.

Integrating Microsemi Acquisition

"Our June-quarter financial results were strong," Chief Executive Steve Sanghi said in a news release.

The company is working on integrating its acquisition of Microsemi, which closed on May 29, he said. That deal was valued at more than $10 billion.

"While we have lots of work to do to achieve our long-term financial targets, we have high confidence in our team's ability to achieve these results over time," Sanghi said.

Microchip Technology makes microcontroller, mixed-signal, analog and flash-memory chip systems.

YOU MAY ALSO LIKE:

Microchip Technology, ON Semiconductor Initiated With Buy Ratings

The post Microchip Technology Stock Falls On Mixed Quarterly Results, Outlook appeared first on Investor's Business Daily.


64. OLED Kingpin Universal Display Rises On Second-Quarter BeatПт., 10 авг.[−]

Universal Display ( OLED), a key supplier of technology and materials for organic light-emitting diode, or OLED, displays and lighting, late Thursday beat Wall Street's targets for the second quarter, sending its stock higher in extended trading.

X

The Ewing, N.J.-based company earned 23 cents a share on sales of $56.1 million in the June quarter. Analysts expected it to earn 15 cents a share on sales of $49.6 million. In the year-earlier quarter, it earned 99 cents a share on sales of $102.5 million.

Universal Display stock popped 10% in after-hours trading on the stock market today. During the regular session, it dipped 0.8% to 101.15.

"In the second quarter, we saw material sales improving off what we believed to be a first quarter 'bottom' for material shipments," Chief Executive Sidney Rosenblatt said in a news release.

Pickup In Orders, Revenue Seen

Universal Display expects to see a pickup in orders and revenue in the second half of the year as device manufacturers launch new products with OLED displays, Rosenblatt said. For instance, Apple ( AAPL) is expected to introduce two new OLED screen iPhones in September.

"As we look to 2019, we continue to anticipate it to be a meaningful year of growth," Rosenblatt said. "We believe that 2019 is poised to be a pivotal year for the OLED industry."

Display manufacturers are getting ready to open new OLED production lines. The resulting increase in OLED capacity should drive wider adoption of the technology in consumer electronics, Rosenblatt said.

Foldable-Screen Smartphone Coming?

"Additionally, we expect the long-awaited introduction of the world's first foldable OLED product next year to pave the cutting-edge and innovative form factor path," Rosenblatt said. Samsung reportedly is working on a smartphone with a folding OLED screen.

"From conformable, to foldable, to rollable, the disruptive and exciting force of OLEDs promises to enlarge the industry with new applications and new markets the imagination has yet to devise," Rosenblatt said.

Universal Display reiterated its full-year guidance of revenue in the range of $280 million to $310 million.

RELATED:

After Hours: Tesla Saga Continues; These 4 Stocks Are Moving On Earnings

Apple Supplier Hints At Greater 3D-Sensing iPhone Production

Universal Display Stock Jumps On Apple iPhone Report

The post OLED Kingpin Universal Display Rises On Second-Quarter Beat appeared first on Investor's Business Daily.


65. Trade Desk Stock Jumps To All-Time High As Earnings, Guidance Top ViewsПт., 10 авг.[−]

Trade Desk stock rocketed higher Thursday after the digital advertising firm reported second-quarter profit and revenue that beat expectations as it added more large customers.

X

The ad-tech firm's September sales guidance topped views.

Trade Desk ( TTD) stock shot up 13% to 105.50, an all-time high, in after-hours trading on the stock market today.

The Ventura, Calif.-based company said that adjusted second-quarter earnings were 60 cents a share, up 15% from a year ago, with revenue rising 54% to $112.3 million, topping estimates. International growth, including China, boosted overall revenue.

Trade Desk Competes With Google

Analysts expected Trade Desk to report earnings of 44 cents on sales of $104 million for the period ended June 30. A year earlier, the provider of automated advertising-buying technology earned 52 cents a share on sales of $73 million.

Trade Desk competes with Alphabet's ( GOOGL) Google as well as startup AppNexus, recently acquired by AT&T ( T)

"Our strategy of being the best platform for media buying and not owning or arbitraging media is more valuable today than it ever was," Trade Desk Chief Executive Jeff Green said in a press release.

Guidance Tops Analyst Estimates

Trade Desk is ranked No. 3 in the IBD 50 roster of growth stocks. The company enables agencies and other ad buyers to purchase online and mobile advertising through its self-service platform. Trade Desk is pushing into the Connected TV market.

For the September quarter, Trade Desk said it expects revenue of $116 million. Analysts had projected $109 million, up 37%.

Trade Desk stock had doubled in 2018 as of Thursday's regular session. Trade Desk stock has been consolidating after shares soared following its first-quarter earnings beat in May.

YOU MAY ALSO BE INTERESTED IN:

After Hours: Tesla Saga Continues; These 4 Stocks Are Moving On Earnings

Google & Facebook Vs. Amazon & AT&T: The Digital Ad Showdown Begins

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

The post Trade Desk Stock Jumps To All-Time High As Earnings, Guidance Top Views appeared first on Investor's Business Daily.


66. Perrigo Dives As Price Chips Away At Topline And Board Mulls SeparationЧт., 09 авг.[−]

Perrigo ( PRGO) stock plunged Thursday after the company cut its outlook for the year and said it will separate its prescription drug business amid price erosion.

X

That prodded Perrigo stock to plunge 10.6% in high volume, to 70.03, on the stock market today. Generic drug stocks dipped a fraction on Perrigo's report, which followed a similarly disappointing report from Mylan ( MYL) on Wednesday.

Perrigo's prescription drugs business chipped away at the company's topline in the second quarter. Board Chairman Rolf Classon says the unit could realize greater value outside of Perrigo. The board will consider a tax-efficient separation to shareholders, a sale or a merger.

"Perrigo's consumer and prescription platforms are both well positioned, but they are also navigating divergent industry dynamics with unique strategic, financial and operational opportunities and requirements," he said in a written statement.

The board noted Perrigo has had limited options in efficiently separating its businesses after the acquisition of Elan in 2013. But those limitations are set to expire at the end of this year. The separation is now expected in the second half of 2019.

Prescription Drugs Tumble

The troubles in Perrigo's second quarter largely stemmed from the prescription drugs business. Sales in that unit declined 13.2% to $209 million. New product sales of $8 million couldn't offset $35 million lower sales of existing products, the firm said.

Perrigo cited price erosion for lower sales of existing products. The generic drugs firm also cited revised expectations for prescription drugs and unfavorable foreign currency translation of $65 million for its guidance cut.

For the year, Perrigo now sees $4.8 billion to $4.9 billion in sales, down from its prior view for $5 billion to $5.1 billion. Analysts had modeled $5.03 billion. The firm also cut its adjusted profit guide 40 cents at the midpoint to $4.75-$4.95 a share, missing estimates for $5.23.

Topline Light

Total sales declined 5.7% on a constant-currency basis to $1.19 billion. That missed the average of analysts polled by Zacks Investment Research for $1.23 billion. Adjusted earnings were flat at $1.22 per share and beat by a penny.

Consumer health care sales in the Americas fell 1.2%, excluding the impact of exchange rates, to $597 million. Perrigo noted strong sales of cold/cough/allergy/sinus products and infant formula, as well as $15 million in new product sales. But smoking cessation sales declined.

International health care sales declined 4.1% in constant currency to $381 million. The business saw lower sales for anti-parasite, lifestyle and analgesics. But new product sales of $19 million and higher net sales in diagnostics partially offset that.

YOU MIGHT ALSO LIKE:

How Much Money Do You Need To Start Investing?

Investing Basics: How To Sell A Stock

Looking For The Next Nvidia? Start With This Simple Routine

The post Perrigo Dives As Price Chips Away At Topline And Board Mulls Separation appeared first on Investor's Business Daily.


67. This Medtech Broke Out In Bullish Fashion On Broad Beat-And-RaiseЧт., 09 авг.[−]

Wright Medical Group ( WMGI) broke out in bullish fashion Thursday on a broad beat-and-raise as its core business returned to market growth for the first time since early 2016.

X

On the stock market today, Wright stock jumped 7% in high volume, to 28.14. Earlier, shares rocketed as high as 9.9%. Wright stock broke out of a cup with a buy point at 27.42. The broader medical products group lifted a fraction.

For the second quarter, Wright generated $205.4 million in sales, rising 12.9% in constant currency to top analyst predictions for $197.1 million, RBC Capital Markets analyst Glenn Novarro said in a report.

The "revenue beat in the second quarter was pretty broad-based," Novarro said.

Upper-Extremities Products Drive Growth

Wright sells surgical products for upper and lower extremities, as well as biologic solutions like its newly approved injectable bone graft.

Sales of products for upper extremities drove growth in the quarter. Globally, those sales grew 23.3% to $99.31 million. In the U.S., they grew 22%. That was driven by 24% growth in the U.S. for shoulder products, Wright said in a news release.

Analysts predicted $95 million in upper-extremities sales, Novarro said.

He noted, "Wright continues to gain meaningful share in shoulders." Further, he sees Wright remaining "a share-gainer in the shoulder market despite increasing competition in the stemless-shoulder space."

More Growth

Revenue from lower-extremities products — foot and ankle — grew 8.7% globally to $75.1 million. In the U.S., sales in that unit rose 9.4%. That was driven by 15% growth in revenue from total sales of ankle products and improved growth in the core business.

"The lower-extremities business returned to market rates of growth well ahead of schedule, driven primarily by increased contributions from our expanded sales organization," Chief Executive Robert Palmisano said in a written statement.

This was the first time the lower-extremities business grew in line with the market since the first quarter of 2016, RBC's Novarro said. Wright expects the launch of a minimally invasive surgical system for forefoot and hind-foot problems to drive momentum.

Analysts estimated about $72 million in sales of lower-extremities products, Novarro said.

Injectable Bone Graft

Palmisano also noted that the Food and Drug Administration granted its injectable bone graft, called Augment, premarket approval. Augment could help Wright's biologics business grow further in the back half of 2018, he said.

Novarro backed up that claim, saying he expects biologics sales to reaccelerate in the second half of the year with the help of Augment bone-graft sales.

During the second quarter, biologics sales grew 9.9% globally to $26.82 million. In the U.S., sales from that unit rose 5%. The consensus had called for $23 million in biologics sales, he said.

Meanwhile, sports medicine and other sales declined 26.9% and 4.2%, respectively, globally and in the U.S.

For the year, Wright boosted its guidance to $808 million to $820 million in sales, up from its prior view for $800 million to $812 million. The firm also expects adjusted losses to come in at 14 to 21 cents per share.

Needham analyst Mike Matson raised his expectations for 2018 and 2019 sales to $818 million and $900 million, respectively. He expects adjusted losses of 18 cents per share this year and profit of 19 cents per share in 2019.

YOU MIGHT ALSO LIKE:

How Much Money Do You Need To Start Investing?

Long-Term Retirement Investing Strategies With ETFs

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The post This Medtech Broke Out In Bullish Fashion On Broad Beat-And-Raise appeared first on Investor's Business Daily.


68. Semiconductor Equipment Stocks Fall On Morgan Stanley DowngradeЧт., 09 авг.[−]

Applied Materials ( AMAT) and other semiconductor equipment stocks tumbled Thursday after investment bank Morgan Stanley soured on the sector.

X

Morgan Stanley analyst Joseph Moore lowered his rating on the semiconductor equipment industry group to in-line from attractive. He also downgraded Applied Materials stock to equal-weight from overweight and trimmed his price target to 54 from 58.

"After having an Attractive view on the industry for over two years, we move to the sidelines," Moore said in a report. "We aren't negative, but we see the stocks as rangebound."

He also cited weakness in the memory chip and foundry businesses for his call.

Semiconductor Equipment Stocks 'Rangebound'

"We see equipment stocks as more rangebound for the next 6-12 months, with limited downside but also limited upside, reflecting our more cautious view of memory and memory capital spending," he said.

Moore does not see a rapid rebound in memory chip equipment spending that some companies have forecast.

Chip-gear stocks already have been impacted by second-quarter results and third-quarter guidance.

Among semiconductor equipment stocks, Moore favors Lam Research ( LRCX). He rates the stock as overweight.

Applied Materials stock fell 2% to 49.16 on the stock market today. Lam Research dropped 2.9% to 184.49.

IBD's Semiconductor Equipment industry group dipped 1.3% on Thursday. It includes 37 stocks.

Cautious On Chip Stocks

Morgan Stanley also shifted to a "cautious" industry view from "in-line" for the semiconductor segment.

"Business is healthy, although upside to estimates is now difficult to come by," Moore said in separate report. "Furthermore, elevated inventory and stretched lead times leave no margin for error as any lead time adjustment or demand slowdown could drive a meaningful correction."

Risk/reward for investors in the sector is "the poorest it has been in three years," he said.

The brokerage downgraded ON Semiconductor ( ON) to underweight from equal weight and cut its price target to 18.50 from 20. ON Semi stock fell 2.2% to 21.92.

The firm still rates some chip stocks as overweight: Nvidia ( NVDA), Xilinx ( XLNX), and Ambarella ( AMBA). Those companies should benefit from secular growth in artificial intelligence, data centers and autonomous driving, Moore said.

RELATED:

Recent IPO NLight Tops Second-Quarter Views In First Public Report

Semiconductor Stocks To Consider Buying When The Time Is Right

The post Semiconductor Equipment Stocks Fall On Morgan Stanley Downgrade appeared first on Investor's Business Daily.


69. Roku Stock Surges Past Buy Point On Second-Quarter EarningsЧт., 09 авг.[−]

Roku stock soared on Thursday after the streaming video company delivered a beat-and-raise report for the second quarter fueled by advertising growth on its platform.

X

Roku ( ROKU) shares jumped 21.3% to 57.32 on the stock market today. The stock blew past a 51.92 handle buy point in a deep cup base. The company went public last September at 14 and hit an all-time high of 58.80 in December.

Late Wednesday, the Los Gatos, Calif.-based company beat Wall Street's estimates for the second quarter and guided higher for revenue and adjusted profit for the full year.

The company broke even on sales of $156.8 million in the June quarter. Analysts expected it to lose 15 cents a share on sales of $141.5 million.

Adds 1.2 Million New Users

Active accounts rose 46% to 22 million users in the second quarter from the same period last year. It added 1.2 million new users from the first quarter.

Average revenue per user climbed 48% year over year to $16.60 in the June quarter. It was $15.07 in the March quarter.

Roku's streaming video platform is a popular way for TV viewers to access content from such services as Netflix ( NFLX), Amazon.com ( AMZN), Hulu and Alphabet's ( GOOGL) YouTube.

It sells streaming video hardware and licenses a smart-TV operating system to television makers. But advertising on its platform is its fastest-growing business.

Roku Stock Gets Price-Target Hikes

At least three Wall Street analysts raised their price targets on Roku stock after the company's earnings report.

KeyBanc Capital Markets analyst Evan Wingren upped his price target to 67 from 54 and kept his overweight rating.

"Roku has continued to exceed our expectations, which is fundamentally driven by its purpose-built TV operating system and the Roku Channel," its advertiser-supported on-demand streaming channel, Wingren said in a report to clients.

Needham analyst Laura Martin speculates that Roku could be a takeover target. She reiterated her buy rating and price target of 60 in a report Thursday.

No Plans For Original Content On Roku Channel

Roku is ramping up its promotion of free, advertiser-supported content on its platform. It is adding new content categories to the Roku Channel. That includes news and expanding into new geographies, starting with Canada.

Roku has no plans to follow Netflix and others into producing original video content, Chief Financial Officer Steve Louden told Investor's Business Daily.

"We don't have any plans to go into original content," he said. "The way we look at it is there's a lot of great content in content owners' libraries that is increasingly underutilized."

Current offerings on the Roku Channel include movies like "The Matrix" trilogy and "School of Rock" and TV series like "Bewitched" and "I Dream of Jeannie."

RELATED:

Roku Stock Jumps On Better-Than-Expected Second Quarter

The post Roku Stock Surges Past Buy Point On Second-Quarter Earnings appeared first on Investor's Business Daily.


70. Booking Holdings Second-Quarter Results Beat But Outlook A MissЧт., 09 авг.[−]

Online travel firm Booking Holdings ( BKNG) reported second-quarter earnings before the market open Tuesday that beat estimates, but its earnings outlook for the current quarter fell short and its shares tumbled.

X

Booking Holdings, formerly known as Priceline, reported revenue of $3.54 billion, up 17% from the year-ago period. That beat the consensus estimate of $3.44 billion. It reported adjusted earnings of $20.67 per share, beating analyst estimates for $17.34.

Shares of Booking closed at 1,942.39, down 5% on the stock market today.

Guidance Below Views

For the current quarter, Booking expects its adjusted per-share earnings to range from $36.70 to $37.70. That's below analyst forecasts for $39.79.

Booking Holdings changed its name from Priceline early this year. The company has six main online properties, the largest being Booking.com. Its main competitor is Expedia ( EXPE).

"We will continue to execute on our long-term strategy to drive profitable growth and invest in capabilities to increase customer loyalty and build a larger direct business." Booking Chief Executive Glenn Fogel said in prepared remarks.
YOU MIGHT ALSO LIKE:

The post Booking Holdings Second-Quarter Results Beat But Outlook A Miss appeared first on Investor's Business Daily.


71. Tesla Stock Stumbles Quickly After Musk Talks Of Going PrivateЧт., 09 авг.[−]

It didn't take long for Tesla stock euphoria to fade. Exactly 48 hours after Chief Executive Elon Musk triggered a frantic rally with a tweet saying he was considering taking Tesla ( TSLA) private, shares erased all their gains Thursday.

X

Doubts have mounted about Musk's ability to take the electric-car maker off the market. That sent Tesla stock tumbling as much as 4.6% to $353.33 in afternoon trading. It's also well off the $420 at which Musk said shareholders would be bought out.

Tesla stock dropped on back-to-back days after having jumped 11% on Tuesday. That's when Musk vowed that he had "funding secured" at a spectacular $82 billion valuation.

Since that initial tweet, though, he has offered no evidence to back up the statement. Nor has anyone stepped forward publicly — or privately — to say they're behind the plan. People with or close to 15 financial institutions and technology firms spoke on the condition of anonymity. All said they weren't aware of financing having been locked in before Musk's tweet.

"I don't really understand the idea of what was suggested in the potential for them to go private," said Dick Weil, CEO of Janus Henderson Group. Weil discussed the idea in an interview with Bloomberg Television.

He went on to say: "That's obviously an incredibly large valuation to somehow take into the private market."

Regulatory Troubles

That could be problematic as the Securities and Exchange Commission starts investigating the matter. Regulators have asked the company if Musk's tweets were factual and why such a disclosure was made via social media rather than a filing, according to the Wall Street Journal, citing unidentified people familiar with the matter. Judith Burns, an SEC spokeswoman, declined to comment. Tesla also declined to comment.

"When Musk tweeted this, was he saying this was something that was definitely going to happen? Something that might happen?" said Ira Matetsky, a partner at Ganfer Shore Leeds & Zauderer in New York. "How would a reasonable investor interpret that and was it consistent with the facts as they existed at the time?"

Musk raised the go-private possibility with the board last week, according to a statement from six of Tesla's nine directors. They said he had "addressed the funding for this to occur," without providing details.

As for Tesla shareholders, Musk said in one of his Twitter posts that "investor support is confirmed" for his plan. The company's largest shareholders have declined to comment. A spokeswoman for the California State Teachers' Retirement System, which as of March owned about 213,000 shares, said there was no heads-up given.

"We have not been contacted by Tesla IR," said Michelle Mussuto, the spokeswoman. "They didn't reach out before the tweet either."

Musk's Previous Talk Of Going Private

Leaving the public marketplace isn't a new vision for Musk.

"I wish we could be private with Tesla," he told Rolling Stone in an interview published in November. "It actually makes us less efficient to be a public company."

In April 2017, Musk held talks with Masayoshi Son about SoftBank Group ( SFTBY) investing in the electric carmaker. They touched on the possibility of fulfilling Musk's wish, according to two people with knowledge of the discussions. The talks failed to progress due to disagreements over ownership and have not started up again.

Musk's personal stake in Tesla stock is almost 20%. That means he would need roughly $70 billion to take it out of the market. That kind of money may be accessible through sovereign wealth funds or other strategic investors, said Dwight Scott, president of Blackstone Group LP's GSO Capital Partners.

The money-losing and cash-burning company is an unlikely candidate for debt investors to be willing to help go private.

Bearish On Tesla Stock

It's possible Musk could persuade some large institutional and strategic investors to either newly become or remain shareholders in the private company. That could reduce his funding needs, said Toni Sacconaghi, an analyst at Bernstein who has long been bearish on Tesla stock.

But "if no firmer details emerge," he wrote in a report to clients, "investors would likely increasingly debate Musk's credibility and seemingly unhealthy focus on the shares' price and volatility."

It's also possible Musk has some unconventional plan that would take Tesla private without using traditional sources. On Twitter, he alluded to the creation of a "special purpose fund enabling anyone to stay with Tesla."

"What investors are waiting for is more details around what is meant when Elon Musk says funding is secured," said George Galliers, analyst at Evercore ISI on Bloomberg Television. "They are raising a lot of sensible questions around who would be providing the funding and how exactly this might work."

Galliers rates Tesla stock the equivalent of a hold.

YOU MIGHT ALSO LIKE:

After Hours: Tesla Saga Continues; These 4 Stocks Are Moving On Earnings

The post Tesla Stock Stumbles Quickly After Musk Talks Of Going Private appeared first on Investor's Business Daily.


72. Spotify Stock Jumps On News Of Samsung PartnershipЧт., 09 авг.[−]

Streaming music service Spotify Technology ( SPOT) and consumer electronics heavyweight Samsung are partnering to take on mutual rival Apple ( AAPL). Spotify stock jumped on the news Thursday.

X

Spotify stock rose 4.8% to 187.33 on the stock market today. It went public on April 3, starting at 165.90. Shares hit a record high of 198.99 on July 26.

Samsung has named Spotify as its "go-to music service provider." The deal covers a range of devices from smartphones to televisions and smart speakers.

In a blog post, Spotify Chief Executive Daniel Ek said the partnership will give Samsung customers a "seamless listening experience between devices." The alliance will combat Apple, which uses Apple Music as its default streaming music service on its iPhone smartphones, the HomePod smart speaker and other devices.

Samsung Unveils Galaxy Home Speaker

Samsung announced the partnership Thursday amid a host of new product announcements, including the Galaxy Note 9 phone-tablet and Galaxy Watch smartwatches. It also introduced the Galaxy Home smart speaker. The speaker is Samsung's answer to Amazon's ( AMZN) Echo speakers, Alphabet's ( GOOGL) Google Home and Apple's HomePod.

It described Galaxy Home as a premium, surround-sound music speaker with voice controls using its Bixby personal assistant. It features Samsung's SmartThings hub. That allows users to control lights, thermostats and other connected gadgets around the house with voice commands to the speaker.

The South Korea-based company didn't provide a price or release date for Galaxy Home. It will share more information on the upcoming device during the Samsung Developer Conference in November, CNBC reported.

"This significant long-term partnership will provide Samsung users across millions of devices with the best possible music streaming experience, and make discovering new music easier than ever — with even more opportunities to come," Ek said.

RELATED:

Apple HomePod Grabs Small, But Meaningful, Share Of Smart Speaker Market

Spotify Stock Surges To Record High On Second-Quarter Subscriber Gain

The post Spotify Stock Jumps On News Of Samsung Partnership appeared first on Investor's Business Daily.


73. These Gene Therapy Stocks Are Spiking — Here's WhyЧт., 09 авг.[−]

Shares of gene therapy companies Sangamo Therapeutics ( SGMO) and Sarepta Therapeutics ( SRPT) popped Thursday on bullish expectations for their respective hemophilia A and Duchenne muscular dystrophy treatments.

X

On the stock market today, Sangamo stock jumped 10.9% in high volume, to 15.30, and Sarepta stock leapt 9.9%, to 132.96. Meanwhile, shares of the broader biotech group rose a fraction.

Gene Therapy Studies

Late Wednesday, Sangamo and partner Pfizer ( PFE) unveiled data from a test of a gene therapy to treat hemophilia A. The field is ripe with contenders including Spark Therapeutics ( ONCE) and BioMarin Pharmaceutical ( BMRN).

Sangamo and Pfizer plan to test up to 20 patients with severe hemophilia A. To date, five patients have received treatment at three different dose levels. So far, patients have tolerated the gene therapy with no treatment-related side effects.

The fifth patient in the study was treated in June. Since then, that patient has experienced an improvement in the level of a key blood-clotting protein called factor VIII. Sangamo and Pfizer didn't go into how much of an improvement the patient saw.

RBC Capital Markets analyst Kennen MacKay expected Spark to dive on the news. Spark and BioMarin also are working on gene therapies to treat hemophilia A. Earlier this week, Spark's results in a recent test seemed to lag BioMarin's.

Two patients in Spark's study experienced damaging immune responses and required on-demand treatment. Spark thinks it can control this kind of side effect by using preventative steroids. But in Sangamo's study, patients didn't require tapering steroids.

Sangamo's release was scant on details, but it could "potentially (add) a competitive threat to Spark," MacKay said in a note to clients. "Further, Sangamo touted that no use of tapering courses of oral steroids was required in these initial five patients, suggestive of a clean safety profile."

Sarepta's Exondys 51 Tops

Sarepta spiked on its earnings report. Sales of Sarepta's approved Duchenne muscular dystrophy drug, Exondys 51, came in at $73.5 million. That more than doubled vs. the year-ago period and topped views for $71 million, Piper Jaffray analyst Edward Tenthoff said in a note.

The biotech firm also reported a loss of $1.67 per share. That was wider than analyst views for a per-share loss of 89 cents, JMP Securities analyst Liisa Bayko said in her report to clients. On an adjusted basis, Sarepta reported a 43-cent loss per share vs. a 48-cent adjusted loss in the year-ago period.

For the year, Sarepta projects $295 million to $305 million in sales. JMP's Bayko sees the company bringing in $301 million. Piper Jaffray's Tenthoff is more bullish and expects $309 million in 2018 sales.

Treating Duchenne Muscular Dystrophy

Analysts are also excited about what's next for Sarepta. The firm has several bites at the apple in treating Duchenne muscular dystrophy, a genetic condition that tends to affect boys. It's characterized by progressive muscle degeneration and weakness.

Sarepta said it's nearing resolution of a clinical hold on a study of its drug, micro-dystrophin. In July, the Food and Drug Administration placed the study on hold after discovering a trace amount of DNA in a material provided by a third party and used in the gene therapy.

To resolve that issue, Sarepta said it's now partnered with Brammer Bio to provide its clinical and commercial manufacturing for micro-dystrophin and future gene therapy platforms. The biotech expects to respond to the FDA's hold by the end of August.

What's Next?

Sarepta expects to complete its rolling application for approval of a drug called golodirsen by the end of the year. Golodirsen is being investigated in Duchenne muscular dystrophy. It works by skipping over faulty or misaligned sections of genetic code.

Tests also show Sarepta's drug called casimersen is just as efficient as golodirsen in skipping over faulty genetic code and promoting a key protein necessary for muscle movement. This could help Sarepta to file for accelerated approval of casimersen by mid-2019, the firm said.

"Golodirsen and casimersen combined serve an even larger population than Exondys 51," Chief Executive Doug Ingram said on the earnings conference call. "So, the near-term opportunity to bring these therapies to the community is very significant."

YOU MIGHT ALSO LIKE:

How To Trade Stocks: Why Most Penny Stocks Fail To Make Investors Rich

Long-Term Retirement Investing Strategies With ETFs

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

The post These Gene Therapy Stocks Are Spiking — Here's Why appeared first on Investor's Business Daily.


74. Facebook (FB) Stock Quotes, Company News And Chart AnalysisЧт., 09 авг.[−]
X


View FB Stock Quote Page
| View FB Ratings

Facebook Stock News & Analysis

Dow Jones Futures: Tesla Stock Falls Below 300; Pepsi To Buy SodaStream; China Trade War Talks LoomDow Jones futures rose modestly Monday morning, along with S&P 500 futures and Nasdaq futures. Tesla continued to slide after CEO Elon Musk tweeted early Sunday that changing his work habits is... Read More
Facebook Drop Doesn't Stop Momentum ETFs From Going ForwardFacebook is down 14% from its July record high. Netflix is off 17%. Twitter sank 30%. Intel declined 14%. Meanwhile, both the Nasdaq and the S&P 500 are nearing record highs. So,... Read More
Dow Jones Futures: Tesla Falls Below Buy Point As These Top Stocks MoveDow Jones futures were little changed early Wednesday, along with S&P 500 futures and Nasdaq futures. The major stock market averages were near record highs. Tesla remained active overnight after surging on CEO... Read More
Berkshire Stock Gaps Up On Earnings; Dow, S&P 500, Nasdaq Edge HigherBerkshire stock gapped up Monday on earnings, while shares of Intel and IBM weighed on the Dow Jones industrial average. Major stock indexes weren't moving much as the stock market kicked off... Read More
Tech Companies Go Old School With Billboards To Promote ThemselvesSilicon Valley's going old school. Tech companies like Facebook and Alphabet's Google vacuum up billions of dollars in online advertising. But they're also pouring their own marketing dollars into billboards and other... Read More

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

More Technology Stocks Coverage

FANG Stocks News: Facebook, Amazon, Netflix, Google

Apple (AAPL) Stock Quotes And Company News

Tesla (TSLA) Stock Quotes And Company News

View More Tech Stocks

The post Facebook (FB) Stock Quotes, Company News And Chart Analysis appeared first on Investor's Business Daily.


75. AI Companies Race To Get Upper Hand In Cybersecurity — Before Hackers DoЧт., 09 авг.[−]

Artificial intelligence, for all its mind-boggling potential, is a double-edged sword.

X

Sure, AI might save lives through early cancer or heart disease detection. In cybersecurity, though, even AI companies worry that the bad guys will use artificial intelligence to launch more potent attacks.

Little wonder, then, that computer security has become an AI hot spot. Venture capital firms are throwing money into "machine learning" startups. Incumbent cybersecurity companies are deploying artificial intelligence in their products and services. Giant tech companies like Google are adding AI defenses to protect their cloud computing data centers. For investors looking for early signs that artificial intelligence will disrupt industries, cybersecurity is clearly a top sector to watch.

State-sponsored attackers, criminal cyber-gangs and ideological hackers all could employ AI. And cybersecurity experts believe criminals will use AI to develop mutating malware that changes its structure to avoid detection.

Hackers also could use artificial intelligence tools to scrub social media for personal data. Then they could customize emails in spear-phishing attacks to con people into disclosing security credentials. Or, they could use AI to identify weaknesses in computer security products. The list goes on.

"The arms race is real," said Jon Oltsik, a senior analyst at Enterprise Strategy Group. "There's a level of sophistication that's needed for artificial intelligence — data science skills, algorithm-building skills — that's going to limit the use of AI on the adversary side to nation states and very profitable cybercrime groups."

"The bad guys are well organized. They share intelligence," Oltsik said. "There's a division of labor. So AI could become a specialization where it's something (hackers) pay for over time."

AI Companies To Watch

The good news is that the computer security industry knows the stakes are high.

With artificial intelligence, startup AI companies aim to spot and block malicious activity on computer networks better than existing technologies can. To detect cyberthreats, their AI software sifts through massive stores of computer network data.

Wall Street analysts are eyeballing Cylance, CrowdStrike, Darktrace, Vectra Networks and a handful of other private firms. With AI tools, the new AI companies are taking customers away from cybersecurity industry incumbents, analysts say.

Cylance in June completed a $120 million funding round, bringing its total to nearly $300 million. CrowdStrike has raised $481 million, including a $200 million funding round in June.

Artificial Intelligence: Incumbent Tech Companies

As corporate America shifts more business workloads to cloud computing service providers, Amazon.com ( AMZN), Microsoft ( MSFT) and Google-parent Alphabet ( GOOGL) are gobbling up AI startups to improve computer security. Google in January also launched its own cybersecurity business. Called Chronicle, the computer security services unit will draw upon Google's strengths in AI and cloud computing.

Cybersecurity industry leaders including Palo Alto Networks ( PANW), Fortinet ( FTNT) and Cisco Systems ( CSCO) hope to stay on top even as artificial intelligence opens the door to new competitors. They're racing to develop AI tools from scratch or acquiring startups. Shares of Palo Alto and Fortinet have moved higher lately, while Microsoft has flattened after a recent runup.

Palo Alto Networks in March bought LightCyber, a behavioral analytics firm, for $105 million.

"I think for a short time it might be OK for security companies not to have AI capabilities," said Lee Klarich, Palo Alto Networks' chief product officer, in an interview. "Midterm and long-term, that's not true. Artificial intelligence absolutely becomes table stakes. We are very much in this space, with resources."

AI As Computer Security Tool

Palo Alto Networks is just one top AI company to watch. AI involves computer algorithms, software programs that mimic the human ability to learn, interpret patterns and make predictions.

Artificial intelligence should improve computer security tools by speeding up incident responses once malicious software is detected on computer networks. It could help thwart email-delivered ransomware or swarming botnets that knock out access to websites.

"There's an opportunity for AI to level the playing field," Oltsik said. "One of the visionary uses for AI and machine learning is to automate the response side." Machine learning is the type of AI used most often in cybersecurity.

More Powerful Attacks Expected

But more powerful cyberattacks are expected as hackers deploy artificial intelligence or machine learning software to hike the frequency and sophistication of attacks.

That's worrisome because hackers already cause plenty of damage without AI. Consider headlines over WannaCry and Not Pety as well as cyberattacks against Equifax, Uber, Aetna and Deloitte just over the past year. The U.S. blamed a hacking entity known as Lazarus Group, which works on behalf of the North Korean government, for unleashing the so-called WannaCry cyber attack. It crippled hospitals, banks and other companies across the globe.

IBM researchers say hackers may use AI to develop new forms of malware. IBM on Aug. 9 released a study at the Black Hat cybersecurity conference detailing how hackers could use a new class of AI-enabled malware called DeepLocker. IBM says AI malware can be designed to be evasive, making it easier to reach its target.

State sponsors of cyberattacks are likely to share their AI toolkit via the "dark web" to disguise their involvement in data breaches, says Parham Eftekhari, executive director of the Institute for Critical Infrastructure Technology.

Thomas Michelli, the Pentagon's acting deputy chief information officer for cybersecurity, on July 17 said the Defense Department plans to announce a new artificial intelligence strategy this summer.

Artificial Intelligence Noise

Another factor also works against those seeking to root out hackers: a sort of artificial intelligence din. Picking out the truly effective tools — and truly worrisome threats — may be like separating wheat from chaff.

U.S. companies should be wary of marketing claims over artificial intelligence technologies embedded into products, says research firm Gartner.

"There is hype. A lot of companies talk about AI and make claims that aren't substantiated," said Dale Gardner, analyst at Gartner. "But there is also a lot of legitimate activity in cybersecurity and companies doing valuable and interesting things."

Surveys show that corporate America doesn't view artificial intelligence as a silver bullet that will prevent hackers from stealing customer data or intellectual property. But many U.S. companies face a shortage of computer security personnel to thwart and detect threats.

And they must deal with surging volumes of security alerts. While human specialists become overloaded at some point, AI software scans huge amounts of data to classify and prioritize attacks. The AI tools narrow down what needs to be reviewed by human security specialists.

"It's as if you're walking down the street in Manhattan and all the car alarms go off," said Stuart McClure, chief executive of Cylance. "That's what happens in our industry. They ignore the noise, because there's more noise than signal. We have to employ AI in the right places to intelligently find the signal inside the noise. We don't care how many haystacks there are. We'll find all the needles."

AI Companies: Two Cybersecurity Examples

Irvine, Calif.-based Cylance says it had over $100 million in 2017 revenue run-rate, with 20% of the Fortune 500 as customers.

Cylance targets the so-called "endpoint" market — detecting malware on laptops, mobile phones and other devices that access corporate networks. IDC forecasts the endpoint cybersecurity market will grow to $12.5 billion in 2021, up from $9.6 billion in 2016.

CrowdStrike also focuses on the endpoint market. The startup AI companies aim to thwart ransomware — malware that infects a computer network and encrypts files. Hackers then extort money to unencrypt the files. The number of ransomware attacks has exploded, Verizon Communications ( VZ) says in a recent report on data breaches.

George Kurtz, CrowdStrike CEO, says artificial intelligence will help companies deal with "adversaries that are constantly changing techniques." He says AI will play a role in threat management, helping companies automate detection and incident response.

"AI is going to become more prevalent in security. It's maturing," Kurtz said. "AI is a feature, not a company. It's going to play a role in solving a specific problem. But not every problem can be solved with AI. There are different levels of expense in terms of compute cycle and just time. It's going to be a tool in the toolkit."

How Artificial Intelligence Works

Jonathan Ho, analyst at William Blair, says startups must build up a customer base that enables them to train their mathematical algorithms on vast amounts of data.

Machine learning works by analyzing and finding patterns in large amounts of data. Machine learning tools look for anomalies in computer networks, such as suspicious traffic or unauthorized behavior.

Older antivirus software looks for "signatures" of known malicious software. More advanced machine learning tools learn to identify malware traits rather than specific signatures. That enables them to detect new types of malware.

Kurtz says CrowdStrike's cloud platform collects and analyzes more than 100 billion endpoint events per day. CrowdStrike rents computing resources worldwide from Amazon Web Services, the biggest cloud services provider, to process the malware scans. All AI software needs powerful computers to parse large quantities of data.

Analysts expect synergy between the new AI companies and companies specializing in "Big Data" analytics. Splunk ( SPLK), for instance, acquired startup Phantom in February for $350 million. Splunk bought Caspida, a provider of behavioral analytics for computer security, in 2015 for $190 million.

Cybersecurity, AI And Cloud Computing

At Palo Alto Networks, a big push is on to use cloud computing to improve cybersecurity. Palo Alto is developing a cloud-based platform that aggregates customer data. Companies will have the option of letting third-party companies that partner with Palo Alto Networks access the data for analysis.

It's expected that AI startups will be included in the cloud platform. Palo Alto in May disclosed one AI partner, Mist Systems.

Ho, at William Blair, says Palo Alto Networks could step up its push into AI under its new chief executive. Palo Alto this month named Nikesh Arora, a former chief business officer at Google, as its CEO.

"Nikesh is going to be integral to the next stage in Palo Alto's evolution, given his background," said Ho.

Palo Alto's Klarich says computer security firms need to share information over growing threats. He notes that Palo Alto founded the Cyber Threat Alliance, along with Intel ( INTC), Symantec ( SYMC), Cisco and Check Point Software Technologies ( CHKP). To recognize the use of AI by hackers, Klarich says security firms may need to build and share "adversary playbooks" as threats evolve.

Google AI Moves

Palo Alto competes in the "firewall" network security market vs. Cisco and Fortinet. Firewalls block unauthorized traffic from entering a private network and monitor web-based apps.

Fortinet in early June said it has integrated new machine learning tools into its web application firewall. The race to develop AI tools is occurring amid other big changes in the cybersecurity industry.

Besides launching its Chronicle cybersecurity business, Google uses AI in self-driving cars as well as its core internet search and advertising business.

Google may be able to go beyond machine learning into more advanced predictive cybersecurity. Chronicle will likely tap Google's cloud platform for speed and computing power. Google, like others, is developing specialized AI chips for data centers.

"They're likely to do things at the high end of the security market at first. It's definitely worth keeping an eye on them," said ESG's Oltsik. "Google knows how to collect, process and analyze lots of data at scale."

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

YOU MAY ALSO LIKE:

Read All The News On Artificial Intelligence Trends And Leading Stocks

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post AI Companies Race To Get Upper Hand In Cybersecurity — Before Hackers Do appeared first on Investor's Business Daily.


76. Roku Stock Jumps On Better-Than-Expected Second QuarterЧт., 09 авг.[−]

Streaming video platform Roku ( ROKU) late Wednesday beat Wall Street's estimates for the second quarter, giving its stock a boost in extended trading.

X

The Los Gatos, Calif.-based company broke even on sales of $156.8 million in the June quarter. Analysts expected it to lose 15 cents a share on sales of $141.5 million. On a year-over-year basis, revenue rose 57%, driven by advertising sales.

Roku also guided analysts higher for revenue and adjusted profit in the current quarter and full year.

Its shares jumped 8% in after-hours trading on the stock market today. During the regular session, the stock dipped 0.4% to 47.25. Roku went public on Sept. 28 at $14 a share.

"We are raising our full-year 2018 outlook and believe Roku is well-positioned to seize the significant opportunities being created by the transition to streaming," Chief Executive Anthony Wood and Chief Financial Officer Steve Louden said in a letter to shareholders. "Our investments are delivering a better streaming experience for consumers, bigger audiences for content owners, and more effective marketing tools for brands."

Roku expects to generate revenue of $168 million in the third quarter, topping views for $165 million.

For the full year, it forecast earnings before interest, taxes, depreciation and amortization of $17 million. It is looking for 2018 revenue of $720 million. Wall Street was modeling for an adjusted loss of $1.2 million on sales of $698 million.

Roku Adds 1.2 Million New Users

Roku said its active accounts jumped 46% to 22 million users in the June quarter from the same period last year. It added 1.2 million new users from the first quarter.

Users streamed 5.5 billion hours of content on the platform in the second quarter. That compares with 3.5 billion hours in the year-earlier period and 5.1 billion in the first quarter.

Average revenue per user rose 48% year over year to $16.60 in the June quarter. It was $15.07 in the March quarter.

Advertiser-Supported Streaming Video

The company also announced a new way for people to access its free, advertiser-supported streaming video service. On Wednesday it launched its Roku Channel on the web in the U.S. So anyone with an internet-connected PC, smartphone or tablet can watch its on-demand programming. Previously users needed a Roku smart TV or set-top box to access the channel.

Plus, it has added an area dedicated to free programming on its home screen. The "Featured Free" section provides direct links to free content from its own channel, ABC, the CW, CW Seed, Fox, Freeform, Pluto TV, Sony Crackle, Tubi and more. "Featured Free" will be rolled out to users in the U.S. in the coming weeks.

Roku's streaming video platform is a popular way for TV viewers to access content from such services as Netflix ( NFLX), Amazon.com ( AMZN), Hulu and Alphabet's ( GOOGL) YouTube.

RELATED:

What Makes This Breakout Special Vs. Apple, Alphabet, Tesla

FANG Stocks: Investors Look For Next Alpha Wolf To Lead Pack

Netflix Subscribers Upgrading To Premium Service Tier

Roku Adds TV Speakers To Streaming Video Hardware Lineup

The post Roku Stock Jumps On Better-Than-Expected Second Quarter appeared first on Investor's Business Daily.


77. Recent IPO NLight Tops Second-Quarter Views In First Public ReportЧт., 09 авг.[−]

Laser maker NLight ( LASR) late Wednesday topped Wall Street's estimates for the second quarter, its first as a publicly traded company.

X

The Vancouver, Wash.-based company earned an adjusted 14 cents a share on sales of $51.7 million in the June quarter. Analysts expected it to earn 13 cents a share on sales of $50.2 million.

NLight shares popped 8% in after-hours trading on the stock market today. During the regular session, the stock fell 4.2% to 30.16. It went public on April 26 at $16 a share.

NLight makes high?power semiconductor and fiber lasers used in the industrial, microfabrication, and aerospace and defense markets.

China Business Strong

"We delivered strong revenue growth and gross profit in the second quarter, driven by meaningful expansion in all three of our end markets," Chief Executive Scott Keeney said in a news release.

He added, "Industrial and microfabrication business was particularly strong in China in the quarter, with the region growing almost 60% year-over-year."

Keeney expects momentum to continue at NLight thanks to a pipeline of new products coming over the next several quarters.

For the current quarter, NLight expects to generate sales of $50 million, based on the midpoint of guidance. It did not give an earnings per share target.

Wall Street was modeling the company to earn 8 cents a share on sales of $46.9 million in the September quarter.

RELATED:

Apple Supplier Hints At Greater 3D-Sensing iPhone Production

The post Recent IPO NLight Tops Second-Quarter Views In First Public Report appeared first on Investor's Business Daily.


78. Yelp Stock Jumps After Second-Quarter Earnings BeatСр., 08 авг.[−]

Yelp stock jumped Wednesday after it reported second-quarter earnings after the market close Wednesday that blew past earnings estimates.

X

Yelp ( YELP), a provider of online business reviews, reported revenue of $235 million. That beat analyst views of $232.3 million. Yelp reported adjusted earnings of 12 cents per share, smashing the consensus of a 1-cent profit.

Shares of Yelp soared by 13%, near 43.15, during after-hours trading on the stock market today.

Outlook Below Views

Yelp provided a third-quarter revenue outlook in the range of $242 million to $246 million. That's below analyst estimates for $247.2 million. It estimated 2018 revenue in the range of $952 million to $967 million. The midpoint of $969 million was in line with estimates.

"Second-quarter results were once again driven by strong revenue growth in our core advertising business," Chief Executive Jeremy Stoppelman said in a prepared statement. "We completed the transition to selling non-term local advertising in the quarter, which helped deliver record advertising account additions."

Yelp held $803 million in cash or cash equivalents.

YOU MIGHT ALSO BE INTERESTED IN:

What Makes This Breakout Special Vs. Apple, Alphabet, Tesla

Roku Stock Jumps On Better-Than-Expected Second Quarter

The post Yelp Stock Jumps After Second-Quarter Earnings Beat appeared first on Investor's Business Daily.


79. Mylan Exploring Options As 'Unsustainable' Trends Hound Sales, ProfitСр., 08 авг.[−]

The U.S. market "continues to underappreciate and undervalue" Mylan's ( MYL) global business, the generic drugmaker said Wednesday after its quarterly metrics and full-year guidance lagged expectations.

X

So Mylan is exploring strategic alternatives. But analysts could only fathom what those alternatives might be. The board said in a statement it hopes to "unlock the true value of our one-of-a-kind platform." It didn't put a timetable on the strategic review process.

Mylan noted that its international business now represents more than 60% of total sales. But in the U.S., "negative trends and dynamics" are "unsustainable," the board said. U.S. regulators are pushing for speedier generic drug approvals to stoke competition and cut prices.

On the stock market today, Mylan stock plummeted as much as 9.1%, but ended the regular session up 1.8%, at 39.23. No. 1 generic drugmaker Teva Pharmaceutical ( TEVA) dipped 3%, to 22.57. Broadly, generic drug stocks rose a fraction.

Quarterly Metrics Lag

For the second quarter, Mylan reported adjusted income of $1.07 per share, declining 3% and missing analyst views for $1.23. Sales of $2.81 billion fell 5% and lagged expectations for $2.96 billion.

The biggest pain came from Mylan's North America segment where $1 billion in sales fell 22% year over year. Mylan cited lower volumes on existing products, including emergency allergic reaction injection EpiPen, for the dip. Pricing "also declined slightly."

In Europe, sales declined 3% on a constant-currency basis to $990.6 million. Sales from the rest of the world climbed 11% on a constant-currency basis to $764.1 million. These segments are growing in line with expectations, Chief Executive Heather Bresch said in a prepared statement.

"However, our efforts to serve patients in the U.S. have been shaped by the industry's transformation here, and our results and guidance for 2018 are directly correlated with the ongoing rebasing of the U.S. health care environment," she said.

Mylan's 2018 guidance also undercut analyst estimates. It projected $11.25 billion to $12.25 billion in sales, missing views for $12.24 billion. Adjusted profit of $4.55-$4.90 per share also lagged analysts' model for $5.28.

Generic Drugs Challenged

Evercore analyst Umer Raffat says the U.S. is key for Mylan. He noted that it's not clear what direction the No. 2 generic drugmaker will take in its strategic review. Better disclosures for key sales drivers could help clear up "valuation disconnects," he said in a report to clients.

"Keep in mind that although (foreign sales) may seem like a higher multiple business for now, the true growth engine for Mylan going forward comes from the U.S.: biosimilar launches," he said.

Biosimilars are copycats of branded biologic drugs created by firms like Amgen ( AMGN) and AbbVie ( ABBV). Mylan has several biosimilars approved including a copycat of Amgen's bone marrow-stimulating drug Neulasta.

Mizuho analyst Irina Koffler noted a number of larger companies are also trying to divest their generic portfolios. Therefore, "we don't expect this announcement to encourage investors," she said in a report.

YOU MAY ALSO LIKE:

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How To Invest In Stocks For Free: New Apps Aim For Beginners

New Option Strategy Limits Risk Around Earnings

The post Mylan Exploring Options As 'Unsustainable' Trends Hound Sales, Profit appeared first on Investor's Business Daily.


80. Apple Supplier Hints At Greater 3D-Sensing iPhone ProductionСр., 08 авг.[−]

Apple's ( AAPL) key supplier of augmented-reality vision components for the iPhone X on Wednesday reported better-than-expected June-quarter results, which implied a quicker ramp up of next-generation iPhones.

X

Lumentum Holdings ( LITE) said a sooner-than-anticipated acceleration in its AR/3D-sensing business drove upside in its fiscal fourth-quarter results.

Lumentum is Apple's primary supplier of vertical-cavity surface-emitting laser (VCSEL) components for the iPhone X with about a 75% market share. The sensor works in the front-facing camera of the iPhone X. It provides 3D sensing and enables facial recognition and the Animoji app.

Milpitas, Calif.-based Lumentum last quarter began shipping higher volumes of the smartphone component to key customers, including Apple. Shipments exceeded expectations, management said.

"More importantly, the company continues to anticipate order volume to significantly accelerate in the September and December quarters," Gene Munster, Loup Ventures managing partner, said in a report. "While the company announced new 3D sensing wins with Android manufacturers, we believe a high percentage of these orders were secured by Apple."

3D Sensing In iPhone

Given the increase in VCSEL shipments, Munster expects Apple to offer three new iPhone models. He says they'll feature 3D sensing for augmented reality, up from just one today.

That should provide a boost to the iPhone's average selling prices, Munster says. There will be a higher bill of materials from the component, he added.

"Lumentum results and guidance are evidence that Apple continues to be committed to augmented reality," Munster said. "We anticipate 3D sensing will only be front-facing on the new iPhones and believe Apple will be incorporating this technology in new product categories such as the iPad."

Lumentum earned an adjusted 95 cents a share on sales of $301 million in its fiscal fourth quarter ended June 30. Analysts expected it to earn 65 cents a share on sales of $288 million. On a year-over-year basis, earnings per share rose 144% and sales climbed 35%.

For the current quarter, it expects to earn an adjusted $1 a share on sales of $350 million. Analysts expected it to earn 94 cents a share on sales of $337 million.

Lumentum makes optical and photonic products for optical networking and commercial laser customers worldwide. Telecom, enterprise and data center networks use its optical components and subsystems. Lumentum's commercial lasers enable advanced manufacturing techniques and applications. That includes next-generation 3D sensing capabilities.

Shares of Lumentum fell 2.3% to 56.50 on the stock market today.

Applied Optoelectronics Jumps On Earnings Report

Meanwhile, rival optical component supplier Applied Optoelectronics ( AAOI) late Tuesday beat expectations for the second quarter, sending its stock higher.

The Sugar Land, Texas-based company earned 64 cents a share on sales of $87.8 million in the June quarter. Analysts expected it to earn 45 cents a share on sales of $77.8 million. On a year-over-year basis, earnings per share fell 58% while sales dropped 25%.

Healthy sales of optical networking gear for cloud data centers boosted results for Applied Optoelectronics last quarter. Facebook ( FB) was Applied Opto's biggest data center customer last quarter. But Applied Opto also got sizable business from Amazon.com ( AMZN) and Microsoft ( MSFT), Piper Jaffray analyst Troy Jensen said in a report to clients.

Applied Opto stock surged 9.9% to 40.92 on Wednesday.

RELATED:

Acacia, Lumentum Gain As U.S. To Lift Ban On ZTE Component Sales

Lumentum To Buy Oclaro; Is Industry Consolidation On Horizon?

The post Apple Supplier Hints At Greater 3D-Sensing iPhone Production appeared first on Investor's Business Daily.


81. IBD 50's Supernus Pharma Topples As Key Epilepsy Drug Sales LagСр., 08 авг.[−]

Supernus Pharmaceuticals ( SUPN) toppled Wednesday as sales from seizure drug Trokendi lagged an estimate, and news emerged that an investment firm pulled nearly 93% of its stake from the biotech.

X

On the stock market today, Supernus stock crashed 8.7%, to 48.70, after hitting a three-month low. Supernus is on the IBD 50 stock list and is also a Sector Leader. It has a Composite Rating of 98 out of a best-possible 99.

Janney analyst Ken Trbovich expressed surprise that Trokendi sales were "not stronger." The drug brought in $76.4 million in sales, growing 36.4%. But that lagged Trbovich's estimate for $81.4 million. Prescriptions outgrew sales, rising 42.7% to 177,052.

"But management conveyed its confidence in the outlook by raising the lower end of its previous revenue guidance," he said in a report. "Still, we will look to the call for clarity on whether we need to adjust our model for higher gross-to-net discounts."

Trokendi Sales Lag

For the quarter, Supernus reported $99.5 million in sales, up 31%. That lagged analysts polled by Zacks Investment Research for $101 million, though Trbovich noted that the company's reported sales met other estimates. Profit of 57 cents per share grew 78% and beat expectations for 44 cents.

Trokendi treats epilepsy and grabbed approval in 2017 as a preventive treatment for migraines. Growth in the second quarter is "an impressive sign of the continued benefit Supernus is deriving from the expanded label it received in April 2017," Trbovich said.

Sales of anti-epileptic drug Oxtellar climbed 19.1% to $20.6 million in the quarter. That narrowly beat Trbovich's view for $19.9 million. Prescriptions of the drug grew 9.6% during that quarter to 37,789, Supernus said in a news release.

Changes In Forecast

The biotech also boosted the lower end of its sales forecast for 2018. It now sees $385 million to $400 million in net product sales. Analysts expected total revenue of $405 million. Analysts also expect full-year earnings of $1.86 per share.

News also emerged Wednesday that equity investment firm Algert Global lessened its stake in the biotech by 92.7% over the second quarter. According to a Securities and Exchange Commission filing, Algert now owns 8,061 shares of Supernus, worth about $482,000.

At the end of the first quarter, its investment in Supernus stock was worth north of $5 million.

YOU MAY ALSO LIKE:

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How To Invest In Stocks For Free: New Apps Aim For Beginners

New Option Strategy Limits Risk Around Earnings

The post IBD 50's Supernus Pharma Topples As Key Epilepsy Drug Sales Lag appeared first on Investor's Business Daily.


82. Could Biotech Giant Celgene Join Tesla In The Private Markets?Ср., 08 авг.[−]

Biotech giant Celgene ( CELG) could go private at 120 per share, an analyst suggested Wednesday after similarly sized electric-car maker Tesla ( TSLA) confirmed it's discussing the possibility.

X

The primary obstacle for Celgene is the massive size of such a deal. Celgene has a market cap around $64 billion, almost identical to Tesla's $63.5 billion value. Most leveraged buyouts are under $10 billion with the largest at $50 billion, RBC Capital Markets analyst Brian Abrahams said.

Celgene and Tesla are in different industries. But both face intense public scrutiny. Celgene's biggest cancer drug, Revlimid, is set to lose patent protection in the mid-2020s. Tesla has yet to reach profitability and investors worry about its slow Model 3 ramp up.

Tesla Chief Executive Elon Musk said Tuesday the firm is considering going private. Musk's suggestion demonstrates that such a transaction "may not be completely unrealistic," Abrahams said in a report. A key difference, though, is that Musk says he has the funding to do it.

"We believe this does potentially illustrate that performing such a transaction even on such a large company, to help better capture trapped value and/or insulate it from public-markets volatility as it seeks to overcome challenges, may not be completely unrealistic," he said.

Celgene Stock Challenged

Celgene stock is still far off its October 2017 highs when shares eclipsed 147, hitting a record. In quick succession, Celgene stock plummeted that month as it scrapped several studies of a drug to treat Crohn's disease and lagged quarterly views. That put shares near 100.

In February, the Food and Drug Administration refused to review an application to approve multiple sclerosis drug ozanimod. That sent shares down 9% in a day. In May, Celgene stock hit a four-year low on a report that a key executive had quietly exited a month before.

Shares have been trapped well below 100 since February. But Abrahams says Celgene could take itself private at 120 per share. He noted that the stock has gained momentum since hitting lows in the 70s. Investor sentiment appears to be "substantially improving."

"The underlying business has stabilized and it has made progress with its pipeline," he said. Celgene is "on track to resolve ozanimod (refusal to file) issues" and it has reported positive data for anemia treatment luspatercept with partner Acceleron Pharma ( XLRN).

No Urgency?

So the urgency to go private may no longer be there, he said.

"Still, such an idea — or perhaps more likely, an acquisition by a larger pharma — could still potentially help capture more value for its commercial plus pipeline products, which we continue to view as underappreciated at the current stock price," said Abrahams.

Abrahams kept his outperform rating and 110 price target on Celgene stock. On the stock market today, Celgene stock rose 1% to close at 91.24.

Celgene representatives didn't immediately return a request from Investor's Business Daily for comment.

YOU MIGHT ALSO LIKE:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Should You Buy A Stock Ahead Of Its Earnings Report?

The post Could Biotech Giant Celgene Join Tesla In The Private Markets? appeared first on Investor's Business Daily.


83. Tesla's Board Responds To Musk's Tweet Thunderstorm On Going PrivateСр., 08 авг.[−]

The Tesla ( TSLA) board of directors confirmed Wednesday that Chief Executive Elon Musk had opened a discussion about taking the company private, as Wall Street struggled to make sense of the stunning proposal.

X

The Tesla board issued a statement, responding to Musk's initial tweets on the idea, which came Tuesday. Musk said he considered taking the electric car maker private at $420 a share, or about $70 billion. As Tesla's largest shareholder with a stake of about 20%, Musk said he had the funding secured.

"The board has met several times over the last week and is taking the appropriate next steps to evaluate this," according to the Tesla board's letter. "This included discussion as to how being private could better serve Tesla's long-term interests, and also addressed the funding for this to occur."

Also on Wednesday, the Securities and Exchange Commission inquired into Musk's Tuesday tweets, media reports said. The SEC reportedly is looking into whether Musk's statement on funding was truthful. It also wants to know why the disclosure was made on Twitter ( TWTR).

Tesla stock finished Tuesday trading up 11% to 379.57. Shares closed at 370.34, down 2.4% on the stock market today.

Wall Street analysts pondered Musk's surprising move. The tweets led to a halt Tesla on stock trades Tuesday afternoon for more than an hour.

Will Tesla's Board Go Along?

Musk has yet to prove he can get the board and shareholders to go along with the deal. It's also unclear whether Tesla can properly raise funds and complete the transactions. It would be one of the largest buyout deals in corporate history.

"Although Tesla did confirm a potential privatization through Musk's statement, no theoretical transaction method, funding plan, or structure was outlined, and there is still some skepticism over whether such a transaction would ultimately be executed," Bank of America Merrill Lynch analyst John Murphy said in a note to clients. "Privatization of the company is still very much unclear at this point."

Musk's plan is to remain chief executive of Tesla and its largest shareholder. Tesla stockholders would have the option of cashing out at a proposed price of $420 per share. Or they could retain their stake in Tesla stock with the possibility to cash out down the road. Perhaps the biggest obstacle of all is acquiring the funds needed to pull off the deal.

"We expect vigorous debate on the fairness of the proposed $420 price," Oppenheimer analyst Colin Rusch wrote in his report to clients. "We believe many shareholders are seeking a liquid security that has significant upside to the indicated take-private price."

Musk's desire to take Tesla private stems from his belief that it would operate better as a privately held company.

"The reason for doing this is all about creating the environment for Tesla to operate best," Musk said in the letter to employees on Tuesday titled " Taking Tesla Private."

Most Shorted Stock In History

"As a public company, we are subject to wild swings in our stock price that can be a major distraction for everyone working at Tesla, all of whom are shareholders," Musk said. He went on to say: "As the most shorted stock in the history of the stock market, being public means that there are large numbers of people who have the incentive to attack the company."

Several analysts agreed with Musk on this point but remained skeptical of the overall plan.

"We sympathize with Elon Musk's argument that Tesla could be better off as a private company," Morgan Stanley analyst Adam Jonas said in his note. "Taking the company private would assume one of 2 factors changing: (1) that the company is on the verge of generating self-sustaining cash flows or (2) that the company can tap into a range of strategic sources of capital not previously at its disposal."

Analysts also questioned why Musk would present such a significant offer to go private via Twitter.

"This is out there, even for Tesla," wrote Barclay's analyst Brian Johnson.

YOU MIGHT ALSO BE INTERESTED IN:

What Makes This Breakout Special Vs. Apple, Alphabet, Tesla

Tesla Earnings Beat On Revenue As Model 3 Production Hits Targets

Tesla Stock Gets Price Target Increase, Upgrades As Model 3 Trust Grows

The post Tesla's Board Responds To Musk's Tweet Thunderstorm On Going Private appeared first on Investor's Business Daily.


84. Sina Stock Takes A Tumble Despite Quarterly Earnings BeatСр., 08 авг.[−]

Sina stock rose then fell Wednesday, after the China internet pioneer reported second-quarter results that topped estimates.

X

Sina ( SINA), the provider of a popular internet portal, said before the market open it had revenue of $537.4 million. That beat the consensus estimate of $535 million, and was up 50% from the year-ago quarter. It reported adjusted earnings of 89 cents per share, beating the consensus of 70 cents and up 27%.

"For Sina businesses, we continued to see robust growth in user scale of Sina mobile apps, which bodes well for improved mobile monetization of Sina media," said Charles Chao, chairman and chief executive, in prepared remarks.

Below Highs

Sina stock jumped more than 6% during premarket trading on the stock market today, but switched gears and tumbled by 7% to close at 74.88. Sina stock sits well below near-record highs set in the first quarter.

The company owns a majority stake in China social networking company Weibo ( WB), which operates a mobile app similar to Twitter. Weibo also reported quarterly earnings Wednesday morning.

Weibo stock initially jumped on the news but gave back its gains and lost 4% by the closing bell.

YOU MIGHT ALSO BE INTERESTED IN:

China Hits Back; How China Trade War May Jolt U.S. GDP

The post Sina Stock Takes A Tumble Despite Quarterly Earnings Beat appeared first on Investor's Business Daily.


85. Weibo Stock Wavers Despite Earnings Beat, Growing User BaseСр., 08 авг.[−]

China-based Weibo ( WB) reported second-quarter earnings before the market open Wednesday that edged past analyst estimates. Weibo stock initially jumped on the news but gave back its gains and lost ground by the close.

Weibo, a social media company with a website comparable to Twitter ( TWTR), reported revenue of $426.6 million. That was virtually in line with the consensus estimate of $427 million. It reported adjusted earnings of 68 cents per share, beating analyst forecasts for 67 cents.

Monthly active users grew by a net addition 70 million year over year to reach 431 million in June 2018. Average daily active users had a net addition of 31 million year over year and reached 190 million.

Forecast Below Views

For the third quarter, Weibo sees net revenue of $465 million-$475 million, below views for $499 million.

Weibo shares jumped nearly 6% during premarket trading on the stock market today, but then the stock gave back those gains. Weibo shares fell 4.1% to close at 80.09. Weibo stock is well off record highs set in the first quarter.

Sina ( SINA) , which operates a popular China internet portal, owns a majority stake in Weibo. Sina also reported strong quarterly earnings Wednesday morning that topped estimates. but shares reversed an upward trend. Sina shares tumbled 7% to finish at 74.88.

The post Weibo Stock Wavers Despite Earnings Beat, Growing User Base appeared first on Investor's Business Daily.


86. Match Group Stock Soars As Profit, Revenue Beat On Tinder App GrowthСр., 08 авг.[−]

Match Group ( MTCH) stock jumped in late trading after the Tinder-app owner reported second-quarter profit and earnings that topped expectations.

X

The company also reported earnings before interest, taxes, depreciation and amortization, or EBITDA, that topped views.

Match Group stock jumped 13.2% to 44.01 in after-hours trading on the stock market today.

Match Group said adjusted earnings were 41 cents a share, up 156% from a year ago, with revenue rising 36% to $421.2 million, topping analyst estimates. A year earlier, Match earned 16 cents a share on sales of $309.5 million.

Match Group Growth Beats

Analysts expected the online dating firm to report earnings of 35 cents on sales of $413 million for the period ended June 30.

The company reported EBITDA of $175.5 million, up 60%, topping estimates of $163 million.

The provider of online dating services said it added 299,000 paid Tinder subscribers in the June quarter vs. 224,000 in the year-earlier period.

For the September quarter, Match Group forecast revenue of $435 million at its midpoint of guidance. Analysts had modeled $425 million.

Facebook Entry Into Dating Space

Tinder had 3.8 million subscribers as of June 30, up 81% year over year.

The company holds its earnings call early Wednesday.

The Tinder owner's stock dived in May when Facebook ( FB) said it would leverage its social media platform for online dating services. Facebook is still testing its online dating service.

YOU MAY ALSO LIKE:

After Hours: Snap Whipsawed On Social Media Limits; Is Tesla A Buy Now?

Twilio Stock Jumps As Revenue Blows Past Estimates, Guidance Hiked

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

The post Match Group Stock Soars As Profit, Revenue Beat On Tinder App Growth appeared first on Investor's Business Daily.


87. Snap Stock Slumps As Quarterly Earnings Reports Shows User DeclineСр., 08 авг.[−]

Snap stock rose then fell in after-hours trading Tuesday as the company reported second-quarter earnings that beat on both the top and bottom lines but it posted its first-ever quarterly drop in users.

X

Snap ( SNAP) reported revenue of $262 million. That beat analyst estimates for $251 million and up 44% from the year-ago quarter. The operator of Snapchat, Snap reported an adjusted loss of 14 cents per share, better than the 17-cent loss that analysts expected.

Snap shares initially jumped 11%, near 14.60, in post-bell trades on the stock market today, then fell back to 14.40, down 2.8%.

Daily active users rose 8% from the year-ago period to 188 million. But it was down 2% sequentially, from the 191 million users it had at the end of the second quarter. Wall Street analysts had low expectations on user growth. The average forecast was for no growth.

Snapchat reported average revenue per user of $1.40, up 34% and above analyst estimates of about $1.29.

Facebook Assault

The company has been under constant assault from Facebook ( FB), which has copied most of Snapchat's best features. Facebook has applied them in its Instagram photo- and video-sharing platform. Snap has also struggled with the impact of a product redesign in February that was widely criticized.

"We are excited by the progress we have been making and are optimistic about the opportunities ahead as we continue to invest in innovation," Evan Spiegel, Snap chief executive, said in prepared remarks.

YOU MIGHT ALSO LIKE:

After Hours: Snap Whipsawed On Social Media Limits; Is Tesla A Buy Now?

Tesla Stock Approaches New Record On Musk Talk Of Going Private

Teens Turn Away From Facebook, Head To YouTube, Instagram, Snapchat

As Facebook Fixes Data-Breach Scandal, Investor Optimism Rises

The post Snap Stock Slumps As Quarterly Earnings Reports Shows User Decline appeared first on Investor's Business Daily.


88. This Top-Rated Medtech Just Crushed Second-Quarter ViewsСр., 08 авг.[−]

Inogen ( INGN) stock popped late Tuesday after the medical technology player beat quarterly expectations and issued an estimate-topping 2018 sales outlook.

X

Late on the stock market today, Inogen stock jumped 5.5% after ending the regular trading session down 0.2% to 213.26. Inogen has a best-possible Composite Rating of 99. Six of 118 stocks in Investor's Business Daily's Medical-Products industry group have ratings of 99. The group itself is ranked third out of 197 industry groups tracked.

For the second quarter, Inogen's sales advanced 51.6% to $97.2 million, topping the average of analysts polled by Zacks Investment Research for $82 million. Net income of 65 cents a share grew 71.1% to beat views for 44 cents.

Growth In U.S.

The company makes oxygen-delivering equipment. The best growth in the period came from direct-to-consumer sales in the U.S., which increased 74.3% to $38.3 million. Direct-to-consumer rentals, on the other hand, declined 13.7% to about $5.3 million.

Business-to-business sales in the U.S. grew 55.7% to $32.9 million. Internationally, business-to-business sales increased 39.1% to about $20.8 million.

For the year, Inogen predicts sales of $340 million to $350 million. The low end of the outlook easily beats analyst estimates for $322 million. The medtech firm expects sales directly to consumers to be its fastest growing channel with rental revenue likely to decline 10%.

YOU MAY ALSO LIKE:

After Hours: Snap Whipsawed On Social Media Limits; Is Tesla A Buy Now?

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How To Invest In Stocks For Free: New Apps Aim For Beginners

Looking For The Next Nvidia? Start With This Simple Routine

The post This Top-Rated Medtech Just Crushed Second-Quarter Views appeared first on Investor's Business Daily.


89. CyberArk Stock Rises As Earnings Blow Past Estimates, Revenue BeatsСр., 08 авг.[−]

CyberArk Software ( CYBR) stock rose in after-hours trading Tuesday after the cybersecurity firm reported second-quarter profit that blew past estimates while revenue topped views.

X

CyberArk said earnings were 36 cents a share, up 71% from a year ago, with revenue rising 35% to $77.7 million, topping views.

A year earlier, CyberArk earned 21 cents a share on sales of $57.4 million. Analysts expected CyberArk to report earnings of 24 cents on sales of $73 million for the period ended June 30.

CyberArk forecast September quarter profit below analyst estimates, with revenue in line.

In the September quarter, CyberArk said it expects profit in a range of 25 cents to 28 cents. Analysts had projected 30 cents. The company forecast revenue of $78.5 million at the midpoint of its forecast. Analysts had estimated $78.3 million.

Shares in the maker of computer security software climbed 1.2% to 62.50 in after-hours trading on the stock market today. Shares had popped 4.8% after the company released earnings.

Carbon Black ( CBLK) stock, meanwhile, fell a fraction to 25.40 in late action.

Endpoint cybersecurity software maker Carbon Black reported a narrower-than-expected loss of 35 cents a share, with revenue rising 32% to $51 million. Analysts had projected a loss of 41 cents a share and revenue of $49 million.

YOU MAY ALSO LIKE:

Twilio Stock Jumps As Revenue Blows Past Estimates, Guidance Hiked

After Hours: Snap Whipsawed On Social Media Limits; Is Tesla A Buy Now?

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post CyberArk Stock Rises As Earnings Blow Past Estimates, Revenue Beats appeared first on Investor's Business Daily.


90. RingCentral Stock Pops As Revenue Beats On Large Contract GrowthСр., 08 авг.[−]

RingCentral stock popped Tuesday after the enterprise software provider reported second-quarter revenue and profit that topped expectations as the company hauled in more large contracts.

X

RingCentral ( RNG) said revenue jumped 34% to $161 million, topping consensus estimates of $155.7 million. Profit jumped 90% to 19 cents a shares. Analysts had predicted earnings of 15 cents a share.

"RingCentral signed more than 15 deals in the quarter with total contract value of over $1 million, including the largest deal in the company's history," Jefferies analyst John DiFucci said in a note to clients.

RingCentral stock popped 6.9% to 87 on the stock market today. The company's cloud communications platform offers customers voice, chat, conferencing and application integration.

RingCentral Stock Moves Up

"The core business (subscription revenue excluding AT&T ( T)) accelerated to 37% growth from 32% growth last year, driven in large part by the company's progression upmarket," William Blair analyst Bhavan Suri said in his report to clients.

In the September quarter, RingCentral forecast revenue in a range of $165 million to $168 million. Analysts had estimated $163.2 million.

Belmont, Calif.-based RingCentral said it expects earnings of 16 cents a share, a penny above estimates.

RingCentral competes with 8x8 ( EGHT) and Five9 ( FIVN). Microsoft ( MSFT) and Alphabet's ( GOOGL) Google offer similar products.

YOU MAY ALSO LIKE:

Twilio Stock Jumps As Revenue Blows Past Estimates, Guidance Hiked

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post RingCentral Stock Pops As Revenue Beats On Large Contract Growth appeared first on Investor's Business Daily.


91. IBD 50 Stock Jazz Pharma Tops Views, But Profit Outlook LightСр., 08 авг.[−]

Jazz Pharmaceuticals ( JAZZ) stock dipped late Tuesday after the drugmaker topped second-quarter expectations but issued a 2018 profit outlook that lagged analyst views.

X

In late action on the stock market today, Jazz stock dipped 3.8% after closing up 1.9%, at 179.90. Shares are forming a flat base with a buy point at 184.10. Jazz is listed on both the IBD 50 and Leaderboard. It has a Composite Rating of 96 out of a best-possible 99, making it second out of 42 pharmaceutical stocks tracked by Investor's Business Daily.

For the second quarter, Jazz reported adjusted income of $3.49 per share on sales of $500.5 million, beating analyst expectations for $3.22 and $470 million, respectively. Adjusted income grew 36% while sales advanced 27% year over year.

Sales of narcolepsy drug Xyrem grew 19% to $356 million. Erwinaze, a cancer drug, advanced 20% to $58.7 million. The best growth came from Defitelio, which treats a liver condition. Defitelio sales generated $40.5 million, growing 34%. New cancer drug Vyxeos brought in $28 million.

Jazz projected $1.88 billion to $1.93 billion in total revenue, including $1.35 billion to $1.38 billion from Xyrem sales. The consensus modeled $1.9 billion in total revenue. Jazz's adjusted profit view for $12.75-$13.25 per share lagged analyst estimates by 10 cents at the midpoint.

YOU MAY ALSO LIKE:

After Hours: Snap Whipsawed On Social Media Limits; Is Tesla A Buy Now?

Can You Make Roaring Stock Profits With A Little Cash? Yes, Here Is The Way

How To Invest In Stocks For Free: New Apps Aim For Beginners

Looking For The Next Nvidia? Start With This Simple Routine

The post IBD 50 Stock Jazz Pharma Tops Views, But Profit Outlook Light appeared first on Investor's Business Daily.


92. Tesla Stock Approaches New Record On Musk Talk Of Going PrivateВт., 07 авг.[−]

Trading in Tesla ( TSLA) stock resumed late Tuesday, soaring in high volume, after shares were halted due to Chief Executive Elon Musk's tweet saying he was pondering taking the electric-car maker private at $420 a share.

X

Musk put out the tweet at 12:48 p.m. Eastern time. A deal taking the company private would cost about $70 billion. Musk maintained that he has the funding.

Musk also is the largest shareholder in Tesla.

At 420 a share, that's also a 19% premium from where Tesla stock was trading when Musk first tweeted. Shares of Tesla rose 11% to 379.57 on the stock market today.

Trading in Tesla stock was halted shortly after 2 p.m. ET, about an hour after Musk's tweet of taking the company private. It resumed trading at about 3:45 p.m. ET.

Tesla Letter To Employees

Around 3:30 p.m. ET, Musk followed up with a letter to employees.

"First, a final decision has not yet been made, but the reason for doing this is all about creating the environment for Tesla to operate best," Musk said in the letter titled " Taking Tesla Private."

"As a public company, we are subject to wild swings in our stock price that can be a major distraction for everyone working at Tesla, all of whom are shareholders," Musk said. He went on to say: "As the most shorted stock in the history of the stock market, being public means that there are large numbers of people who have the incentive to attack the company."

In his letter, Musk made no reference on the deal's funding, as he did in the tweet. Musk did say, however, that he would keep the concerns of shareholders in mind.

"Either they can stay investors in a private Tesla or they can be bought out at $420 per share, which is a 20% premium over the stock price following our Q2 earnings call (which had already increased by 16%)," he wrote. "My hope is for all shareholders to remain, but if they prefer to be bought out, then this would enable that to happen at a nice premium."

Tesla reported second-quarter earnings on Aug. 1 that showed another loss. It did, however, exceed revenue forecasts and defied skeptics in key areas, including Model 3 production.

No Controlling Vote In Tesla Stock

Earlier Tuesday, the Financial Times reported that the Saudi Arabia Public Investment Fund built a stake in Tesla. The stake reportedly is somewhere between $1.7 billion and $2.9 billion, or between 3% and 5%. Saudi Prince Mohammed bin Salman apparently built up the stake after touring the U.S. in March.

The Financial Times report said the Saudi Arabia fund initially approached Musk about purchasing newly issued shares. Musk reportedly rebuffed the offer.

Fred Lambert, editor of Tesla follower Electrek, asked Musk via Twitter if he would retain control over the company.

Musk replied: "I don't have a controlling vote now and wouldn't expect any shareholder to have one if we go private. I won't be selling in either scenario."

Earlier Discussion

Musk has previously said he would like to take Tesla private. He made such a reference in an interview with Rolling Stone published in November 2017.

Musk said companies run best "when there are not perverse incentives for people to try to harm what we're all trying to achieve." That's a reference to the short sellers of Tesla stock.

SpaceX, the rocket ship company Musk built from the ground up serves as an example, he said.

"It is far more operationally efficient, and that is largely due to the fact that it is privately held," he wrote. "This is not to say that it will make sense for Tesla to be private over the long term. In the future, once Tesla enters a phase of slower, more predictable growth, it will likely make sense to return to the public markets."

YOU MIGHT ALSO BE INTERESTED IN:

Tesla Stock Gets Price Target Increase, Upgrades As Model 3 Trust Grows

Tesla Stock Yawns Over Latest Elon Musk Tweet On Hitler Parody

The post Tesla Stock Approaches New Record On Musk Talk Of Going Private appeared first on Investor's Business Daily.


93. This Midcap Biotech Popped Nearly 20% On Hope In Cancer, InflammationВт., 07 авг.[−]

Xencor ( XNCR) stock popped to a record high Tuesday on investor excitement for the biotech company's inflammation and cancer drugs, though it reported no revenue for the second quarter.

X

Xencor stock jumped 7.5% to 40.63 on the stock market today. Earlier, shares rose as much as 18.7%, touching an all-time high of 44.88. At the same time, biotech stocks crept up a fraction. Shares of partner Novartis ( NVS) rose a fraction to 83.59.

For its second quarter, Xencor reported a loss of 46 cents per share vs. the estimate of analysts polled by Zacks for a 55-cent loss. This widened from a loss of 17 cents in the year-ago period. Xencor had $555.4 million in cash and equivalents, which should be sufficient into 2023.

Upcoming Catalysts

Most of the excitement seemed to stem from upcoming catalysts. Xencor plans to have data from tests of lupus and leukemia drugs in the fourth quarter. It also plans to begin an inflammation study and file to begin studies of cancer drugs later this year.

But Instinet analyst Christopher Marai says the "meaningful catalysts (are) more than one year out." He reiterated his neutral rating and price target of 28 on Xencor stock.

"The next catalyst, systemic lupus erythematous data, is expected in the second half of 2018," he said in a note to clients. "However, a novel trial design and traditionally difficult pivotal paths set an incredibly high bar for positive data to move the needle — or the stock."

Inflammation Drugs

Lupus, known formally as systemic lupus erythematous, is an autoimmune disease. This means the immune system turns against parts of the body it's designed to protect. This can cause inflammation and affect many parts of the body.

Xencor expects to present data from a Phase 2 lupus study in the fourth quarter. Positive data could lead to a partnership for developing the drug, Marai said.

Also regarding inflammation, Xencor is working on treatments for IgG4-related diseases. Patients with these conditions tend to develop tissue-destructive lesions which can lead to organ dysfunction. A pivotal Phase 3 study is expected to begin in the second half of 2018.

"However, the enrollment period may take as long as two years, with an 18-month treatment period for the collective of natural history data," Marai said.

Cancer Drugs

In cancer research, Xencor is working on bispecific antibodies and checkpoint inhibitors. Bispecific antibodies are artificial proteins that can bind to two different molecules in the immune system. Checkpoint inhibitors block a specific interaction in the immune system to help identify cancer.

Xencor plans to ask the Food and Drug Administration to approve clinical studies for two of these drugs in 2018. If the FDA blesses its study designs, these tests could begin in 2019. The biotech also plans to ask the FDA to approve a study of another bispecific antibody in 2019.

Leerink analyst Jonathan Chang notes in a report, "Xencor's bispecific antibody technology is a key aspect of the company's growth strategy in oncology."

The firm also reiterated its plan to have Phase 1 data from a leukemia study in the fourth quarter. Novartis partners on the drug, which treats a form of cancer called acute myeloid leukemia. Initial Phase 1 data from a Novartis-partnered blood cancer drug is expected in 2019.

But Instinet's Marai noted, "Novartis failed to mention (its Xencor-partnered cancer drugs) on their earnings call or deck, suggesting first data may be preliminary at best — a year-end 2018 nonevent."

YOU MAY ALSO LIKE:

Chart-Reading Basics: How A Buy Point Marks A Time Of Real Opportunity

How To Invest In Stocks For Free: New Apps Aim For Beginners

Long-Term Retirement Investing Strategies With ETFs

The post This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation appeared first on Investor's Business Daily.


94. Why Spark Therapeutics' Crash On Hemophilia A Led This Rival To PopВт., 07 авг.[−]

Spark Therapeutics ( ONCE) crashed Tuesday after its hemophilia A study results seemingly lagged those of a rival treatment from BioMarin Pharmaceutical ( BMRN).

X

Spark stock plunged 27.8% to 56.01 in high volume on the stock market today. Shares of BioMarin diverged, popping 7.9% higher to 105.72. Broadly, shares of biotech companies rose a fraction.

Leerink analyst Joseph Schwartz noted that BioMarin's gene therapy, valoctocogene roxaparvovec — or valrox — appears to be more effective in hemophilia A.

"Management emphasized that the hemophilia A patients treated with SPK-8011 benefited clinically with reductions in bleed rates and (factor VIII) replacement usage, but one cannot deny that the profile looks comparatively worse than BioMarin's Valrox," he said in a report to clients.

Spark's Gene Therapy

The goal of Spark's drug, SPK-8011, is to raise levels of a blood-clotting protein called factor VIII. Patients with severe hemophilia A have less than 1% of factor VIII protein in their blood. Those with moderate disease have 1%-5% factor VIII, and mild patients have 6%-49% of the protein.

Spark highlighted data from five patients who received a high dose of SPK-8011. On average, the level of factor VIII in the blood was 30% in these patients 12 weeks after receiving the drug. Responses ranged from 16%-49%, the biotech said in a news release.

But two patients had an immune response that drove factor VIII levels down to less than 5%. The two patients moved to on-demand treatment rather than continue receiving SPK-8011 as a preventive drug. One was hospitalized to receive treatment.

Spark believes that, long term, it can hit factor VIII levels of 12% at the high dose. To do this, it plans to use preventive steroids to suppress damaging immune responses. Now, Spark plans to move the high dose of SPK-8011 into Phase 3 testing.

BioMarin In Hemophilia A

Piper Jaffray analyst Christopher Raymond favors BioMarin's approach over Spark's. At week 104 after receiving valrox, higher-dose patients had factor VIII levels of 59%, on average. At the median, factor VIII levels were 46%. And there were no comparable immune responses, he said.

Raymond also wondered how likely hemophilia A patients are to enroll in Spark's late-stage study with "more consistent and robust responses" seen from valrox. Leerink's Schwartz called the decision to move SPK-8011 into Phase 3 testing "risky" based on the results so far.

"We think BioMarin will be advantaged not only with a quicker to market therapy, but a stronger data package for regulators and a better argument for adoption for payers and patients," Piper Jaffray's Raymond said in his note to clients.

YOU MAY ALSO LIKE:

New Option Strategy Limits Risk Around Earnings

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Should You Buy A Stock Ahead Of Its Earnings Report?

The post Why Spark Therapeutics' Crash On Hemophilia A Led This Rival To Pop appeared first on Investor's Business Daily.


95. Twilio Stock Jumps As Revenue Blows Past Estimates, Guidance HikedВт., 07 авг.[−]

Twilio stock catapulted higher Tuesday after the communications software maker reported second-quarter revenue that blew past estimates and swung to a profit.

X

Twilio stock soared 18.7% to close at 74.17 on the stock market today.

Late Monday, San Francisco-based Twilio ( TWLO) said revenue jumped 54% to $148 million, topping estimates of $130.6 million. Twilio reported a profit of 3 cents, swinging from a 5-cent loss a year earlier. Analysts had estimated another 5-cent loss for the period ended June 30.

"On both an absolute and percentage basis, this is the largest quarterly beat in the company's history," Piper Jaffray analyst Alex Zukin said in a report to clients. "The company noted that investors should not expect beats of this size to continue as the company is now better capturing increased sales productivity into its guidance."

Twilio Stock Helped By Outlook

The company raised full-year 2018 revenue outlook by $46.5 million at the midpoint to a range $585.5 million to $589.5 million, up 47%. Analysts had projected $543 million.

Twilio's software provides real-time communications, which app developers use for text messaging and other communications. The company added 3,365 new customers in the second quarter, raising its total to 57,350.

Twilio stock had gained 165% in 2018 as of Monday's regular session close.

Twilio launched its initial public offering in 2016 with shares priced at 15. The stock peaked at 70.96 on Sept. 28, 2016. It slumped to a low of 24.52 in February 2018.

YOU MAY ALSO LIKE:

Sell And Take Profits Or Hold? Here Are Several Guidelines To Follow

Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks

The Basics: How To Analyze A Stock's Cup With Handle

How To Find Great Growth Stocks: Learn To Spot The Flat Base, A Bullish Chart Pattern

The post Twilio Stock Jumps As Revenue Blows Past Estimates, Guidance Hiked appeared first on Investor's Business Daily.


96. Bausch Health Stock Pops As Blockbuster Hopeful Delivers BeatВт., 07 авг.[−]

Bausch Health ( BHC) stock popped Tuesday after the drugmaker topped second-quarter views on better-than-expected sales of gastrointestinal drugs, including blockbuster hopeful Xifaxan.

X

On the stock market today, Bausch Health stock jumped 4.5%, to 23.52. Earlier, shares lifted as much as 10.5%. Meanwhile, drug stocks advanced a fraction, tacking on gains for the seventh consecutive day and touching their highest point since January 2016.

Mizuho analyst Irina Koffler classified Bausch Health's second quarter as a strong "beat and raise," noting the drugmaker outperformed "in most segments." This is Bausch Health's first report under its new name. It was formerly known as Valeant Pharmaceuticals.

Bausch Health reported a net loss of $2.49 per share on about $2.13 billion in sales. Net losses widened from an 11-cent per-share loss in the year-ago period. Sales declined 6% on a constant-currency basis, but grew 3% organically.

Adjusted income worked out to 93 cents per share, declining nearly 10% vs. last year. But that still topped the consensus of analysts polled by Zacks Investment Research for 81 cents. Sales also beat expectations for $2.05 billion.

Gastrointestinal Drugs Strength

Organically, the best growth came from Bausch Health's Salix business. The drugmaker acquired Salix and its suite of gastrointestinal drugs in 2015. Salix unit sales grew 14% to $441 million.

That included $294 million in sales of Xifaxan, a gastrointestinal drug and blockbuster hopeful. Mizuho's Koffler noted the consensus had called for $274.3 million in Xifaxan sales. Revenue from the drug grew 26% year over year, Bausch Health said in a news release.

Sales of Relistor, which treats opioid-induced constipation, grew 43% vs. the year-ago period. But growth from ulcerative colitis drugs Uceris and Apriso was more muted. Sales of both drugs advanced 3% year over year. Both are facing generic competition.

Bausch and Lomb/international sales grew 4% on an organic basis to $1.209 billion. That was in line with the consensus view for $1.2 billion, Koffler said in a note to clients. Organic growth in the quarter was driven by volume increases and strength in China and Europe, the firm said.

Dermatology sales declined 11% organically to $142 million. Still, that "surprisingly beat" views for $116.3 million, Koffler said. Diversified sales of $336 million fell 8% organically, but topped expectations for $271 million, showing strength among drugs soon to lose patent protection.

For the year, Bausch Health reiterated sales guidance for $8.15 billion to $8.35 billion despite a negative $60 million impact from foreign exchange rates, Koffler said. The consensus had seen about $8.3 billion in sales and adjusted profit of $3.41 a share.

Bausch Health also boosted guidance for adjusted earnings before interest, taxes, depreciation and amortization. For the year, it now sees $3.2 billion to $3.35 billion adjusted EBITDA, vs. its prior outlook for $3.15 billion to $3.3 billion.

YOU MAY ALSO LIKE:

How Do You Spot A Major Market Top? Easy: Look For Heavy Distribution

New Option Strategy Limits Risk Around Earnings

Still The No. 1 Rule For Stock Investors: Always Cut Your Losses Short

The post Bausch Health Stock Pops As Blockbuster Hopeful Delivers Beat appeared first on Investor's Business Daily.


97. Zebra Technologies Stock Surges On Second-Quarter Beat, RaiseВт., 07 авг.[−]

Enterprise asset tracking firm Zebra Technologies ( ZBRA) on Tuesday posted better-than-expected sales and earnings for the June quarter and guided analysts higher for the September quarter, giving its stock a huge boost.

X

Zebra shares rocketed 17.2% to 166.62 on the stock market today. The stock hit a record high intraday of 167.24. Zebra ranks No. 45 on the IBD 50 list of top-performing growth stocks.

The Lincolnshire, Ill.-based company earned an adjusted $2.48 a share in the second quarter, up 64% year over year. Sales climbed 13% to $1.012 billion. Analysts expected it to earn $2.23 a share on sales of $989 million.

For the third quarter, Zebra Technologies guided to adjusted earnings per share of $2.60 on sales of $1.061 billion, based on the midpoint of its forecast. Wall Street was modeling $2.37 a share in earnings and $988 million in sales.

Zebra Technologies Boosts 2018 Sales Outlook

It also raised its outlook for the full year. Zebra now expects sales to grow 10% to 12% in 2018. It previously expected a gain of 6% to 9%.

"Our second-quarter results were driven by strong growth from our product and service offerings and disciplined operational execution," Chief Executive Anders Gustafsson said in a news release. "Given the strength of our results, we are raising our full-year outlook for sales growth and free cash flow. We continue to deliver digital innovation that enables our customers to compete effectively in today's on-demand economy."

Zebra makes rugged mobile computers, RFID tracking chips, and bar code scanners and printers enhanced with software and services to enable real-time enterprise visibility of inventory and other assets. It offers products and services for retail, health care, manufacturing, transportation and other industries.

Q2 Growth Broad-Based

In an interview with Investor's Business Daily, Zebra Chief Financial Officer Olivier Leonetti said the company's gains came from across its business segments last quarter.

"This was a broad-based performance across regions, across products, across verticals," he said. "Clearly today our company is uniquely positioned to satisfy the requirements of the on-demand economy."

The company's guidance does not include its pending acquisition of Xplore Technologies ( XPLR). Zebra expects that $90 million deal to close this quarter. Austin, Texas-based Xplore makes rugged mobile computers for industrial, enterprise, government, and field-service organizations.

RELATED:

IoT Is Here: Internet Of Things Eclipses The Internet Of People

Zebra Technologies Sprints On Beat-And-Raise Quarterly Report

The post Zebra Technologies Stock Surges On Second-Quarter Beat, Raise appeared first on Investor's Business Daily.


98. Cloud Computing: Find Top Cloud Stocks And Track Industry TrendsВт., 07 авг.[−]

Cloud computing offers investors a wide range of opportunities that span internet infrastructure, as well as consumer and business services delivered via fast connections to the web. The industry leaders and top cloud stocks cover a similarly wide range, from Amazon.com ( AMZN) and Google parent Alphabet ( GOOGL) to Microsoft ( MSFT), Alibaba ( BABA) and Oracle ( ORCL).

X

To visualize the internet cloud, think of warehouse-sized data centers packed with computer servers and data storage systems. Then think of the cloud supply chain.

Companies such as Intel ( INTC), artificial intelligence (AI) leader Nvidia ( NVDA) and Micron Technology ( MU) sell chips built into servers. Fiber-optic device makers sell parts for high-speed communications networks. Seagate Technology sells solid-state data storage systems. Arista Networks ( ANET) and Cisco Systems ( CSCO) sell specialized network switches and routers that make the cloud superfast.

Cloud Computing And Top Cloud Stocks

IBD 50 Stocks To Watch: Palo Alto Near Buy Point Ahead Of Earnings ReportWhen Palo Alto Networks reports earnings next month, will its stock follow the downward path of Proofpoint and Symantec or the upward trajectory of fellow IBD 50 stocks CyberArk and Fortinet? CyberArk... Read More
Which Stocks Make This List Of The Fastest-Growing Companies?What do Amazon.com, Paycom Software and Palo Alto Networks have in common with Tabula Rasa Healthcare, ServiceNow and RingCentral? They've all earned a spot on the latest list of today's fastest-growing companies. The biggest stock market... Read More
Breakout Watch: 46 A+ Funds Own This No. 1-Ranked Cloud-Computing StockWith the rapid rise of mobile apps and cloud computing, the demand for network speed, reliability and security is also increasing. Cloud networking stock F5 Networks has tapped into that demand. And... Read More
Nike Stock Is In Buy Range, As This Cloud-Computing Leader Breaks OutAs the general market hangs out near record highs, action among growth stocks remains tentative. Last Friday, longtime IBD 50 stock and graphics-chip maker Nvidia broke a key support level on disappointing... Read More
Cloud Stock Sketches New Base As Price Target Gets UpgradeCloud stock ServiceNow is at a bit of a crossroads. Despite being up 38% since the start of the year, the IBD 50 stock has been trying to claw above a buy zone... Read More
View More Cloud Computing Articles

Cloud Computing Services

The biggest buyers of data center infrastructure are Amazon Web Services, Microsoft's Azure and Alphabet's Google, as well as consumer-facing companies like Apple ( AAPL) and Facebook ( FB).

Cloud computing services are new growth engines for AWS, Microsoft and Google. Companies rent their powerful computers and software platforms to process business workloads remotely via the web. Apple relies on cloud infrastructure for its fast-growing services business, whisking music and other content to iPhones.

Companies like Salesforce.com ( CRM) that offer subscription-based software-as-a-services (SaaS) arrived before the term cloud computing was coined. Many SaaS companies are now working with AWS and other cloud vendors to reach new markets.

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

YOU MAY ALSO LIKE:

AI News: Artificial Intelligence Trends And Top AI Stocks

FANG Stocks News: Facebook, Amazon, Netflix, Google

Best Stocks To Buy And Watch

The post Cloud Computing: Find Top Cloud Stocks And Track Industry Trends appeared first on Investor's Business Daily.


99. Semiconductor Stocks To Consider Buying When The Time Is RightВт., 07 авг.[−]

Finding the best semiconductor stocks to buy involves understanding the health of the markets that buy chips for their products.

X

When smartphone sales rise or fall, chipmakers are impacted. The same goes for sales of automobiles, personal computers, data centers and other end-markets for microprocessors.

Computer chips also are the enabling technology behind a host of emerging trends, ranging from the Internet of Things and robotics to self-driving cars and artificial intelligence.

Top-Performing Semiconductor Stocks

The IBD 50 list of top-performing growth stocks currently includes four semiconductor companies: Electro Scientific Industries ( ESIO), Micron Technology ( MU), Nanometrics ( NANO) and Nvidia ( NVDA).

Remember, when looking for semiconductor stocks to buy, watch-lists like the IBD 50 are just a starting point. Before you buy, make sure the stocks are forming proper bases and hitting appropriate buy points.

Electro Scientific Industries

Chip-gear supplier Electro Scientific Industries has been forming a cup base over the past 37 weeks with a buy point of 27.82. It hit a 15-year high of 27.72 on Nov. 27.

Portland, Ore.-based ESI makes laser-based manufacturing systems for the microtechnology industry.

Micron Technology

Shares of memory-chip maker Micron have been consolidating over the past 11 weeks with a buy point of 64.76. The stock attempted a breakout of a cup base on May 29 when it touched a buy point of 63.52, but it soon reversed.

The Boise, Idaho-based company makes DRAM and Nand flash memory chips for computers, smartphones, consumer electronics and other devices.

Nanometrics

Semiconductor-equipment provider Nanometrics has been forming a cup base for the past 10 weeks with a buy point of 44.27. It is trading just below a 17-year high of 44.17, reached on June 6.

Nanometrics broke out of a six-week cup base with a buy point of 30.59 on May 2, before consolidating again.

The Milpitas, Calif.-based company makes advanced process control systems used in the production of semiconductors.

Nvidia

Graphics-chip maker Nvidia is a longtime member of the IBD 50 list. It busted out of a seven-week double-bottom base at a buy point of 239.35 on May 7. It hit an all-time high of 269.20 on June 14. The stock now trades near its 50-day moving average. It has formed a flat base over the past eight weeks with a buy point of 269.30.

Santa Clara, Calif.-based Nvidia also is on the MarketSmith Growth 250 list of high-potential stocks. The list currently features 11 semiconductor industry stocks.

Get instant access to more trading ideas, exclusive stock lists and IBD proprietary ratings for only $5.

RELATED:

Taiwan Semi Cuts Outlook After Computer Virus; Applied Materials, Qualcomm Upgraded

Chipmaker Qorvo Crushes Quarterly Views, Gets Apple Lift

Integrated Device Technology Rises After Beating Quarterly Targets

Chip Gear Maker KLA-Tencor Tops Fiscal Q4 Views

The post Semiconductor Stocks To Consider Buying When The Time Is Right appeared first on Investor's Business Daily.


100. Headset Maker Turtle Beach Smashes Quarterly Views, Guides HigherВт., 07 авг.[−]

Turtle Beach ( HEAR), a top maker of headsets for video game players, late Monday crushed Wall Street's estimates for the second quarter and raised its outlook for the full year. That news sent its stock soaring in extended trading.

X

The San Diego-based company earned 40 cents a share on sales of $60.8 million in the June quarter. Analysts expected it to lose 2 cents a share on sales of $47.9 million. In the year-ago period, it lost 57 cents a share on sales of $19.1 million.

For the current quarter, Turtle Beach expects to earn 44 cents a share vs. a loss of 4 cents a share in the year-earlier period. It forecast sales rising 81% to $65 million. Wall Street was modeling it to lose 4 cents a share, same as a year earlier, on sales of $38.3 million, up 6%, in the third quarter.

For the full year, the company now expects to earn $1.95 a share on sales of $255 million. In May it forecast earning 95 cents a share on sales of $205 million in 2018. Last year, Turtle Beach lost 26 cents a share on revenue of $149.1 million.

Turtle Beach stock jumped 10% in after-hours trading on the stock market today. During the regular session, it fell 6.1% to 30.35. Turtle Beach stock hit a four-year high of 32.60 on Friday.

Boost From Battle Royale Games

"The strong start to 2018 has only gained momentum in the second quarter, with another period of record results," Turtle Beach Chief Executive Juergen Stark said in a news release.

He credited market share gains and a healthy market for console gaming headsets for its quarterly performance. Popular games "Fornite Battle Royale" from Epic Games and "PlayerUnknown's Battlegrounds" from Bluehole also gave it a lift.

The company's strong cash flow enabled it to recently pay down $5 million of its subordinated debt, Stark said. Turtle Beach expects to further reduce its debt over time. It currently has total outstanding debt of $27.6 million.

RELATED:

After Hours: Six Top Stocks Moving On Earnings, Including This Breakout

These Stocks Got The Biggest Bounce From E3 Video Game Expo

Headset Maker Turtle Beach Riding High From 'Fortnite Effect'

The post Headset Maker Turtle Beach Smashes Quarterly Views, Guides Higher appeared first on Investor's Business Daily.



 
Каталог RSS-каналов (лент) — RSSfeedReader
Всего заголовков: 100
По категориям:
Все заголовки
AAOI (1)
AAPL (17)
ABBV (1)
ADBE (1)
AGN (2)
AI (2)
AKCA (2)
ALDR (1)
ALNY (2)
ALXN (1)
AMAT (4)
Amazon Stock News (3)
AMBA (1)
AMD (1)
AMGN (2)
AMPH (1)
AMRX (1)
AMZN (11)
ANET (2)
Apple Stock News (10)
Artificial Intelligence (2)
Auto Industry News & Stocks To Watch (3)
AVGO (1)
BABA (6)
BBY (1)
BHC (1)
BHVN (1)
BIIB (1)
Biotech And Pharma Stock News (27)
BKNG (1)
BMRN (2)
BMY (1)
BOX (1)
BRKB (1)
BZUN (3)
CBLK (2)
CCMP (1)
CELG (1)
Chinese Stocks To Watch (6)
Chip Stocks Semiconductor Industry News (14)
CHKP (2)
CHTR (2)
Click (13)
Cloud Computing (1)
CMCSA (2)
CREE (1)
CRM (3)
CSCO (5)
CTS (1)
CTXS (1)
CYBR (2)
DBX (1)
DIS (1)
DISH (1)
Dow Jones Industrial Average Stock News (5)
DTEGY (2)
DWDP (1)
Earnings (46)
Editor's Picks (2)
EGHT (1)
ENDP (1)
EOLS (1)
ESIO (1)
Evergreen (1)
EXPE (1)
F (1)
FANG Stocks: Facebook Amazon Netflix Google (4)
FB (7)
FEYE (1)
FIT (1)
FIVN (1)
FSCT (1)
FTNT (2)
FTSV (1)
GILD (1)
GOOGL (16)
google (1)
Google Stock News (4)
GRMN (1)
GS (2)
GSK (1)
HEAR (1)
HOLX (2)
HUYA (7)
IAC (1)
ICPT (1)
Industry Trends And Stock News (7)
INGN (1)
INTC (4)
IONS (2)
IPO News (4)
JAZZ (1)
JD (5)
JNPR (1)
JPM (1)
KEYS (1)
KMG (1)
LASR (1)
LITE (1)
LLY (2)
LRCX (1)
LYV (1)
MCHP (2)
MDGL (1)
MDT (1)
MIME (1)
MOMO (2)
MRK (1)
MSFT (7)
MTCH (2)
MU (6)
MYL (4)
NANO (1)
Netflix Stock News (3)
NFLX (7)
NTGN (1)
NVDA (8)
NVS (2)
NXPI (1)
OKTA (1)
OLED (1)
ON (1)
ONCE (2)
ORCL (1)
P (1)
PANW (2)
PBYI (2)
PFE (5)
PFPT (1)
PRGO (1)
PRTA (1)
PYPL (1)
QCOM (3)
QLYS (1)
REGN (2)
Retail And E-Commerce Stocks And Industry News (6)
RHHBY (1)
RNG (1)
ROKU (2)
RPD (1)
RUBY (1)
S (1)
SAIL (1)
SFTBY (2)
SGMO (1)
SIMO (1)
SINA (4)
SNAP (1)
SOXX (1)
SPLK (1)
SPOT (2)
SRPT (1)
SUPN (1)
SYMC (3)
T (6)
TCEHY (5)
TEAM (1)
Tech Earnings (46)
Technology (87)
Telecom Stocks To Watch And Industry News (3)
Tesla Stock News (7)
TEVA (5)
TMUS (2)
TSLA (12)
TSM (3)
TTD (1)
TWLO (1)
TWTR (2)
TXN (1)
VCSEL (1)
VUZI (1)
VZ (4)
WB (4)
WDC (1)
WMGI (1)
XLNX (1)
XLRN (1)
XNCR (1)
XPLR (1)
YELP (1)
YY (7)
ZBRA (1)
По датам:
Все заголовки
2018-08-20, Пн. (10)
2018-08-17, Пт. (7)
2018-08-16, Чт. (11)
2018-08-15, Ср. (10)
2018-08-14, Вт. (10)
2018-08-13, Пн. (6)
2018-08-11, Сб. (2)
2018-08-10, Пт. (9)
2018-08-09, Чт. (12)
2018-08-08, Ср. (14)
2018-08-07, Вт. (9)
По авторам:
Все заголовки
ALLISON GATLIN (27)
BRIAN DEAGON (20)
IBD STAFF (7)
PATRICK SEITZ (27)
REINHARDT KRAUSE (16)
RUSS BRITT (3)